<body style="font: 10pt Times New Roman, Times, Serif"> <document>  <type>   10-K   <sequence>    1    <filename>     tm211070d1_10k.htm     <description>      FORM 10-K      <text>       <title>       </title>       <p style="margin: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%">        <div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         UNITED STATES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SECURITIES AND EXCHANGE COMMISSION        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Washington, D.C. 20549        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         FORM 10-K        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          x         </font>        </font>        <b>         Annual report pursuantto Section 13 or 15(d) of the Securities Exchange Act of 1934        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         For the fiscal year ended December 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         or        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          ¨         </font>        </font>        <b>         Transition reportpursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         For the transition period from          to        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Commission File Number 001-35853        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         BIOSTAGE, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        (Exact Name of Registrant as Specified in Its Charter)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; width: 50%">           <u>            Delaware           </u>          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; width: 50%">           <u>            45-5210462           </u>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center; font: 10pt Times New Roman, Times, Serif">           (State or other jurisdiction of           <br/>           Incorporation or organization)          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">           (I.R.S. Employer           <br/>           Identification No.)          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <u>         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <u>          84 October Hill Road, Suite 11, Holliston,Massachusetts 01746         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        (Address of Principal Executive Offices, includingzip code)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <u>          (774) 233-7300         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        (Registrant’s telephone number, includingarea code)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Securities registered pursuant to Section 12(b)of the Act: None       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="padding: 2pt; width: 35%; border: black 1pt solid">           Title of each class          </td>          <td style="padding: 2pt; width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">           Trading Symbol(s)          </td>          <td style="padding: 2pt; width: 32%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">           Name of each exchange on which registered          </td>         </tr>         <tr style="vertical-align: top">          <td style="padding: 2pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">          </td>          <td style="padding: 2pt; border-bottom: black 1pt solid; border-right: black 1pt solid">          </td>          <td style="padding: 2pt; border-bottom: black 1pt solid; border-right: black 1pt solid">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Securities registered pursuant to Section12(g) of the Act:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Common Stock, $0.01 par value       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">        Indicate by check mark if the registrant is awell-known seasoned issuer, as defined in Rule 405 of the Securities Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">        YES        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          ¨         </font>        </font>        NO        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          x         </font>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.3pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">        Indicate by check mark if the registrant is notrequired to file reports pursuant to Section 13 or Section 15(d) of the Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">        YES        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          ¨         </font>        </font>        NO        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          x         </font>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.3pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">        Indicate by check mark whether the registrant(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirementsfor the past 90 days.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">        YES        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          x         </font>        </font>        NO        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          ¨         </font>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.3pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">        Indicate by check mark whether the registranthas submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">        YES        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          x         </font>        </font>        NO        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          ¨         </font>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.3pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">        Indicate by check mark whether the registrantis a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”and “emerging growth company” in Rule 12b-2 of the Exchange Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 65%">           Large accelerated filer           <font style="font-family: Wingdings">            <font style="font-family: Wingdings">             ¨            </font>           </font>          </td>          <td style="width: 1%; text-align: center">          </td>          <td style="width: 34%">           Accelerated filer           <font style="font-family: Wingdings">            <font style="font-family: Wingdings">             ¨            </font>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           Non-accelerated filer           <font style="font-family: Wingdings">            <font style="font-family: Wingdings">             x            </font>           </font>          </td>          <td style="text-align: center">          </td>          <td>           Smaller reporting company           <font style="font-family: Wingdings">            <font style="font-family: Wingdings">             x            </font>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: center">          </td>          <td>           Emerging growth company           <font style="font-family: Wingdings">            <font style="font-family: Wingdings">             ¨            </font>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">        If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accountingstandards provided pursuant to Section 13(a) of the Exchange Act.        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          ¨         </font>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.3pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">        Indicate by check mark whether the registrantis a shell company (as defined in Rule 12b-2 of the Exchange Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">        YES        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          ¨         </font>        </font>        NO        <font style="font-family: Wingdings">         <font style="font-family: Wingdings">          x         </font>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.3pt; color: red">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">        The aggregate market value of the voting and non-votingcommon equity held by non-affiliates of the registrant, computed by reference to the price at which the common equity was last sold, orthe average bid and asked price of such common equity, as of June 30, 2020 was approximately $13,875,400. Shares of the registrant’scommon stock held by each officer and director and each person known to the registrant to own 10% or more of the outstanding voting powerof the registrant have been excluded in that such persons may be deemed affiliates. This determination of affiliate status is not a determinationfor other purposes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">        At April 8, 2021, there were 9,388,407 sharesof the registrant’s common stock issued and outstanding.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         DOCUMENTS INCORPORATED BY REFERENCE        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 17.6pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">        Portions of the Company’s definitive ProxyStatement in connection with the 2021 Annual Meeting of Stockholders (the Proxy Statement), to be filed within 120 days after the endof the Registrant’s fiscal year, are incorporated by reference into Part III of this Form 10-K. Except with respect to informationspecifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part hereof.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%">        <div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">       </p>       <!-- Field: Page; Sequence: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="margin-top: 0; margin-bottom: 0">        </p>        <p style="margin-top: 0; margin-bottom: 0">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         BIOSTAGE, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         TABLE OF CONTENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         ANNUAL REPORT ON FORM 10-K        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         For the Year Ended December 31, 2020        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         INDEX        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr>          <td style="vertical-align: top; width: 9%">          </td>          <td style="vertical-align: top; width: 82%">          </td>          <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: center">           <b>            Page           </b>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_019">            PART I           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#Split1_001">            <font style="font-size: 10pt">             Item 1.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#Split1_001">            Business           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#Split1_001">            <font style="font-size: 10pt">             1            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_020">            <font style="font-size: 10pt">             Item 1A.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_020">            Risk Factors           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_020">            <font style="font-size: 10pt">             16            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_021">            <font style="font-size: 10pt">             Item 1B.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_021">            Unresolved Staff Comments           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_021">            <font style="font-size: 10pt">             36            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_022">            <font style="font-size: 10pt">             Item 2.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_022">            Properties           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_022">            <font style="font-size: 10pt">             36            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_023">            <font style="font-size: 10pt">             Item 3.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_023">            Legal Proceedings           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_023">            <font style="font-size: 10pt">             36            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_024">            <font style="font-size: 10pt">             Item 4.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_024">            Mine Safety Disclosures           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_024">            <font style="font-size: 10pt">             36            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_026">            PART II           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_025">            <font style="font-size: 10pt">             Item 5.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_025">            <font style="font-size: 10pt">             Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_025">            <font style="font-size: 10pt">             37            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_027">            <font style="font-size: 10pt">             Item 6.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_027">            Selected Financial Data           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_027">            <font style="font-size: 10pt">             37            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_028">            <font style="font-size: 10pt">             Item 7.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_028">            Management's Discussion and Analysis of Financial Condition and Results of Operations           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_028">            <font style="font-size: 10pt">             38            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_011">            <font style="font-size: 10pt">             Item 7A.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_011">            Quantitative and Qualitative Disclosures About Market Risk           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_011">            <font style="font-size: 10pt">             44            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_012">            <font style="font-size: 10pt">             Item 8.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_012">            Financial Statements and Supplementary Data           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_012">            <font style="font-size: 10pt">             44            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_009">            <font style="font-size: 10pt">             Item 9.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_009">            Changes in and Disagreements with Accountants on Accounting and Financial Disclosure           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_009">            <font style="font-size: 10pt">             45            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_010">            <font style="font-size: 10pt">             Item 9A.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_010">            Controls and Procedures           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_010">            <font style="font-size: 10pt">             45            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_008">            <font style="font-size: 10pt">             Item 9B.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_008">            Other Information           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_008">            <font style="font-size: 10pt">             46            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_032">            <font style="font-size: 10pt">             PART III            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_003">            <font style="font-size: 10pt">             Item 10.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_003">            Directors, Executive Officers and Corporate Governance           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_003">            <font style="font-size: 10pt">             47            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_004">            <font style="font-size: 10pt">             Item 11.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_004">            Executive Compensation           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_004">            <font style="font-size: 10pt">             47            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_005">            <font style="font-size: 10pt">             Item 12.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_005">            Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_005">            <font style="font-size: 10pt">             47            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_006">            <font style="font-size: 10pt">             Item 13.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_006">            Certain Relationships and Related Transactions, and Director Independence           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_006">            <font style="font-size: 10pt">             47            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_007">            <font style="font-size: 10pt">             Item 14.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_007">            Principal Accounting Fees and Services           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_007">            <font style="font-size: 10pt">             47            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_001">            <font style="font-size: 10pt">             PART IV            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_002">            <font style="font-size: 10pt">             Item 15.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_002">            Exhibits, Financial Statement Schedules           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_002">            <font style="font-size: 10pt">             48            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">           <a href="#zz_029">            <font style="font-size: 10pt">             Index to Consolidated Financial Statements            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_029">            <font style="font-size: 10pt">             F-1            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_030">            <font style="font-size: 10pt">             Item 16.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#zz_030">            Form 10-K Summary           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_030">            <font style="font-size: 10pt">             49            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">          </td>          <td style="vertical-align: top">           <a href="#zz_031">            <font style="font-size: 10pt">             Signatures            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_031">            <font style="font-size: 10pt">             50            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">         i        </p>        <p style="margin-top: 0; margin-bottom: 0">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Forward-Looking Statements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         This Annual Report on Form 10-K contains statements that are notstatements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section21E of the Securities Exchange Act of 1934 (the Exchange Act), each as amended. The forward-looking statements are principally, but notexclusively, contained in “Item 1: Business” and “Item 7: Management’s Discussion and Analysis of Financial Conditionand Results of Operations.” These statements involve known and unknown risks, uncertainties and other factors that may cause ouractual results, performance or achievements to be materially different from any future results, performance or achievements expressedor implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about management’sconfidence or expectations and our plans, objectives, expectations and intentions that are not historical facts and the potential impactof COVID-19 on our business and operations. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “seek,” “expect,” “plans,” “aim,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “intends,” “think,” “continue,” “potential,” “is likely,” “permit,” “objectives,” “optimistic,” “new,” “goal,” “target,” “strategy”and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to futureevents and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue relianceon these forward-looking statements. We discuss many of these risks in detail under the heading “Item 1A. Risk Factors” beginningon page 16 of this Annual Report on Form 10-K. You should carefully review all of these factors, as well as other risks described in ourpublic filings, and you should be aware that there may be other factors, including factors of which we are not currently aware, that couldcause these differences. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report.We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations underthe federal securities laws to update and disclose material developments related to previously disclosed information. Biostage, Inc. isreferred to herein as “we,” “our,” “us,” and “the Company.”        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 3 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">         ii        </p>        <p style="margin-top: 0; margin-bottom: 0">        </p>        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="zz_019">        </a>        <b>         PART I        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 10%">           <a name="Split1_001">           </a>           <b>            Item 1.           </b>          </td>          <td style="width: 89%">           <b>            <i>             Business.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         OVERVIEW        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are a biotechnology company developing bioengineered organ implantsbased on our novel technology. Our technology is comprised of a proprietary biocompatible scaffold, which is the foundation of our Cellframe        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        technology, that is seeded with the patient’s own mesenchymal stromal cells to form our Cellspan        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        implant, combining the clinically proven principles of tissue engineering, cell biology and materials science. Our platform technologyis being developed to treat life-threatening conditions of the esophagus, bronchus and trachea. By focusing on these underserved patients,we hope to dramatically improve the treatment paradigm for these patients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe our technology may provide surgeons a new paradigm to addresslife-threatening conditions of the esophagus, bronchus, and trachea due to congenital abnormalities, diseases, infections and traumas.Our novel technology harnesses the body’s response and modulates it toward the healing process to regenerate tissue and restorethe continuity and integrity of the organ. We are pursuing our Cellspan Esophageal Implant (CEI) technology as our first product candidateto address both esophageal disease and pediatric esophageal atresia, and we are also developing our technology’s applications toaddress conditions of the bronchus and trachea.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In collaboration with world-class institutions, such as Mayo Clinicand Connecticut Children’s Medical Center, we are advancing our technology. Our product development program is based on the greatestmedical unmet needs, analysis of existing surgical options and physician validation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In October 2019, we filed an Investigational New Drug (IND) applicationwith the U.S. Food and Drug Administration (FDA) to treat patients with esophageal disease, absent of cancer, in adults that would requirea short segment esophageal implant following clinically indicated short segment resection of the thoracic esophagus with our CEI productcandidate. In November 2019, we received notice from the FDA placing our IND on clinical hold and providing a preliminary list of clinicalhold and non-clinical hold questions. In December 2019, we received the formal letter with clinical hold and non-clinical hold questionsand submitted our response to the clinical hold questions on February 18, 2020. On March 19, 2020, the FDA notified us that the IND forour CEI product candidate had been removed from clinical hold and that we could proceed with our study. This FDA approval enables us tostart our transition to a clinical-stage biotechnology company, and start clinical planning, engaging with a clinical research organizationand site readiness in advance of starting the clinical trial for our CEI product candidate. On May 7, 2020, we submitted responses tocertain non-clinical hold questions and finalized a majority of the remaining non-clinical hold responses in the third quarter of 2020,and submitted the remaining responses in the fourth quarter of 2020, except as it relates to our clinical trial details that we will submitonce a clinical research organization is selected. The ongoing COVID-19 pandemic could continue to adversely impact our business, includingplanned clinical trials, as discussed elsewhere in this document.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe that receiving regulatory approval to treat pediatric esophagealatresia with our CEI may provide a shorter time to a commercial product and the greater overall potential value in the U.S. market. Inaddition to providing a novel solution for a great medical need, approval of our pediatric esophageal atresia product candidate may resultin receipt of a priority review voucher, which if achieved, could potentially provide significant value and non-dilutive funding to Biostagein the future. We have continued to advance our CEI pediatric esophagus program and plan to file a protocol amendment with the FDA toupdate our CEI esophageal disease clinical program after the initial adult patients are treated in the esophageal disease trial, subjectto FDA approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         We have alsoformed        </font>        a subsidiary in Hong Kong, Harvard Apparatus Regenerative Technology Limited, as we continue to assess the market and regulatoryapproval pathway in China as to our implant products. We are not certain at this time as to which market, including U.S. or China forexample, may provide the most viable initial pathway for regulatory approval to a commercial product. This will depend on a number offactors, including the approval and development processes, related costs, ability to raise capital and the terms and conditions thereof,as well as the ongoing impact of the COVID-19 pandemic, among other factors. Any development and capital raising efforts in China mayinclude a joint venture in relation to our Hong Kong subsidiary, and would also involve a number of commercial variables, including rightsand obligations pertaining to licensing, development and financing, among others. Our failure to receive or obtain such clearances orapprovals on a timely basis or at all, whether that be in the U.S., China or otherwise, would have an adverse effect on our results ofoperations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         1         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Our Technology Platform: How It Works        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our Cellspan process begins with the collection of an adipose (fat)tissue biopsy from the patient followed by the use of standard tissue culture techniques to isolate and expand the patient’s own(autologous) mesenchymal (multipotent) stromal cells, or MSC. The cells are seeded onto a proprietary biocompatible, synthetic scaffold,produced to mimic the dimensions of the organ to be regenerated, and incubated in a proprietary bioreactor. The scaffold is electrospunfrom polyurethane to form a non-woven, hollow tube. The specific microstructures of the Cellspan implants are designed to allow the culturedcells to attach to and cover the scaffold fibers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <img alt="" src="tm211070d1_10kimg001.jpg"/>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have conducted large-animal studies to investigate the use of theCellspan implants for the reconstitution of the continuity and integrity of tubular shape organs, such as the esophagus and the largeairways, following a full circumferential resection of a clinically relevant segment, just as would occur in a clinical setting. We announcedfavorable preliminary preclinical results of large-animal studies for the esophagus, bronchus and trachea in November 2015. Based on theresults of those studies, we chose the esophagus to be the initial focus for our organ regeneration technology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <img alt="" src="tm211070d1_10kimg002.jpg"/>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 249.7pt; text-align: center; text-indent: -249.7pt">        <i>         Illustrationof intersection of Cellspan esophageal implant and native        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 249.7pt; text-align: center; text-indent: -249.7pt">        <i>         esophagusat time of implant and proposed mechanism of action        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 249.7pt; text-align: center; text-indent: -249.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In May 2016, we reported an update of results from additional, confirmatorypre-clinical large-animal studies. We disclosed that the studies had demonstrated in a predictive large-animal model the ability of ourCellspan implant to successfully stimulate the regeneration of a section of esophagus that had been surgically removed. CEIs, consistingof a proprietary biocompatible synthetic scaffold seeded with the recipient animal’s own mesenchymal stromal cells, were surgicallyimplanted in place of the esophagus section that had been removed. After the surgical full circumferential resection of a portion of thethoracic esophagus, the Cellspan implant stimulated the reconstitution of full esophageal structural integrity and continuity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <img alt="" src="tm211070d1_10kimg003.jpg"/>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 249.7pt; text-align: center; text-indent: -249.7pt">        <i>         Illustrationof esophageal reconstitution over Cellspan esophageal        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 249.7pt; text-align: center; text-indent: -249.7pt">        <i>         implant followingtime of implant and proposed mechanism of action        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 249.7pt; text-align: center; text-indent: -249.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 249.7pt; text-align: center; text-indent: -249.7pt">       </p>       <!-- Field: Page; Sequence: 5; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         2         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 249.7pt; text-align: center; text-indent: -249.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Study animals were returned to a solid diet three weeks after the implantationsurgery. The scaffold portions of the Cellspan implants, which are intended to be in place only temporarily, were retrieved approximatelythree weeks post-surgery via the animal’s mouth in a non-surgical endoscopic procedure. Within 2.5 to 3 months, a complete innerepithelium layer and other specialized esophagus tissue layers were regenerated. Two animals in the study were kept in life for almosttwo years to evaluate the long-term viability of the newly regenerated tubular conduit and were then sacrificed for histological data.Prior to their sacrifice, these animals demonstrated normal weight gain, appeared healthy and free of any significant side effects andreceived no specialized care.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Platform Technology in Life-threatening Orphan Indications        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In November 2016, we were granted Orphan Drug Designation for our CEIby the FDA to restore the structure and function of the esophagus subsequent to esophageal damage due to cancer, injury or congenitalabnormalities. Orphan Drug Designation provides a seven-year marketing exclusivity period against competition in the U.S. from the dateof a product’s approval for marketing. This exclusivity would be in addition to any exclusivity we may obtain from our patents.Additionally, orphan designation provides certain incentives, including tax credits and a waiver of the Biologics License Application(BLA) fee. We also plan to apply for Orphan Drug Designation for our CEI in Europe. Orphan Drug Designation in Europe provides marketexclusivity in Europe for ten years from the date of the product’s approval for marketing.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have advanced the development of our technology, specifically aCEI, in a series of preclinical studies, including large-animal studies with collaborators. In order to seek approval for the initiationof clinical trials for our CEIs in humans, Good Laboratory Practice (GLP) studies to support the safety of the CEI are required to submitan IND application with the FDA. We have now performed GLP studies to demonstrate that our technology, personnel, systems, processes andpractices are sufficient for advancing into human clinical trials. We have conducted a number of IND-enabling GLP studies demonstratingsafety and feasibility of the Cellspan implant. During 2018 we also performed additional non-GLP studies for the pediatric esophagealatresia program to optimize that product candidate. Some of the results from these studies were included in the IND for our CEI that wefiled with the FDA in October 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         First-In-Human Use of Esophageal Implant ProductCandidate        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On August 7, 2017, we announced the use of our CEI product candidatein a patient at a major U.S. hospital via an FDA-approved single-use expanded access application. The surgery took place at Mayo Clinic,but we were not allowed to identify the institution publicly at that time. The patient was a 75-year-old male with a life-threateningcancerous mass in his chest that spanned his heart, a lung and his esophagus. The surgery was performed in May 2017 to remove the tumor,repair the heart, part of one lung, and a section of the esophagus. The CEI was interpositioned into the gap in the esophagus createdby the removal of the tumor. The patient’s surgeon informed us at that time that the surgery was a success and the patient was laterdischarged from the hospital. In February 2018 the surgeon informed us that the patient had died after living approximately eight monthsafter surgery. The surgeon stated that the cause of death was a stroke, and that the stroke was unrelated to the esophageal implant. Thesurgeon also informed us that a preliminary autopsy had shown that the esophageal implant resulted in a regenerated esophageal tube inthe patient, except for a very small (approximately 5mm) hole outside the implant zone on the lateral wall that was right up against asynthetic graft inserted as part of the patient’s heart repair on the vena cava in that same surgery. The synthetic graft on thepericardium was not related to our esophageal implant product and may have acted as an irritant to esophageal tissue where it contactedthe esophageal implant. The surgeon also informed us that the esophageal regeneration in this patient was consistent with the regenerationpreviously observed in our large-animal studies. In January 2019, the surgeon presented the case study publicly at a major U.S. medicalconference, including histological data supporting his earlier statements regarding successful regeneration. Mayo Clinic expects to publishan article in a peer-reviewed journal and we expect to be in a position to release additional information on this landmark case at thattime. Some of the results of this expanded access case was included in the IND for our CEI that we filed with the FDA in October 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our product candidates are currently in development and have not yetreceived regulatory approval for sale anywhere in the world.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 6; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         3         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Changing the Surgical Treatment of EsophagealDisease        </b>       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="width: 50%">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <img alt="" src="tm211070d1_10kimg004.jpg"/>           </p>          </td>          <td style="width: 1%">          </td>          <td style="width: 49%">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <img alt="" src="tm211070d1_10kimg005.jpg"/>           </p>          </td>         </tr>         <tr>          <td style="vertical-align: top; text-align: center">           <i>            Illustration of esophageal disease site           </i>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <i>            Illustration of potential human application of Cellspan esophageal implant at site of esophageal disease (depicting implant prior to esophageal tissue reconstitution over implant)           </i>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 249.7pt; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe our technology may provide surgeons a new paradigm to addresslife-threatening conditions of the esophagus due to infection, trauma, cancer or congenital abnormalities. Initially, our focus is totreat patients with esophageal disease, absent of cancer, in adults that would require a short segment esophageal implant following clinicallyindicated short segment resection of the thoracic esophagus with our CEI product candidate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        According to the World Health Organization’s International Agencyfor Research on Cancer, there are approximately 572,000 new cases of esophageal cancer worldwide each year. A portion of all patientsdiagnosed with esophageal cancer are treated via a surgical procedure known as an esophagectomy. The current standard of care for an esophagectomyrequires a complex surgical procedure that involves moving the patient’s stomach or a portion of their colon into the chest to replacethe portion of esophagus resected by the removal of the tumor. These current procedures have high rates of complications and can leadto a severely diminished quality of life and require costly ongoing care. Our CEI product candidate aims to provide a simpler surgicalprocedure, with reduced complications, that may result in a better quality of life after the operation and reduce the overall cost ofthese patients to the healthcare system.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Focus on Pediatric Esophageal Atresia: a CongenitalAbnormality in Need of a Better Solution        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Each year, several thousand children worldwide are born with a congenitalabnormality known as esophageal atresia, a condition where an infant is born with an esophagus that does not extend completely from themouth to the stomach. When a long segment of the esophagus is lacking, the current standard of care is a series of surgical procedureswhere surgical sutures are applied to both ends of the esophagus in an attempt to stretch them and pull them together so they can be connectedat a later date. This process can take weeks and the procedure is plagued by serious complications and may carry high rates of failure.Such approach also requires, in time, at least two separate surgical interventions. Other options include the use of the child’sstomach or intestine that would be pulled up into the chest to allow a connection to the mouth. We are working to develop a CEI solutionto address the complications of esophageal atresia, that could potentially be life-changing, organ-sparing, or both.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Our Mission and Our Strategy        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our mission is to revolutionize regenerative medicine by bioengineeringpatient-specific Cellspan implants that use the patient’s own mesenchymal stromal cells to stimulate organ regeneration and restorean organ’s structure and continuity. Our business strategy to accomplish this mission includes:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Targeting life-threatening medical conditions.        </i>        We arefocused on creating products to help physicians treat life-threatening conditions to the esophagus, central lung and trachea caused byinfection, trauma, cancer, or infection. We are also developing products for the treatment of congenital abnormalities of the esophagusand airways. We are not targeting less severe conditions that have reasonable existing treatment options. Solutions for life-threateningmedical conditions present a favorable therapeutic index, or risk/benefit relationship, by providing the opportunity of a significantmedical benefit for patients who have poor or no treatment alternatives. We believe that product candidates targeting life-threateningmedical conditions may be eligible for review and approval by regulatory authorities under established expedited review programs, whichmay result in savings of time in the regulatory approval process. Also, we believe that products targeting life-threatening medical conditionsmay be more likely to receive favorable reimbursement compared with treatments for less critical medical conditions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">        <i>        </i>       </p>       <!-- Field: Page; Sequence: 7; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         4         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Developing products that have a relatively short time to market.        </i>        Since the number of patients diagnosed each year in the U.S. with a life-threatening esophageal condition that would requirea short segment esophageal implant following clinically indicated short segment resection of the thoracic esophagus is relatively small,we expect the number of patients that we would likely need to enroll in a clinical trial will also be relatively small. We expect upto 10 patients to be enrolled in our first clinical trial, which implies a relatively fast enrollment time, subject to milestone achievementrequirements on initial patient(s) imposed by the FDA prior to enrolling additional patients, and a less expensive clinical developmentprogram. Therefore, we expect to be able to conduct a clinical trial in a relatively short period of time, subject to enrollment timeconstraints, compared to clinical trials in indications with larger patient populations. We intend to work closely with regulatory agenciesand clinical experts to design and size the clinical studies appropriately based on the specific conditions our products are intendedto treat. We are evaluating the potential impact of the COVID-19 pandemic on our study timelines and costs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Using our Cellframe and Cellspan technology as a platform to addressmultiple organs.        </i>        We believe that pre-clinical data we have produced to date may suggest that our technology is a novel and innovativeapproach to restoring organ function that may provide an ability to develop products that would address life-threatening conditions impactingorgans like the esophagus, bronchus and trachea, and perhaps lower portions of the gastrointestinal (GI) tract. We believe that our technologymay allow physicians to treat certain life-threatening conditions in ways not currently possible, and in some combination, to save patients’lives, avoid or reduce complications experienced in the current standard of care, and improve the patients’ quality of life, whileat the same time reducing the overall cost of patient care to the healthcare system.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Supplying the finished Cellspan esophageal implant to the surgeon.        </i>        Our technology includes our proprietary bioreactor, as well as our proprietary biocompatible scaffold that is seeded with the patient’sown mesenchymal stromal cells. We believe there is considerable value in supplying the final cell-seeded scaffold implant to the surgeonso that the hospital and surgeon may focus solely on performing the implantation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Collaborating with leading medical and research institutions.        </i>        We have and will continue to collaborate with leading medical and research institutions. We have a co-development initiative withMayo Clinic for regenerative medicine organ implant products for the esophagus and airways based on our technology. We are also collaboratingwith Connecticut Children’s Medical Center on a co-development project to translate our technology for pediatric esophageal atresiafrom pre-clinical studies to clinical trials. We believe the use of our product candidates by leading surgeons and institutions will increasethe likelihood that other surgeons and institutions will use our products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Our Technology        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our technology is comprised of our proprietary bioengineered scaffold,which is the foundation of our Cellframe technology, that is seeded with the patient’s own mesenchymal stromal cells in our proprietarybioreactor to form our Cellspan implant prior to implantation. We believe that our technology combines a highly-engineered, biocompatiblescaffold and a robust population of cells that, by tapping into the stem cell niche of the surrounding native tissue after implantation,will stimulate a tubular organ to remodel or regenerate tissue to close the gap created by a surgical resection of a portion of that organ.This unique combination of technologies, developed through our extensive testing performed during the last few years, may potentiallyprovide solutions to life-threatening conditions for patients with unmet medical needs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe that our technology is unique, in that its mode of actionappears to be different from other tissue engineering scaffold products developed previously, of which we are aware. Prior to our developmentof the technology, our approach attempted to implant a biocompatible scaffold that would be incorporated into the patient’s bodyby the surrounding native tissue growing into the scaffold. To our knowledge, all previous research and development efforts by other investigatorswere based on that same concept. Our technology appears to work very differently. We believe that the unique combination of our highly-engineeredbiocompatible scaffold with a population of the patient’s own mesenchymal cells enables an organ to develop new native tissue aroundour scaffold, but not into it, so the scaffold acts as a type of frame or staging for the new tissue. As a result, our scaffold is notincorporated into the body. Instead, it is retrieved from the body via an endoscopic procedure, not surgically, after sufficient tissueremodeling and regeneration has occurred.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Biocompatible Scaffold Component        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our proprietary biocompatible scaffold component of the CEI is constructedprimarily of polyurethane. This material was chosen based on extensive testing of various materials. The scaffold is made using a manufacturingprocess known as electrospinning. The combination of the electrospinning process, which provides control over the desired microstructureof the scaffold fabric, with the polyurethane results in a scaffold that we believe has favorable biocompatibility characteristics.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">        <i>        </i>       </p>       <!-- Field: Page; Sequence: 8; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         5         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         The Patient’s Cells        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Based on current pre-clinical development efforts, the cells we seedonto the scaffold are obtained from the patient’s adipose tissue (abdominal fat). This fat tissue is obtained from a standard biopsybefore the implant surgery. Mesenchymal stromal cells are extracted and isolated from the adipose tissue biopsy. The isolated cells arethen expanded, or grown, for a short period prior to surgery in order to derive a sufficient cell population to be seeded on the scaffold.The cells are then seeded on the scaffold in our proprietary bioreactor and incubated there before the implant surgery.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe our CEI product candidate has the potential to provide amajor advance over the current therapeutic options for treating esophageal disease, damage from infection or trauma and congenital abnormalities.We believe our CEI has the potential to overcome the major challenges in restoring organ function for a damaged esophagus. With our CEIwe are developing a surgical procedure that has the objective of reconstituting the continuity of the patient’s esophagus withouthaving to relocate another organ in its place. In addition, by reducing or eliminating complications that occur in the current standardof care, we expect to reduce the costs of addressing and treating those additional complications. Because these substantial costs canbe reduced or even eliminated with our technology, we believe our products, if successfully developed, can help save lives, improve thequality of life for patients and reduce overall healthcare costs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Unmet Patient Needs and Cellspan Implant Solutions        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Esophageal Disease        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There are approximately 572,000 new diagnoses of esophageal cancerglobally each year, according to the World Health Organization’s International Agency for Research on Cancer. According to the AmericanCancer Society, there are approximately 20,000 new diagnoses of esophageal cancer in the U.S. each year, and there are more than 16,000deaths from esophageal cancer each year. Esophageal cancer is very deadly - the five-year survival rate for people with esophageal canceris 18% in the U.S. Approximately 5,000 esophagectomy surgeries occur in the U.S. annually to treat esophageal cancer, and approximately10,000 esophagectomies occur in Europe annually. We believe that approximately one half of the world’s esophageal cancer cases occurin China, which would represent the largest potential patient population for our adult esophageal product candidate. We believe that ourCEI, if approved, has the potential to provide a major advance over the current esophagectomy procedures for addressing esophageal disease,which have high complication and morbidity rates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The current standard of care for the esophagectomy requires either(A) a gastric pull-up, where the stomach is cut and sutured into a tubular shape, then pulled up through the diaphragm to replace a portionof the esophagus resected by the removal of the cancerous tumor; or (B) a colon interposition, where a portion of the colon is resectedand used to replace the portion of the esophagus resected by the removal of the cancerous tumor. Esophagectomies have 90-day mortalityrates of up to 19%. Serious complications, such as leakage at the anastomoses, which can lead to infections and sepsis, and pulmonarycomplications, such as impaired pulmonary function or pneumonia, occur in up to 30% of esophagectomy cases. Other complications from esophagectomies,such as a narrowing of the esophagus post-surgery, gastroesophageal reflux and dumping syndrome (repetitive nausea, dizziness and vomiting)can also pose significant quality of life issues for patients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe that our CEI has the potential to provide physicians a new,simpler procedure to restore organ function while significantly reducing complication and morbidity rates compared with the current standardof care, and without creating significant quality of life issues for patients. Our current CEI product candidate that was removed fromclinical hold by the FDA on March 19, 2020 will treat patients with esophageal disease, absent of cancer, in adults that would requirea short segment esophageal implant following clinically indicated short segment resection of the thoracic esophagus with our CEI productcandidate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Pediatric Esophageal Atresia        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Esophageal Atresia (EA) is a rare congenital abnormality in which aninfant is born without part of the esophagus. About 1 in 4,000 infants in the U.S. is born with EA. In some cases, the two sections canbe connected surgically. However, in cases where the gap is too great for a simple surgical reconnection, the current standard of careis a gastric pull-up, a colon interposition, or a procedure known as the Foker process. In the Foker process, traction devices are surgicallyattached to the two ends of the esophagus. Traction is then applied, usually for several weeks during which time the infant remains inan Intensive Care Unit, to stimulate the ends of the esophagus to grow and narrow the gap. If the Foker process is successful in narrowingthe gap sufficiently, a second surgery is necessary to connect the two ends of the esophagus. In addition to the Foker process being complex,it is also a very expensive procedure because the infant will normally be in the hospital for several months during the process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe that a pediatric CEI may provide pediatric surgeons witha better procedure to treat EA that would result in a connected esophagus with higher success rates, lower complications and lower overallcosts to the healthcare system.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 9; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         6         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: split 2 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Central Lung Cancer        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Lung cancer is the most common form of cancer and the most common causeof death from cancer worldwide. There are more than 450,000 new lung cancer diagnoses annually in the U.S. and Europe. In approximately25% of all lung cancer cases, the cancerous tumor resides only in a bronchus and not in the lobes of the lungs, and is known as centrallung cancer. Approximately 33,000 central lung cancer cases diagnosed in the U.S. and Europe are Stage I and II and are considered eligiblefor surgical resection, often with adjuvant chemotherapy and radiation. Approximately 5,000 of those patients are treated via pneumonectomy,a surgical procedure involving the resection of the cancer tumor, the whole bronchus below the tumor and the entire lung to which it isconnected. It is a complex surgery and, due to the removal of a lung, results in a 50% reduction in the patient’s respiratory capacity.The procedure has reported rates of post-surgical (in hospital) mortality of 8% to 15%. Complication rates associated with pneumonectomyare reported as high as 50%, and include post-operative pneumonia, supraventricular arrhythmias and anastomotic leakage, placing patientsat significant mortality risk post-discharge.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe that a Cellspan bronchial implant, once developed and approvedfor marketing, has the potential to provide physicians a treatment alternative superior to the sleeve pneumonectomy to address centrallung cancer, a simpler procedure to restore organ function of the bronchus without sacrificing one of the patient’s lungs, resultingin fewer post-surgery complications, improved mortality rates and improved quality of life for the patient.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Life-threatening conditions of the Trachea        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There are approximately 8,000 patients per year in the U.S. and Europewho suffer from a condition of the trachea that put the patient at high risk of death. These conditions can be due to tracheal trauma,tracheal stenosis or trachea cancer. There are approximately 40,000 tracheal trauma patients diagnosed each year in the U.S. Of those,approximately 1,000 are severe enough to need surgical resection procedures. Tracheal stenosis is a rare complication from tracheostomiesbut may have a devastating impact on respiratory function for patients. Approximately 2,000 patients are diagnosed with stenosis fromtracheostomy in the U.S. each year. Trachea cancer is a very rare but extremely deadly cancer. Trachea cancer patients in the U.S. havea median survival of 10 months from diagnosis and a 5-year survival of only 27%. There were approximately 200 cases of primary tracheacancer diagnosed in the U.S. in 2013. Based on these facts, we estimate that there are approximately 8,000 patients in the U.S. and Europewith conditions of the trachea that put them at high risk of death, but for whom there is currently no clinically effective tracheal implantor replacement method currently available.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe that a Cellspan tracheal implant may potentially providephysicians a treatment to re-establish the structural integrity and function of a damaged or diseased trachea to address life-threateningconditions due to tracheal trauma, stenosis or cancer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Our History        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We were incorporated under the laws of the State of Delaware on May3, 2012 as a wholly-owned subsidiary of Harvard Bioscience, Inc. (Harvard Bioscience) to provide a means for separating its regenerativemedicine business from its other businesses. Harvard Bioscience decided to separate its regenerative medicine business into our company,a separate corporate entity (the Separation), and it spun off its interest in our business to its stockholders in November 2013. Sincethe Separation we have been a separately-traded public company and Harvard Bioscience has not been a stockholder of our common stock orcontrolled our operations. Following the Separation, we continued to innovate our bioreactors based on our physiology expertise, we developedour materials science capabilities and we investigated and developed a synthetic tracheal scaffold. By that time, we had built and staffedcell biology laboratories at our Holliston facility, to give ourselves the ability to perform and control our scientific investigationand developments internally. At that point, we began the second phase of our company’s development.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In mid-2014, we increased the pace of our scientifically-based internalanalysis and development of our first-generation tracheal implant product, the HART-Trachea. From large-animal studies conducted thereafterwe found that the product elicited an unfavorable inflammatory response after implantation, which required additional development andtesting. These requirements extended our expectations regarding our regulatory milestones and we announced the additional testing andextended milestone expectations in January 2015. During 2015 we isolated and tested all major variables of the organ scaffold and thecell source and protocols, examining the effects of alternatives against the then-existing product approach. Through extensive        <i>         in vitro        </i>        preclinical studies, and small-animal and large-animal studies, we made dramatic improvements, and discovered that the mechanism of actionof our approach was very different from our hypothesis regarding that of the first-generation product. Our technology uses a differentscaffold material and microstructure, a different source and concentration of the patient’s cells and several other changes fromour earlier trachea initiative.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 10; Options: NewSection; Value: 7 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         7         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe that our technology, although built on learnings from ourearlier-generation product initiative, represents a new technology platform resulting from our rigorous science and development. We havefocused our development efforts on our Cellframe technology and Cellspan product candidates, which we have and will continue to developinternally, and with our collaborators, via a rigorous scientific development process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Clinical Trials        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our CEI has been designated by the FDA as a combination product. Webelieve that this is a favorable designation as it allows for orphan designation and a more participatory path to approval. We have conductednumerous pre-clinical studies in our esophageal implant programs and continue to see consistent regeneration. Additionally, our CEI productcandidate was used in an FDA-approved first-in-human compassionate use successfully in 2017. In October 2019, we filed an InvestigationalNew Drug (IND) application with the U.S. Food and Drug Administration (FDA) to treat patients with esophageal disease in adults that wouldrequire a short segment esophageal implant following clinically indicated short segment resection of the thoracic esophagus with our CEIproduct candidate. In November 2019, we received notice from the FDA placing our IND on clinical hold and providing a preliminary listof clinical hold and non-clinical hold questions. In December 2019, we received the formal letter with clinical hold and non-clinicalhold questions and submitted our response to the clinical hold questions on February 18, 2020. On March 19, 2020, the FDA notified usthat the IND for our CEI product candidate has been removed from clinical hold and that we can proceed with our study. This FDA approvalenables us to start the transition to a clinical-stage biotechnology company, and start clinical planning, engaging with a clinical researchorganization and site readiness in advance of starting the clinical trial for our CEI product candidate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are also pursuing a pediatric program and plan to file a protocolamendment to our CEI clinical program after the initial adult patients are treated in the esophageal disease trial, subject to FDA approval.In order to market our product candidate for both esophageal disease and pediatric esophagus atresia, we will need to successfully completeapplicable clinical trial requirements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe that we have excellent pre-clinical and clinical supportof the pediatric atresia program through our collaboration with Connecticut Children’s Medical Center and our primary investigatorDr. Christine Finck, who is also a member of our Scientific Advisory Board. Essentially, we liken the pediatric atresia market to a raredisease market. Accordingly, the clinical trial population should reflect the ultra-orphan nature of the disease state.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Because life-threatening conditions of the esophagus requiring a shortsegment esophageal implant following clinically indicated short segment resection of the thoracic esophagus affects a small populationin the U.S., and based on our IND submission, we anticipate that our clinical trial using our CEI product candidate will involve up to10 patients. Therefore, once commenced, we expect to be able to conduct a clinical trial in a relatively short period of time comparedto clinical trials in indications with larger patient populations. We intend to work closely with regulatory agencies and clinical expertsto design and size the clinical studies appropriately based on the specific conditions our products are intended to treat. We also intendto request expedited review from the FDA for our CEI product. Receipt of expedited review would reduce the overall time through the regulatoryapproval process. These expedited requests are submitted during the IND process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe that receiving regulatory approval to treat pediatric esophagealatresia with our CEI product candidate may provide a shorter time to a commercial product and the greater overall potential value in theU.S. market. In addition to providing a novel solution for a great medical need, approval of our pediatric esophageal atresia productcandidate may result in receipt of a priority review voucher, which if achieved, could potentially provide significant value to our companyin the future. We have continued to advance our CEI pediatric esophagus program and plan to file a protocol amendment with the FDA toour CEI esophageal disease clinical program after the initial adult patients are treated in the esophageal disease trial, subject to FDAapproval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We intend to initially pursue regulatory approval for our CEI productcandidate in the U.S., however as described above we are assessing the regulatory approval pathway in China and it is possible that thispathway may end up being the initial pathway. We believe that approximately one half of the world’s esophageal disease cases occurin China, which would represent the largest potential patient population for our adult esophageal implant product candidate, and we areconsequently preparing to address that market. Following clinical trials in other foreign markets, we expect to pursue regulatory approvalfor our CEI in those foreign markets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 11; Value: 7 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         8         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Research and Development        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our primary research and development activities are focused in threeareas: materials science, cell biology and engineering. In materials science, we focus on designing and testing biocompatible organ scaffolds,testing the structural integrity and the cellularization capacities of the scaffolds. In cell biology, we focus on developing and testingisolation and expansion protocols, cell characterization and fate studies, investigating the effects of various cell types and concentrations,evaluating the biocompatibility of scaffolds, experimenting with different cell seeding methodologies, and developing protocols for implantationexperiments. Our engineering group supports the materials science and cell biology groups across an array of their activities, i.e. designing,engineering and making our proprietary bioreactors and autoseeders. All three of our R&amp;D groups combine to plan and execute our        <i>         invitro        </i>        studies. A fundamental part of our R&amp;D effort in developing our technology has been dedicated to the discovery and developmentof small and large-animal model studies. The large-animal model employs the use of Yucatan mini-pigs. Our Cellspan scaffolds were implantedin the cervical portion as well as the thoracic portion of the esophagus and the airways in studies to date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In addition to our in-house engineering and scientific developmentteam, we collaborate with leaders in the field of regenerative medicine who are performing the fundamental research and surgeries in thisfield to develop and test new products that will advance and improve the procedures being performed. We will work with our collaboratorsto further enhance our products to make them more efficient and easier to use by surgeons. In the U.S., our principal collaborations havebeen with Mayo Clinic and Connecticut Children’s Medical Center. Collaboration typically involves us developing new technologiesspecifically to address issues these researchers and clinicians encounter, and then working together to translate our technology frompre-clinical studies to clinical trials. In certain instances, we have entered into agreements that govern the ownership of the technologiesdeveloped in connection with these collaborations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We incurred approximately $2.1 million and $4.9 million of researchand development expenses in 2020 and 2019, respectively. As we have not yet applied for or received regulatory approval to market anyclinical products, no amount of these research and development costs have been passed on to our customers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On March 28, 2018, we were awarded a Fast-Track Small Business InnovationResearch (SBIR) grant by the Eunice Kennedy National Institute of Child Health and Human Development (NICHD) to support testing of pediatricCellspan™ Esophageal Implants (CEIs). The award for Phase I provided for the reimbursement of approximately $0.2 million of qualifiedresearch and development costs which was received and recognized as grant income during 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On October 26, 2018, we were awarded the Phase II Fast-Track SBIR grantfrom the Eunice Kennedy NICHD grant aggregating $1.1 million to support development, testing, and translation to the clinic through September2019 and represented years one and two of the Phase II portion of the award. On August 3, 2020, we were awarded a third year of the PhaseII grant totaling $0.5 million for support of development, testing, and translation to the clinic covering qualified expenses incurredfrom October 1, 2019 through September 30, 2020. In September of 2020, we filed and were granted a one year, no-cost extension for thePhase II grant period extending through September 30, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the years ended December 31, 2020 and 2019, we recognized $0.4million and $0.5 million of grant income, respectively, from Phase II of the SBIR grant. The aggregate SBIR grant to date provides uswith a total award of $1.8 million, of which, approximately $1.3 million has been recognized through December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In March 2021, we received additional cash proceeds of $0.2 millionfrom the Phase II grant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <br/>        <b>         Manufacturing and Resources        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Biostage has developed a comprehensive manufacturing process for ourproduct candidates, including cell biology, scaffold production, cell isolation and expansion, seeding of cells on the scaffold, incubationand expansion processes in the bioreactor and product transportation. We currently perform certain manufacturing steps in-house and subcontractcertain processes and activities, primarily those related to cell expansion, seeding and incubation, to experienced partners.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For our scaffolds we use a process called electrospinning tocreate the fabric part of the scaffold. Electrospinning is a well-known fabrication process. It is useful for cell cultureapplications as it can create extremely thin fibers (much thinner than a human hair) that can make a fabric with pores approximatelythe same size as a cell. The electrospinning process parameters can be tuned to create a structure that is very similar to thenatural structure of the collagen fibers in human extracellular matrix. Our process and end product have been developed over manyyears and involve many trade secrets and proprietary know-how. Our Cellspan scaffolds are made from polyurethane, an inert polymerthat is not bioresorbable. However, we also perform studies on the use of scaffolds made from bioresorbable materials. While we donot manufacture the cells, as they will come from the patient’s adipose tissue, for regulatory purposes we are responsible forthe quality control of the cells and the seeding of the cells onto the scaffold in the bioreactor. For this we have, incollaboration with our partners, developed standard operating procedures for the seeding of cells on the scaffold. For U.S. clinicaltrials we anticipate that the seeding will be performed using our Cellspan automatic cell seeder with our bioreactor at a pre-qualified third-party contract manufacturer using current Good Manufacturing Practices (cGMP) using our proprietary protocol andunder the supervision of our staff.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <!-- Field: Page; Sequence: 12; Value: 7 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         9         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For our scaffolds, our primary materials are medical-grade plasticresins and solvents used to liquefy the resins in our manufacturing process. These materials are readily available from a variety of suppliersand do not currently represent a large proportion of our total costs. For our autoseeders and bioreactors, we perform final assembly andtesting of components that we buy from third parties like machine shops, parts distributors, molding facilities and printed circuit boardmanufacturers. These manufacturing operations are performed primarily at our Holliston, MA headquarters.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Sales and Marketing        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We expect that most surgeries using our CEI product will be performedat a relatively small number of major hospitals in the U.S., China and other countries that will establish themselves as specialized centersof excellence based on countries that we receive regulatory approval in. We believe that a relatively small number of centers of excellencein each country would be able to treat a large percentage of that country’s patients annually, given the expected number of patientsto be treated each year. So, we expect our markets to be served by a concentrated number of treatment centers. Further, our technologyplatform is for the esophagus, the bronchi and the trachea, three organs all treated by thoracic surgeons. Therefore, all of those productcandidates, once approved, would be marketed primarily to physicians practicing in a single surgical specialty, so we expect that thetotal number of physicians using our products will be a much smaller population than if our products were to be used by physicians inmultiple areas of surgical specialties. Due to our expectation of a population of physicians in one surgical specialty being the primaryusers of our products in a concentrated number of centers of excellence in each national market, we expect to be able to support our marketswith a fairly small field sales force.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We expect to price the product commensurate with the medical valuecreated for the patient and the costs avoided with the use of our product. We further expect to be paid by the hospital that buys theproduct from us. Finally, we expect that the hospital would seek reimbursement from payers for the entire transplant procedure, includingthe use of our products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Harvard Bioscience will be the exclusive distributor for the researchversions of our bioreactors. Harvard Bioscience can only sell those products to the research markets in accordance with the terms of adistribution agreement we entered into with Harvard Bioscience. We retain all rights to manufacture and sell all our products for clinicaluse.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Intellectual Property and Related Agreements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We actively seek to protect our products and proprietary informationby means of U.S. and foreign patents, trademarks and contractual arrangements. Our success will depend in part on our ability to obtainand enforce patents on our products, processes and technologies to preserve our trade secrets and other proprietary information and toavoid infringing on the patents or proprietary rights of others.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We anticipate that we will sell products in various markets in theU.S. and various jurisdictions under brand name, logo and product design trademarks and service marks and that these marks will attainmaterial importance in the future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We also own select U.S. Patents as well as certain patents in Germany.These patents cover aspects of device and processes currently under development by our company. Patents for various processes and devicesextend for varying periods according to the date of patent filing or grant and the legal term of patents in the country or countries inwhich the patent was obtained. The actual protection afforded by a patent can vary from country to country and depends on factors suchas the type of patent, scope of protection and available legal remedies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In addition to issued patents, we have several pending patent applicationsin the U.S. and key target jurisdictions. We believe that one or more of these pending patent applications may be of importance to materialposition depending upon factors such as the relevant patent jurisdiction, type of patent granted, and scope of patent claims ultimatelyallowed in a given jurisdiction. Depending upon factors such as the type of grant and the date on which the patent application was filed,we anticipate that the term of certain pending patents may extend to 2036.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We also rely on unpatented proprietary technologies in the developmentand commercialization of our products, and we depend upon the skills, knowledge and experience of our scientific and technical personnel,and those of our advisors, consultants and other contractors. To help protect our proprietary know-how that may not be patentable, andour inventions for which patents may be difficult to enforce, we rely on trade secret protection and confidentiality agreements to protectour interests. To this end, we require employees, consultants and advisors to enter into agreements that prohibit the disclosure of confidentialinformation and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions thatarise from their activities for us. Additionally, these confidentiality agreements require that our employees, consultants and advisorsdo not bring to us, or use without proper authorization, any third party’s proprietary technology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 13; Value: 7 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         10         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Sublicense Agreement with Harvard Bioscience        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have entered into a sublicense agreement with Harvard Biosciencepursuant to which Harvard Bioscience has granted us a perpetual, worldwide, royalty-free, exclusive, except as to Harvard Bioscience andits subsidiaries, license to use the mark “Harvard Apparatus” in the name Harvard Apparatus Regenerative Technology. The mark “Harvard Apparatus” is used under a license agreement between Harvard Bioscience and Harvard University, and we have agreedto be bound by such license agreement in accordance with our sublicense agreement. We currently have no affiliation with Harvard University.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Separation Agreements with Harvard Bioscience        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On November 1, 2013, to effect the Separation, Harvard Bioscience distributedall of the shares of our common stock to the Harvard Bioscience stockholders (or the Distribution). Prior to the Distribution, HarvardBioscience contributed the assets of its regenerative medicine business, and approximately $15 million in cash, to our company to fundour operations following the Distribution.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.6pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In connection with the Separation and immediately prior to the Distribution,we entered into a Separation and Distribution Agreement, Intellectual Property Matters Agreement, Product Distribution Agreement, TaxSharing Agreement, Transition Services Agreement, and Sublicense Agreement with Harvard Bioscience to effect the Separation and Distributionand provide a framework for our relationship with Harvard Bioscience after the Separation. These agreements govern the current relationshipsamong us and Harvard Bioscience and provided for the allocation among us and Harvard Bioscience of Harvard Bioscience’s assets,liabilities and obligations (including employee benefits and tax-related assets and liabilities) attributable to periods prior to theSeparation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Government Regulation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Any product that we may develop based on our technology, and any otherclinical products that we may develop, will be subject to considerable regulation by governments. We were informed by the FDA that ourprevious-generation tracheal product candidate would be regulated under the BLA pathway in the U.S. and we were informed by the EuropeanMedicines Agency (EMA) that the previous generation tracheal product would be regulated under the Advanced Therapy Medicinal Products(ATMP), pathway in the European Union (E.U.). On October 18, 2016, we also received written confirmation from FDA’s Center for BiologicsEvaluation and Research (CBER), that the FDA intends to regulate our CEI as a combination product under the primary jurisdiction of CBER.We further understand that CBER may choose to consult or collaborate with the FDA’s Center for Devices and Radiological Health (CDRH),with respect to the characteristics of the synthetic scaffold component of our product based on CBER’s determination of need forsuch assistance. Although our current technology differs in design and performance from the first-generation product candidate, we expectthat cellframe-based products will be regulated by the FDA and EMA under the same pathways as the first-generation tracheal product candidate.This expectation is based on the fact that the cellframe-based technology is centered on the delivery of the patient’s own cellsseeded on an implanted synthetic scaffold in order to restore organ function and our belief that the cells provide the primary mode ofaction. Of course, it is possible that some of our current and future products may use alternative regulatory pathways.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Regulatory Strategy        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Domestic Regulation of Our Products and Business        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The testing, manufacturing, and potential labeling, advertising, promotion,distribution, importing and marketing of our products are subject to extensive regulation by governmental authorities in the U.S. andin other countries. In the U.S., the FDA, under the Public Health Service Act, the Federal Food, Drug and Cosmetic Act, and its implementingregulations, regulates biologics and medical device products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The labeling, advertising, promotion, marketing and distribution ofbiopharmaceuticals, or biologics and medical devices also must be in compliance with the FDA and U.S. Federal Trade Commission (FTC),requirements which include, among others, standards and regulations for off-label promotion, industry sponsored scientific and educationalactivities, promotional activities involving the internet, and direct-to-consumer advertising. The FDA and FTC have very broad enforcementauthority, and failure to abide by these regulations can result in penalties, including the issuance of a warning letter directing usto correct deviations from regulatory standards and enforcement actions that can include seizures, injunctions and criminal prosecution.Further, we are required to meet regulatory requirements in countries outside the U.S., which can change rapidly with relatively shortnotice.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <!-- Field: Page; Sequence: 14; Value: 7 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         11         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have been informed by the FDA that our CEI product candidates arecombination biologic/device products. Biological products must satisfy the requirements of the Public Health Services Act and the Food,Drug and Cosmetics Act and their implementing regulations. In order for a biologic product to be legally marketed in the U.S., the productmust have a BLA approved by the FDA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         The BLA Approval Process        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The steps for obtaining FDA approval of a BLA to market a biopharmaceutical,or biologic product in the U.S. include:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 93%">           completion of pre-clinical laboratory tests, animal studies and formulation studies under the FDA’s GLP regulations;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 93%">           submission to the FDA of an IND application, for human clinical testing, which must become effective before human clinical trials may begin and which must include Institutional Review Board (IRB), approval at each clinical site before the trials may be initiated;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.1pt; text-indent: -29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 93%">           performance of adequate and well-controlled clinical trials in accordance with Good Clinical Practices (GCP), to establish the safety and efficacy of the product for each indication;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 93%">           submission to the FDA of a BLA, which contains detailed information about the chemistry, manufacturing and controls for the product, extensive pre-clinical information, reports of the outcomes of the clinical trials, and proposed labeling and packaging for the product;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.1pt; text-indent: -29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 93%">           the FDA’s acceptance of the BLA for filing;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.1pt; text-indent: -29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 93%">           satisfactory review of the contents of the BLA by the FDA, including the satisfactory resolution of any questions raised during the review or by the advisory committee, if applicable;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.1pt; text-indent: -29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 93%">           satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP regulations, to assure that the facilities, methods and controls are adequate to ensure the product’s identity, strength, quality and purity; and          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.1pt; text-indent: -29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 93%">           FDA approval of the BLA.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Based on discussions with the FDA, we expect clinical trials for ouresophageal implant product candidates to be conducted in two sequential phases:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 93%">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            A Phase 1, or Pilot Trial, where our product would be tested on a small    number of patients, up to 10, to demonstrate the product’s safety. In addition, a protocol amendment could be submitted to the phase    1 trial after the treatment of a to be determined number of patients to add the treatment of patients with pediatric esophageal atresia.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           If successful, the Phase 1 (or Pilot) Trial would be followed by a Phase II Registration, or Pivotal Trial, to test the product’s efficacy. We believe that the nature of our esophageal products and the sizes of their targeted patient populations would lead to a small number of patients in this trial, relative to most biotechnology clinical trials.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Clinical testing may not be completed successfully within any specifiedtime period, if at all. The FDA closely monitors the progress of each phase of clinical trials that are conducted under an IND and may,at its discretion, reevaluate, alter, suspend, or terminate the testing based upon the data accumulated to that point and the FDA’sassessment of the risk/benefit ratio to the patient. The FDA or the sponsor may suspend or terminate clinical trials at any time for variousreasons, including a finding that the subjects or patients are being exposed to an unacceptable health risk. The FDA can also requestthat additional pre-clinical studies or clinical trials be conducted as a condition to product approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Companies also may seek Fast Track or Breakthrough Therapy designationfor their products. Fast Track or Breakthrough Therapy products are those that are intended for the treatment of a serious or life-threateningcondition and that demonstrate the potential to address unmet medical needs for such a condition. If awarded, the Fast Track or BreakthroughTherapy designation applies to the product only for the indication for which the designation was received.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 15; Value: 7 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         12         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        If the FDA determines after review of preliminary clinical data submittedby the sponsor that a Fast Track or Breakthrough Therapy product may be effective, it may begin review of portions of a BLA before thesponsor submits the complete BLA (rolling review), thereby accelerating the date on which review of a portion of the BLA can begin. Therecan be no assurance that any of our products will be granted Fast Track or Breakthrough Therapy designation. And even if they are designatedas Fast Track or Breakthrough Therapy products, we cannot ensure our products will be reviewed or approved more expeditiously for theirFast Track or Breakthrough Therapy indications than would otherwise have been the case or will be approved promptly, or at all. Furthermore,the FDA can revoke Fast Track or Breakthrough Therapy designation at any time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In addition, products studied for their safety and effectiveness intreating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive AcceleratedApproval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effecton a surrogate endpoint that is reasonably likely to predict clinical benefit or on the basis of an effect on a clinical endpoint otherthan survival or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor of a product receiving AcceleratedApproval perform adequate and well-controlled post-approval clinical trials to verify and further define the product’s clinicalbenefit and safety profile. There can be no assurance that any of our products will receive Accelerated Approval. Even if AcceleratedApproval is granted, the FDA may withdraw such approval if the sponsor fails to conduct the required post-approval clinical trials, orif the post-approval clinical trials fail to confirm the early benefits seen during the Accelerated Approval Process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Priority Review Voucher        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Fast Track or Breakthrough Therapy designation and Accelerated Approvalshould be distinguished from Priority Review designation although products awarded Fast Track or Breakthrough Therapy designation mayalso be eligible for Priority Review designation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Products regulated by the CBER may receive Priority Review designationif they provide significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious or life-threateningdisease. The agency has agreed to the performance goal of reviewing products awarded Priority Review designation within six months, whereasproducts under standard review receive a ten-month target. The review process, however, can be significantly extended by FDA requestsfor additional information or clarification regarding information already provided in the submission. Priority Review designation is requestedat the time the BLA is submitted, and the FDA makes a decision as part of the agency’s review of the application for filing.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Separately, but somewhat related, is a product’s ability to qualifyits sponsor to receive a Priority Review Voucher (PRV). For a product aimed at prevention or treatment of a “rare pediatric disease”as defined in the Food, Drug and Cosmetics Act, and that also meets certain other qualifying attributes, the product’s sponsor mayqualify, apply for and receive a PRV, from the FDA. A PRV entitles its holder to Priority Review for a drug application, and the PRV istransferable. Some companies who have received PRV’s have sold their PRV’s to other companies who have then used the PRV toreceive Priority Review for a drug application with the FDA. Recent transfers of PRV’s from one company to another have occurredat prices in the $80 – 125 million range. We intend to apply for rare pediatric disease designation for our pediatric esophagealimplant product candidate as a first step in pursuit of a PRV. A PRV is earned only upon marketing approval of the product. There is nocertainty that our pediatric esophageal product will achieve marketing approval from the FDA, or that if it does, that FDA would awardus a PRV. Further, if received, there is no certainty that the value of a PRV at that future date will compare favorably with the valuesreflected in recent transfers of PRVs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Orphan Drug Designations        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Orphan Drug Act provides incentives to manufacturers to developand market drugs and biologics for rare diseases and conditions affecting fewer than 200,000 persons in the U.S. at the time of applicationfor Orphan Drug Designation. In September 2014 the FDA granted orphan designation to our HART-Trachea product in the U.S. In November2016, we were granted Orphan Drug Designation for our CEI by the FDA to restore the structure and function of the esophagus subsequentto esophageal damage due to injury congenital abnormalities, or cancer. The first developer to receive FDA marketing approval for an orphanbiologic is entitled to a seven-year exclusive marketing period in the U.S. for that product. The marketing exclusivity prevents FDA approvalof another application for the same product for the same indication for a period of seven years. Orphan status also entitles the product’ssponsor to certain other benefits, such as a waiver of the BLA user fee, which is currently a $2 million value. Orphan product designationdoes not convey any advantage in or shorten the duration of the regulatory review and approval process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">        <b>         <i>         </i>        </b>       </p>       <!-- Field: Page; Sequence: 16; Value: 7 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         13         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         International        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We plan to seek required regulatory approvals and comply with extensiveregulations governing product safety, quality, manufacturing and reimbursement processes in order to market our products in other majorforeign markets. The regulation of our products in the Asian and European markets, and in other foreign markets varies significantly fromone jurisdiction to another. The classification of the particular products and related approval or CE marking procedures can involve additionalproduct testing and additional administrative review periods. The time required to obtain these foreign approvals or to CE mark our productsmay be longer or shorter than that required in the U.S., and requirements for approval may differ from the FDA requirements. Regulatoryapproval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in onecountry may negatively impact the regulatory process in others.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Legislation similar to the Orphan Drug Act has been enacted in otherjurisdictions, including the E.U. The orphan legislation in the E.U. is available for therapies addressing conditions that affect fiveor fewer out of 10,000 persons. The marketing exclusivity period is for ten years, although that period can be reduced to six years if,at the end of the fifth year, available evidence establishes that the product is sufficiently profitable not to justify maintenance ofmarket exclusivity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Employees and Human Capital Resources        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As of December 31, 2020, we had 7 employees working in our business,of whom 6 were full-time and one was part-time. At that date, all of our employees were based in the U.S. None of our employees are unionized.In general, we consider our relations with our employees to be good. Our employees are highly skilled, and many hold advanced degrees.Our future performance depends significantly upon the continued service of our key scientific, technical and senior management personneland our continued ability to attract and retain highly skilled employees. We have taken proactive steps throughout the COVID-19 pandemicto protect the health and safety of our employees. We expect to continue to implement these measures until we determine that the COVID-19pandemic is adequately contained for purposes of our business. We may take further actions, in compliance with all appropriate governmentregulations, that we determine to be in the best interest of our employees.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Competition        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are not aware of any companies whose products are directly competitivewith our cell-seeded biocompatible synthetic scaffold system. However, in our key markets we may in the future compete with multiple pharmaceutical,biotechnology, and medical device companies, including, among others, Aldagen, Asterias Biotherapeutics, Athersys, BioTime, CaladriusBiosciences, Cytori Therapeutics, E. I. du Pont de Nemours and Company, InVivo Therapeutics, Mesoblast, Miramatrix Medical, NanofiberSolutions, Neuralstem, Orgagen, Organovo, Osiris Therapeutics, Pluristem, Smiths Medical, Tissue Genesis, Inc., Tissue Growth Technologies,United Therapeutics, Vericel Corporation and W.L. Gore and Associates. In addition, there are many academic and clinical centers thatare developing regenerative technologies that may one day become competitors of ours.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Many of our potential competitors have substantially greater financial,technological, research and development, marketing, and personnel resources than we do. We cannot forecast if or when these or other companiesmay develop competitive products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We expect that other products will compete with our products and potentialproducts based on efficacy, safety, cost, and intellectual property positions. While we believe that these will be the primary competitivefactors, other factors include, in certain instances, obtaining marketing exclusivity under the Orphan Drug Act, availability of supply,manufacturing, marketing and sales expertise and capability, and reimbursement coverage.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         JOBS Act        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Effective December 31, 2020, we are no longer considered an “emerginggrowth company” under the Jumpstart Our Business Startups Act of 2012.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 17; Value: 7 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         14         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Information about our Executive Officers        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table shows information about our executive officers:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 23%; border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name            </b>           </font>          </td>          <td style="width: 1%; text-align: center">          </td>          <td style="width: 3%; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Age            </b>           </font>          </td>          <td style="width: 1%; text-align: center">          </td>          <td style="width: 72%; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Position(s)            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Hong Yu           </font>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            48           </font>          </td>          <td style="text-align: center">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            President           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Dr. William Fodor           </font>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            62           </font>          </td>          <td style="text-align: center">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Scientific Officer           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Peter Pellegrino           </font>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            46           </font>          </td>          <td style="text-align: center">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Interim Vice President of Finance           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Hong Yu – President        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Mr. Yu has served as our President since May 31, 2018. Mr. Yu is aseasoned executive with extensive knowledge in strategic analytics, wealth management, and investment research. Prior to Biostage, Mr.Yu was most recently a Senior Vice President responsible for strategic analytics at Bank of America, where he was employed for nearly20 years. During his career, Mr. Yu has built strong business connections in various industries, including biotech/healthcare, financialservices, and robotics/artificial intelligence. He developed an expertise in matching emerging companies with cross-border investors,often providing U.S. companies with market access to the vast capital supply in China. Mr. Yu graduated from Huanggang High School (Hubei,China) in 1990 and obtained a B.S. in biophysics from Peking University (Beijing, China), and M.S. in biostatistics from School of PublicHealth, University of Illinois (Chicago, IL). Mr. Yu is a charterholder of Chartered Financial Analyst (CFA).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Dr. William Fodor - Chief Scientific Officer        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Dr. William Fodor has served as our Chief Scientific Officer sinceJuly 2017. On July 2, 2018, Dr. Fodor became an employee of Biostage after serving via a consulting arrangement. Dr. Fodor was a foundingscientist at Alexion Pharmaceuticals, where he served as an executive management team member and Senior Director of the Cell/Tissue Engineering,Transgenic Animal and Transplant Programs. He has also served as an Associate Professor at the University of Connecticut Department ofMolecular Cell Biology and the Center for Regenerative Biology, extending research areas into cells and cell engineering. Dr. Fodor wasSenior Director of Product Development at ViaCell Inc., leading programs in hematopoietic stem cell process development and manufacturing,mesenchymal stem cell basic research and manufacturing for cardiac repair and pancreatic stem cell research. He was a consultant for thebiotechnology industry, serving clients in stem cell research, gene therapy, stem cell manufacturing and stem cell genome engineering.Dr. Fodor has expertise in programs targeting transplant immunology, hematopoiesis, cardiac repair, stem cell potency, gene therapy forliver diseases, tissue engineering, design and oversight of pre-clinical non-GLP and GLP animal models and IND Applications (Pre-clinicaland CMC Modules). Dr. Fodor earned a PhD. in genetics from Ohio State University. He completed post-doctoral work at Yale University Schoolof Medicine in the department of immunobiology, investigating the regulation of MHC class I and MHC class II genes in the histocompatibilitycomplex.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Peter Pellegrino – Interim Vice President of Finance        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         Mr. Pellegrinohas been working as a consultant for the Company since March 1, 2020 pursuant to our engagement of Point Providence Consulting, a financialconsultancy firm that specializes in working with life sciences companies. Mr. Pellegrino was appointed as our Interim Vice Presidentof Finance prior to the filing of this Form 10-K and        </font>        is currently President of Point Providence Consulting. In his tenure at PointProvidence, Mr. Pellegrino serves in a variety of financial roles to a number of public and private companies in various stages of research,clinical development and commercialization. Immediately prior to forming Point Providence Consulting, Mr. Pellegrino served as Vice President,Corporate Controller and Treasurer of Verastem, Inc., a publicly traded biopharmaceutical company, from 2018 to 2019. From 2017 to 2018,Mr. Pellegrino was employed by Merus, Inc., a publicly traded oncology company, as Vice President, Corporate Controller. Previously, Mr.Pellegrino was Corporate Controller of Aspen Aerogels, Inc., a publicly traded designer, developer, and manufacturer of insulation productsfrom 2009 to 2017. Prior to 2009, he served in various managerial positions in the areas of accounting and financial reporting. Mr. Pellegrinoholds a B.S. in business administration from Bryant University.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Available Information and Website        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our website address is        <i>         www.biostage.com        </i>        . Our Quarterly Reportson Form 10-Q, Current Reports on Form 8-K, and exhibits and amendments to those reports filed or furnished with the Securities and ExchangeCommission (SEC) pursuant to Section 13(a) of the Exchange Act are available for review on our website and the SEC website at www.sec.gov.Any such materials that we file with, or furnish to, the SEC in the future will be available on our website as soon as reasonably practicableafter they are electronically filed with, or furnished to, the SEC. The information on our website is not incorporated by reference intothis Annual Report on Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 18; Value: 7 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         15         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 10%">           <a name="zz_020">           </a>           <b>            Item 1A.           </b>          </td>          <td style="width: 89%">           <b>            <i>             Risk Factors.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Summary of Risk Factors        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Below is a summary of the principal factorsthat make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additionaldiscussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading “RiskFactors” and should be carefully considered, together with other information in this Annual Report on Form 10-K and our other filingswith the SEC before making an investment decision regarding our common stock.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           Our audited financial statements for the year ended December 31, 2020 contain a going concern qualification. Our financial statuscreates doubt whether we will continue as a going concern. We will need additional funds in the near future and our operations will beadversely affected if we are unable to obtain needed funding.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           We have generated insignificant revenue to date and have an accumulated deficit. We anticipate that we will incur losses for the foreseeablefuture. We may never achieve or sustain profitability.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="font-size: 10pt">           We have identified a material weakness in our internal control over financial reporting. Our ability to remediate this, our discovery of additional weaknesses, and our inability to achieve and maintain effective internal control over financial reporting,could adversely affect our results of operations, our stock price and investor confidence in our company.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           The COVID-19 pandemic could continue to adversely impact our business, including clinical trials.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           Our products are in an early stage of development. If we are unable to develop or market any of our products, our financial conditionwill be negatively affected, and we may have to curtail or cease our operations.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           Our products will subject us to liability exposure.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           The results of our clinical trials or pre-clinical development efforts may not support our product claimsor may result in the discovery of adverse side effects.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="text-align: justify">           If we fail to obtain, or experience significant delays in obtaining, regulatory approvals in the U.S.,China or the E.U. for our products, including those for the esophagus and airways, or are unable to maintain such clearances or approvalsfor our products, our ability to commercially distribute and market these products would be adversely impacted.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           Even if our products are cleared or approved by regulatory authorities, if we or our suppliers fail to comply with ongoing FDA orother foreign regulatory authority requirements, or if we experience unanticipated problems with our products, these products could besubject to restrictions or withdrawal from the market.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           Our principal stockholders hold a majority of voting power and will be able to exert significant control over us.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           We do not intend to pay cash dividends on our common stock.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 19 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         16         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Split-Segment; Name: split 3 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Risk Factors        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         The following factors should be reviewed carefully, in conjunctionwith the other information contained in this Annual Report on Form 10-K. As previously discussed, our actual results could differ materiallyfrom our forward-looking statements. Our business faces a variety of risks. We describe below what we believe are currently the materialrisks and uncertainties we face, but they are not the only risks and uncertainties we face. Additional risks and uncertainties of whichwe are unaware, or that we currently believe are not material, may also become important factors that adversely affect our business. Inaddition, past financial performance may not be a reliable indicator of future performance and historical trends should not be used toanticipate results or trends in future periods. If any of the following risks and uncertainties develops into actual events, these eventscould have a material adverse effect on our business, financial condition or results of operations. In such case, the trading price ofour common stock could decline, and you may lose all or part of your investment in our securities. The risk factors generally have beenseparated into three groups: (i) risks relating to our business, (ii) risks relating to the Separation and (iii) risks relating to ourcommon stock. These risk factors should be read in conjunction with the other information in this Annual Report on Form 10-K.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Relating to Our Financial         <font style="font-family: Times New Roman, Times, Serif">          Position,Need for Capital         </font>         and Operating Risks        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Our audited financial statements for the year ended December 31,2020 contain a going concern qualification. Our financial status creates doubt whether we will continue as a going concern. We will needadditional funds in the near future and our operations will be adversely affected if we are unable to obtain needed funding.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We ended December 31, 2020 with approximately $1.0 million of operatingcash on-hand and will need to raise additional capital in the second quarter and beyond to fund operations. If we do not raise additionalcapital from outside sources before or during early June 2021, we will be forced to further curtail or cease our operations. Based onthese circumstances, our ability to continue as a going concern is at risk and our independent registered public accounting firm includeda “going concern” qualification as to our ability to continue as a going concern in their audit report dated April 13, 2021,included in this Form 10-K. Our cash requirements and cash resources will vary significantly depending upon the timing, and the financialand other resources that will be required to complete ongoing development and pre-clinical and clinical testing of our products as wellas regulatory efforts and collaborative arrangements necessary for our products that are currently under development. In addition to developmentand other costs, we expect to incur capital expenditures from time to time. These capital expenditures will be influenced by our regulatorycompliance efforts, our success, if any, at developing collaborative arrangements with strategic partners, our needs for additional facilitiesand capital equipment and the growth, if any, of our business in general. We will require additional funding to continue our anticipatedoperations and support our capital and operating needs. We are currently seeking and will continue to seek financings from other existingand/or new investors to raise necessary funds through a combination of public or private equity offerings. We may also pursue debt financings,other financing mechanisms, strategic collaborations and licensing arrangements. We may not be able to obtain additional financing onterms favorable to us, if at all. In addition, general market conditions, including the effect of the COVID-19 pandemic on financial markets,as well as the effects of laws and regulations on foreign investment in the United States under the jurisdiction of the Committee on ForeignInvestment in the United States (CFIUS), and other agencies and related regulations, including the Foreign Investment Risk Review ModernizationAct (FIRRMA), adopted in August 2018, may make it difficult for us to seek financing from the capital markets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Any additional equity financings could result in significant dilutionto our stockholders and possible restrictions on subsequent financings. Debt financing, if available, could result in agreements thatinclude covenants limiting or restricting our ability to take certain actions, such as incurring additional debt, making capital expendituresor paying dividends. Other financing mechanisms may involve selling intellectual property rights, payment of royalties or participationin our revenue or cash flow. In addition, in order to raise additional funds through strategic collaborations or licensing arrangements,we may be required to relinquish certain rights to some or all of our technologies or products. If we cannot raise funds or engage strategicpartners on acceptable terms when needed, we may not be able to continue our research and development activities, develop or enhance ourproducts, take advantage of future opportunities, grow our business, respond to competitive pressures or unanticipated requirements, orat worst may be forced to curtail or cease our operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         We have generated insignificant revenue to date and have an accumulateddeficit. We anticipate that we will incur losses for the foreseeable future. We may never achieve or sustain profitability.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have generated        <i>         insignificant        </i>        revenues to date, and we havegenerated no revenues from sales of any clinical products, and, as of December 31, 2020, we had an accumulated deficit of approximately$69.0 million. We expect to continue to experience losses in the foreseeable future due to our limited anticipated revenues and significantanticipated expenses. We do not anticipate that we will achieve meaningful revenues for the foreseeable future. In addition, we expectthat we will continue to incur significant operating expenses as we continue to focus on additional research and development, preclinicaltesting, clinical testing and regulatory review and/or approvals of our products and technologies. As a result, we cannot predict when,if ever, we might achieve profitability and cannot be certain that we will be able to sustain profitability, if achieved.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <!-- Field: Page; Sequence: 20; Options: NewSection; Value: 17 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         17         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Our products are in an early stage of development. If we are unableto develop or market any of our products, our financial condition will be negatively affected, and we may have to curtail or cease ouroperations.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are in the early stage of product development. One must evaluateus in light of the uncertainties and complexities affecting an early-stage biotechnology company. Our products require additional researchand development, preclinical testing, clinical testing and regulatory review and/or approvals or clearances before marketing. In addition,we may not succeed in developing new products as an alternative to our existing portfolio of products. If we fail to successfully developand commercialize our products, including our esophageal or airway products, our financial condition may be negatively affected, and wemay have to curtail or cease our operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         We have a limited operating history and it is difficult to predictour future growth and operating results.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have a limited operating history and limited operations and assets.Accordingly, one should consider our prospects in light of the costs, uncertainties, delays and difficulties encountered by companiesin the early stage of development, particularly companies in new and evolving markets, such as bioengineered organ implants, and regenerativemedicine. These risks include, but are not limited to, unforeseen capital requirements, delays in obtaining regulatory approvals, failureto gain market acceptance and competition from foreseen and unforeseen sources. As such, our development timelines have been and may continueto be subject to delay that could negatively affect our cash flow and our ability to develop or bring products to market, if at all. Ourestimates of patient population are based on published data and analysis of external databases by third parties and are subject to uncertaintyand possible future revision as they often require inference or extrapolations from one country to another or one patient condition toanother.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         If we fail to retain key personnel and/or attract satisfactory replacements,we may not be able to compete effectively, which would have an adverse effect on our operations.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our success is highly dependent on the continued services of key management,technical and scientific personnel and collaborators. Our management and other employees may voluntarily terminate their employment atany time upon short notice. In February 2020 our Chief Executive Officer, James McGorry resigned; and in July 2019 our Chief FinancialOfficer, Thomas McNaughton, resigned; and in October 2020, we determined that Peter Chakoutis, our former Vice President of Finance, whohad been on a temporary leave of absence for personal reasons, would not be returning to us. The loss of the services of any member ofour senior management team, including our President, Hong Yu, our Chief Scientific Officer, Dr. William Fodor, our interim Vice Presidentof Finance, Peter Pellegrino, and our other key scientific, technical and management personnel, may significantly delay or prevent theachievement of product development and other business objectives. We can give no assurance that we could find satisfactory replacementsfor our current and future key scientific and management employees, including recently terminated executives, on terms that would notbe unduly expensive or burdensome to us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         If our collaborators do not devote sufficient time and resourcesto successfully carry out their duties or meet expected deadlines, we may not be able to advance our products in a timely manner or atall.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are currently collaborating with multiple academic researchers andclinicians at a variety of research and clinical institutions. Our success depends in part on the performance of our collaborators. Somecollaborators may not be successful in their research and clinical trials or may not perform their obligations in a timely fashion orin a manner satisfactory to us. Typically, we have limited ability to control the amount of resources or time our collaborators may devoteto our programs or potential products that may be developed in collaboration with us. Our collaborators frequently depend on outside sourcesof funding to conduct or complete research and development, such as grants or other awards. In addition, our academic collaborators maydepend on graduate students, medical students, or research assistants to conduct certain work, and such individuals may not be fully trainedor experienced in certain areas, or they may elect to discontinue their participation in a particular research program, creating an inabilityto complete ongoing research in a timely and efficient manner. As a result of these uncertainties, we are unable to control the precisetiming and execution of any experiments that may be conducted.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Although we have co-development collaboration arrangements with MayoClinic and Connecticut Children’s Medical Center, we do not have formal agreements in place with other collaborators, and most ofour collaborators retain the ability to pursue other research, product development or commercial opportunities that may be directly competitivewith our programs. If any of our collaborators elect to prioritize or pursue other programs in lieu of ours, we may not be able to advanceproduct development programs in an efficient or effective manner, if at all. If a collaborator is pursuing a competitive program and encountersunexpected financial or capability limitations, they may be motivated to reduce the priority placed on our programs or delay certain activitiesrelated to our programs. Any of these developments could harm or slow our product and technology development efforts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <!-- Field: Page; Sequence: 21; Value: 17 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         18         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         We have identified a material weakness in ourinternal control over financial reporting. Our ability to remediate this, our discovery of additional weaknesses, and our inability toachieve and maintain effective internal control over financial reporting, could adversely affect our results of operations, our stockprice and investor confidence in our company.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        <font style="font-family: Times New Roman, Times, Serif">         Section404 of the Sarbanes-Oxley Act of 2002 requires that companies evaluate and report on their systems of internal control over financialreporting. As disclosed in more detail under "Controls and Procedures" in Part II, Item 9A of this Report, we have identifieda material weakness as of December 31, 2020 in our internal control over financial reporting resulting from our failure to        </font>        designor maintain effective internal controls over the timely identification and recording of financial statement adjustments. Specifically,we did not identify, analyze, record, and disclose certain non-routine accounting matters, such as a lease extension and a grant contract,timely and accurately.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        Our management has taken immediate action to beginremediating this material weakness. Additional details regarding the initial remediation efforts are disclosed in more detail under "Controlsand Procedures" in Part II, Item 9A of this Report. In addition, we may in the future identify additional internal control deficienciesthat could rise to the level of a material weakness or uncover errors in financial reporting. During the course of our evaluation, wemay identify areas requiring improvement and may be required to design additional enhanced processes and controls to address issues identifiedthrough this review. In addition, there can be no assurance that such remediation efforts will be successful, that our internal controlover financial reporting will be effective as a result of these efforts or that any such future deficiencies identified may not be materialweaknesses that would be required to be reported in future periods.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        If, as a result of deficiencies in our internalcontrol over financial reporting we cannot provide reliable financial statements, our business decision processes may be adversely affected,our business and results of operations could be harmed, investors could lose confidence in our reported financial information and ourability to obtain additional financing, or additional financing on favorable terms, could be adversely affected. In addition, if we failto remediate this material weakness and maintain an effective system of internal control over financial reporting, we may not be ableto rely on the integrity of our financial results, which could result in inaccurate or late reporting of our financial results, as wellas delays or the inability to meet our reporting obligations or to comply with SEC rules and regulations. Any of these could result indelisting actions, result in investigation and sanctions by regulatory authorities, impair our ability to produce accurate financialstatements on a timely basis, lead to a restatement of our financial statements and adversely affect our business and the trading priceof our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Public perception of ethical and social issues surrounding the useof cell technology may limit or discourage the use of our technologies, which may reduce the demand for our products and technologiesand reduce our revenues.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our success will depend in part upon our collaborators’ abilityto develop therapeutic approaches incorporating, or discovered through, the use of cells. If either bioengineered organ implant technologyis perceived negatively by the public for social, ethical, medical or other reasons, governmental authorities in the U.S. and other countriesmay call for prohibition of, or limits on, cell-based technologies and other approaches to bioengineering and tissue engineering. Althoughthe surgeons using our products have not, to date, used the more controversial stem cells derived from human embryos or fetuses in thehuman transplant surgeries using our products, claims that human-derived stem cell technologies are ineffective or unethical may influencepublic attitudes. The subject of cell and stem cell technologies in general has at times received negative publicity and aroused publicdebate in the U.S. and some other countries. Ethical and other concerns about such cells could materially harm the market acceptance ofour products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Our products will subject us to liability exposure.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We face an inherent risk of product liability claims, especially withrespect to our products that will be used within the human body, including the scaffolds we manufacture. Product liability coverage isexpensive and sometimes difficult to obtain. We may not be able to obtain or maintain insurance at a reasonable cost. We may be subjectto claims for liabilities for unsuccessful outcomes of surgeries involving our products, which may include claims relating to patientdeath. We may also be subject to claims for liabilities relating to patients that suffer serious complications or death during or followingimplantations involving our products, including the patients who had surgeries utilizing our first-generation scaffold device or our bioreactortechnology or our esophageal implant, or patients that may have surgeries utilizing any of our products in the future. Our current productliability coverage is $10 million per occurrence and in the aggregate. We will need to increase our insurance coverage if and when webegin commercializing any of our products. There can be no assurance that existing insurance coverage will extend to other products inthe future. Any product liability insurance coverage may not be sufficient to satisfy all liabilities resulting from product liabilityclaims. A successful claim may prevent us from obtaining adequate product liability insurance in the future on commercially desirableitems, if at all. If claims against us substantially exceed our coverage, then our business could be adversely impacted. Regardless ofwhether we are ultimately successful in any product liability litigation, such litigation could consume substantial amounts of our financialand managerial resources and could result in, among others:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%; text-align: justify">           significant awards or judgments against us;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%; text-align: justify">           substantial litigation costs;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%; text-align: justify">           injury to our reputation and the reputation of our products;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%; text-align: justify">           withdrawal of clinical trial participants; and          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%; text-align: justify">           adverse regulatory action.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Any of these results would substantially harm our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         If restrictions on reimbursements or other conditions imposed bypayers limit our customers’ actual or potential financial returns on our products, our customers may not purchase our products ormay reduce their purchases.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our customers’ willingness to use our products will depend inpart on the extent to which coverage for these products is available from government payers, private health insurers and other third-partypayers. These payers are increasingly challenging the price of medical products and services. Significant uncertainty exists as to thereimbursement status of newly approved treatments and products in the fields of biotechnology and regenerative medicine, and coverageand adequate payments may not be available for these treatments and products. In addition, third-party payers may require additional clinicaltrial data to establish or continue reimbursement coverage. These clinical trials, if required, could take years to complete and couldbe expensive. There can be no assurance that the payers will agree to continue reimbursement or provide additional coverage based uponthese clinical trials. Failure to obtain adequate reimbursement would result in reduced sales of our products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 22; Value: 17 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         19         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         We depend upon single-source suppliers for the hardware used forour proprietary automatic cell seeder, bioreactor control and acquisition system. The loss of a single source supplier, or future single-sourcesuppliers we may rely on, or their failure to provide us with an adequate supply of their products or services on a timely basis, couldadversely affect our business.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        We currently have single-source suppliers forcertain components that we use for our proprietary automatic cell seeder, bioreactor control and acquisition systems as well as materialsused in scaffolds. We may also rely on other single-source suppliers for critical components of our products in the future. If we wereunable to acquire hardware or other products or services from applicable single-source suppliers, we could experience a delay in developingand manufacturing our products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         We use and generate hazardous materials in our business and mustcomply with environmental laws and regulations, which can be expensive.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our research, development and manufacturing involve the controlleduse of hazardous chemicals, and we may incur significant costs as a result of the need to comply with numerous laws and regulations. Forexample, certain volatile organic laboratory chemicals we use, such as fluorinated hydrocarbons, must be disposed of as hazardous waste.We are subject to laws and regulations enforced by the FDA, foreign health authorities and other regulatory requirements, including theOccupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation andRecovery Act, and other current and potential federal, state, local and foreign laws and regulations governing the use, manufacturing,storage, handling and disposal of our products, materials used to develop and manufacture our products, and resulting waste products.Although we believe that our safety procedures for handling and disposing of such materials comply with the standards prescribed by stateand federal regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the eventof such an accident, our operations could be interrupted. Further, we could be held liable for any damages that result and any such liabilitycould exceed our resources.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Our products are novel and will require market acceptance.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Even if we receive regulatory approvals for the commercial use of ourproducts, their commercial success will depend upon acceptance by physicians, patients, third party payers such as health insurance companiesand other members of the medical community. Market acceptance of our products is also dependent upon our ability to provide acceptableevidence and the perception of the positive characteristics of our products relative to existing or future treatment methods, includingtheir safety, efficacy and/or other positive advantages. If our products fail to gain market acceptance, we may be unable to earn sufficientrevenue to continue our business. Market acceptance of, and demand for, any product that we may develop and commercialize will dependon many factors, both within and outside of our control. If our products receive only limited market acceptance, our business, financialcondition and results of operations would be materially and adversely affected.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Our long-term growth depends on our ability to develop productsfor other organs.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our growth strategy includes expanding the use of our products in treatmentspertaining to organs other than the esophagus and airways, such as the lungs, GI tract, among others. These other organs are more complexthan the esophagus and airways. There is no assurance that we will be able to successfully apply our technologies to these other morecomplex organs, which might limit our expected growth.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Our success will depend partly on our ability to operate withoutinfringing on, or misappropriating, the intellectual property or confidentiality rights of others.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We may be sued for infringing on the intellectual property or confidentialityrights of others, including the patent rights, trademarks and trade names and confidential information of third parties. To the extentthat any of such claims are valid, if we had utilized, or were to utilize, such patent applications or patents without an agreement fromthe owner thereof, it could result in infringement of the intellectual property rights of the respective owner. Intellectual propertyand related litigation is costly and the outcome is uncertain. If we do not prevail in any such intellectual property or related litigation,in addition to any damages we might have to pay, we could be required to stop the infringing activity, or obtain a license to or designaround the intellectual property or confidential information in question. If we are unable to obtain a required license on acceptableterms or are unable to design around any third-party patent, we may be unable to sell some of our products and services, which could resultin reduced revenue.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <!-- Field: Page; Sequence: 23; Value: 17 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         20         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         We may be involved in lawsuits to protect or enforce our patentsthat would be expensive and time consuming.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In order to protect or enforce our patent rights, we may initiate patentlitigation against third parties. We may also become subject to interference proceedings conducted in the patent and trademark officesof various countries to determine the priority of inventions. The defense and prosecution, if necessary, of intellectual property suits,interference proceedings and related legal and administrative proceedings would be costly and may divert our technical and managementpersonnel from their normal responsibilities. We may not prevail in any of these suits should they occur. An adverse determination ofany litigation or defense proceedings could put our patents at risk of being invalidated or interpreted narrowly and could put our patentapplications at risk of being rejected and patents not being issued.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Furthermore, because of the substantial amount of discovery requiredin connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised bydisclosure during this type of litigation. For example, during the course of this kind of litigation, there could be public announcementsof the results of hearings, motions or other interim proceedings or developments in the litigation. Securities analysts or investors mayperceive these announcements to be negative, which could cause the market price of our stock to decline.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         If we are unable to effectively protect our intellectual property,third parties may use our technology, which would impair our ability to compete in our markets.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our continued success will depend significantly on our ability to obtainand maintain meaningful patent protection for certain of our products throughout the world. Patent law relating to the scope of claimsin the biotechnology, regenerative medicine, and medical device fields in which we operate is still evolving. The degree of future protectionfor our proprietary rights is uncertain. We may rely on patents to protect a significant part of our intellectual property and to enhanceour competitive position. However, our presently pending or future patent applications may not be accepted and patents might not be issued,and any patent previously issued to us may be challenged, invalidated, held unenforceable or circumvented. Furthermore, the claims inpatents which have been issued or which may be issued to us in the future may not be sufficiently broad to prevent third parties fromproducing competing products similar to our products. We may also operate in countries where we do not have patent rights and in thosecountries we would not have patent protection. We also rely on trademarks and trade names in our business. The laws of various foreigncountries in which we compete may not protect our intellectual property to the same extent as do the laws of the U.S. If we fail to obtainadequate patent protection for our proprietary technology, our ability to be commercially competitive could be materially impaired. Itis also possible that our intellectual property may be stolen via cyber-attacks or similar methods.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In addition to patent protection, we also rely on protection of tradesecrets, know-how and confidential and proprietary information. To maintain the confidentiality of trade-secrets and proprietary information,we generally seek to enter into confidentiality agreements with our employees, consultants and strategic partners upon the commencementof a relationship. However, we may not be able to obtain these agreements in all circumstances in part due to local regulations. In theevent of unauthorized use or disclosure of this information, these agreements, even if obtained, may not provide meaningful protectionfor our trade-secrets or other confidential information. In addition, adequate remedies may not exist in the event of unauthorized useor disclosure of this information. The loss or exposure of our trade secrets and other proprietary information would impair our competitiveadvantages and could have a materially adverse effect on our operating results, financial condition and future growth prospects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Our competitors and potential competitors may have greater resourcesthan we have and may develop products and technologies that are more effective or commercially attractive than our products and technologiesor may develop competing relationships with our key collaborators.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We expect to compete with multiple pharmaceutical, biotechnology, medicaldevice and scientific research product companies. In addition, there are many academic and clinical centers that are developing bioengineeredor regenerative organ technologies that may one day become competitors for us. Many of our competitors and potential competitors havesubstantially greater financial, technological, research and development, marketing, and personnel resources than we do. We cannot, withany accuracy, forecast when or if these companies are likely to bring bioengineered organ or regenerative medicine products to marketfor indications that we are also pursuing. Many of these potential competitors may be further along in the process of product developmentand also operate large, company-funded research and development programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We expect that other products will compete with our current and futureproducts based on efficacy, safety, cost, and intellectual property positions. While we believe that these will be the primary competitivefactors, other factors include obtaining marketing exclusivity under certain regulations, availability of supply, manufacturing, marketingand sales expertise and capability, and reimbursement coverage. Our competitors may develop or market products that are more effectiveor commercially attractive than our current or future products and may also develop competing relationships with our key collaborators.In addition, we may face competition from new entrants into the field. We may not have the financial resources, technical expertise ormarketing, distribution or support capabilities to compete successfully in the future. The effects of any such actions of our competitorsmay have a materially adverse effect on our business, operating results and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 24; Value: 17 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         21         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         If we do not successfully manage our growth, our business goalsmay not be achieved.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        To manage growth, we will be required to continue to improve existing,and implement additional, operational and financial systems, procedures and controls, and hire, train and manage additional employees.Our current and planned personnel, systems, procedures and controls may not be adequate to support our anticipated growth and we may notbe able to hire, train, retain, motivate and manage required personnel. Competition for qualified personnel in the biotechnology and regenerativemedicine area is intense, and we operate or plan to operate in geographic locations where labor markets are particularly competitive,including Boston, Massachusetts, where demand for personnel with these skills is extremely high and is likely to remain high. As a result,competition for qualified personnel is intense and the process of hiring suitably qualified personnel is often lengthy and expensive,and may become more expensive in the future. If we are unable to hire and retain a sufficient number of qualified employees or otherwisemanage our growth effectively, our ability to conduct and expand our business could be seriously reduced.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         All or a portion of the PPP Loan may not be forgivable and our applicationfor the PPP Loan could in the future be determined to have been impermissible which could adversely impact our business and reputation.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On May 4, 2020, we obtained a loan (the “Loan”) from theBank of America (the “Lender”) in the aggregate amount of $404,221, pursuant to the Paycheck Protection Program (the “PPP”),established as part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”). Our application for thePPP Loan could in the future be determined to have been impermissible which could adversely impact our business and reputation. Underthe CARES Act, we may be eligible to apply for forgiveness of all loan proceeds used to pay payroll costs, rent, utilities and other qualifyingexpenses, provided that we retain a certain number of employees and maintain compensation within certain regulatory parameters of thePPP. However, we cannot provide any assurance that we will be eligible for loan forgiveness or that any amount of the PPP Loan will ultimatelybe forgiven.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In applying for the PPP Loan, we were required to certify, among otherthings, that the then current economic uncertainty made the PPP Loan necessary to support our ongoing operations. We made these certificationsin good faith after analyzing, among other things, the requirements of the PPP loan, our current business activity and our ability toaccess other sources of liquidity sufficient to support our ongoing operations in a manner that would not be significantly detrimentalto our business. We believe that we satisfied all eligibility criteria for the PPP Loan, and that our receipt of the PPP Loan was consistentwith the broad objectives of the PPP of the CARES Act. The certification regarding necessity described above did not at the time containany objective criteria and continues to be subject to interpretation. If, despite our good-faith belief that we satisfied all eligibilityrequirements for the PPP Loan, we are later determined to have violated any of the laws or governmental regulations that apply to us inconnection with the PPP Loan, or it is otherwise determined that we were ineligible to receive the PPP Loan, we may be subject to civil,criminal and administrative penalties. Any violations or alleged violations may result in adverse publicity and damage to our reputation,a review or audit by the SBA or other government entity or claims under the False Claims Act. These events could consume significant financialand management resources and could have a material adverse effect on our business, results of operations and financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 25; Value: 17 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         22         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Associated with Clinical Trials and Pre-Clinical Development        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         The results of our clinical trials or pre-clinicaldevelopment efforts may not support our product claims or may result in the discovery of adverse side effects.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Even if our pre-clinical development efforts or clinical trialsare completed as planned, we cannot be certain that their results will support our product claims or that the U.S. Food and DrugAdministration (FDA), foreign regulatory authorities or notified bodies will agree with our conclusions regarding them. Although wehave obtained some positive results from the use of our scaffolds and bioreactors for esophageal and trachea implants performed todate, we also discovered that our first-generation trachea product design encountered certain body response issues that we havesought to resolve with our ongoing development of our Cellframe implant design. We cannot be certain that our Cellframe implantdesign or any future modifications or improvements with respect thereto will support our claims, and any such developments mayresult in the discovery of further adverse side effects. We also may not see positive results when our products undergo clinicaltesting in humans in the future. Success in pre-clinical studies and early clinical trials does not ensure that later clinicaltrials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinicalstudies. Our pre-clinical development efforts and any clinical trial process may fail to demonstrate that our products are safe andeffective for the proposed indicated uses, which could cause us to abandon a product and may delay development of others. Also,patients receiving surgeries using our products under compassionate use or in clinical trials may experience significant adverseevents following the surgeries, including serious health complications or death, which may or may not be related to materialsprovided by us. In 2017, our Cellspan Esophageal Implant (CEI) product candidate was used in a human surgery at Mayo Clinic via anFDA-approved single-use expanded access application. In 2013 and 2014 we had provided a previous generation trachea scaffold devicethat was used in implants in human patients under compassionate use. To date, we believe that at least four of the six patients whoreceived those tracheal implants have died. While we believe that none of those patients died because of a failure of the applicabledevice, these and any other such adverse events have and may cause or contribute to the delay or termination of our clinical trialsor pre-clinical development efforts. Any delay or termination of our pre-clinical development efforts or clinical trials will delaythe filing of our product submissions and, ultimately, our ability to commercialize our products and generate revenues. It is alsopossible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of theproduct’s profile.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Clinical trials necessary to support a biologicalproduct license or other marketing authorization for our products will be expensive and will require the enrollment of sufficient patientsto adequately demonstrate safety and efficacy for the product’s target populations. Suitable patients may be difficult to identifyand recruit. Delays or failures in our clinical trials will prevent us from commercializing any products and will adversely affect ourbusiness, operating results and prospects.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In the U.S., initiating and completing clinical trials necessary tosupport Biological License Applications (BLAs), will be time consuming, expensive and the outcome uncertain. Moreover, the FDA may notagree that clinical trial results support an application for the indications sought in the application for the product. In other jurisdictionssuch as the E.U., the conduct of extensive and expensive clinical trials may also be required in order to demonstrate the quality, safetyand efficacy of our products, depending on each specific product, the claims being studied, and the target condition or disease. The outcomeof these clinical trials, which can be expensive and are heavily regulated, will also be uncertain. Moreover, the results of early clinicaltrials are not necessarily predictive of future results, and any product we advance into clinical trials following initial positive resultsin early clinical trials may not have favorable results in later clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Conducting successful clinical trials will require the enrollment ofa sufficient number of patients to support each trial’s claims, and suitable patients may be difficult to identify and recruit.Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the sizeof the patient population, the nature of the trial protocol, the attractiveness of, or the discomfort and risks associated with, the treatmentsreceived by enrolled subjects, the availability of appropriate clinical trial investigators, support staff, and proximity of patientsto clinical sites and ability to comply with the eligibility and exclusion criteria for participation in the clinical trial and patientcompliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergoextensive post-treatment procedures or follow-up to assess the safety and effectiveness of our products, or if they determine that thetreatments received under the trial protocols are not attractive or involve unacceptable risks or discomfort. Also, patients may not participatein our clinical trials if they choose to participate in contemporaneous clinical trials of competitive products. In addition, patientsparticipating in clinical trials may die before completion of the trial or suffer adverse medical events unrelated to investigationalproducts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Development of sufficient and appropriate clinical protocols to demonstratesafety and efficacy are required and we may not adequately develop such protocols to support clearance and approval. Further, the FDAand foreign regulatory authorities may require us to submit data on a greater number of patients than we originally anticipated and/orfor a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. Delays inpatient enrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs and delays inthe approval and attempted commercialization of our products or result in the failure of the clinical trial. In addition, despite considerabletime and expense invested in our clinical trials, the FDA and foreign regulatory authorities may not consider our data adequate to demonstratesafety and efficacy. Although FDA regulations allow submission of data from clinical trials outside the U.S., there can be no assurancethat such data will be accepted or that the FDA will not apply closer scrutiny to such data. Increased costs and delays necessary to generateappropriate data, or failures in clinical trials could adversely affect our business, operating results and prospects. In the U.S., clinicalstudies for our products will be reviewed through the Investigational New Drug (IND), pathway for biologics or combination products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 26; Value: 17 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         23         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         If the third parties on which we rely to conductour clinical trials and to assist us with pre-clinical development do not perform as contractually-required or expected, we may not beable to obtain regulatory approval for or commercialize our products.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We do not have the ability to independently conduct our pre-clinicaland clinical trials for our products and we must rely on third parties, such as contract research organizations, medical institutions,clinical investigators and contract laboratories to conduct, or assist us in conducting, such trials, including data collection and analysis.We do not have direct control over such third parties’ personnel or operations. If these third parties do not successfully carryout their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if thequality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or any regulatory requirements,or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, andwe may not be able to seek or obtain regulatory approval for, or successfully commercialize, our products on a timely basis, if at all.Our business, operating results and prospects may also be adversely affected. Furthermore, any third-party clinical trial investigatorspertaining to our products may be delayed in conducting our clinical trials for reasons outside of their control.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Associated with Regulatory Approvals        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         If we fail to obtain, or experience significantdelays in obtaining, regulatory approvals in the U.S., China or the E.U. for our products, including those for the esophagus and airways,or are unable to maintain such clearances or approvals for our products, our ability to commercially distribute and market these productswould be adversely impacted.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We currently do not have regulatory approval to market any of our implantproducts, including those for the esophagus and airways (trachea and bronchus). Our products are subject to rigorous regulation by theFDA, and numerous other federal and state governmental authorities in the U.S., as well as foreign governmental authorities. In the U.S.,the FDA permits commercial distribution of new medical products only after approval of a Premarket Approval (PMA), New Drug Application(NDA) or BLA, unless the product is specifically exempt from those requirements. A PMA, NDA or BLA must be supported by extensive data,including, but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling data, to demonstrate to the FDA’ssatisfaction the safety and efficacy of the product for its intended use. There are similar approval processes in China, the E.U. andother foreign jurisdictions. Our failure to receive or obtain such clearances or approvals on a timely basis or at all would have an adverseeffect on our results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The first bioengineered trachea implant approved in the U.S. usingour first-generation trachea scaffold in an implant was approved under the IND pathway through the FDA’s Center for Biologics Evaluationand Research (CBER) for a single compassionate use. Such initial U.S. surgery was led by Professor Paolo Macchiarini, M.D., a surgeonpioneering tracheal replacement techniques. Dr. Macchiarini was not employed or affiliated with our company, and we did not pay him anycompensation or consulting fees. In June 2014, shortly after our Chief Medical Officer joined our company, we ceased support of any humansurgeries with Dr. Macchiarini. Since the time we withdrew from involvement with Dr. Macchiarini, allegations that Dr. Macchiarini hadfailed to obtain informed consent and accurately report patient conditions, among other things, for surgeries performed at the KarolinskaInstitutet in Stockholm, Sweden, were made public.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Karolinska Institutet investigated the allegations and concludedthat while in some instances Dr. Macchiarini did act without due care, his actions did not qualify as scientific misconduct. Subsequentto this investigation, further negative publicity and claims continued to be released questioning the conduct of Dr. Macchiarini, theKarolinska Institutet, the Krasnodar Regional Hospital in Krasnodar, Russia as well as our company relating to surgeries performed byDr. Macchiarini and other surgeons at such facilities. In February 2015, the Karolinska Institutet announced that it would conduct anadditional investigation into the allegations made about Dr. Macchiarini and the Karolinska Institutet’s response and actions inthe earlier investigation. In March 2015, the Karolinska Institutet announced that it was terminating Dr. Macchiarini’s employment,and in December 2016 the Karolinska Institutet found Dr. Macchiarini, along with three co-authors, guilty of scientific misconduct. Theseallegations, the results of the investigation and any further actions that may be taken in connection with these matters, have and maycontinue to harm the perception of our product candidates or company and make it difficult to recruit patients for any clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">        <b>         <i>         </i>        </b>       </p>       <!-- Field: Page; Sequence: 27; Value: 17 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         24         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         The FDA has informed us that our CEI would be viewed by the FDAas a combination product comprised of a biologic (cells) and a medical device component. Nevertheless, we cannot be certain how the FDAwill regulate our products. The FDA may require us to obtain marketing clearance and approval from multiple FDA centers. The review ofcombination products is often more complex and more time consuming than the review of products under the jurisdiction of only one centerwithin the FDA.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        While the FDA has informed us that our CEI would be regulated by theFDA as a combination product, we cannot be certain that any of our other products would also be regulated by the FDA as a combinationproduct. For a combination product, the Office of Combination Products (OCP) within FDA can determine which center or centers within theFDA will review the product and under what legal authority the product will be reviewed. Generally, the center within the FDA that hasthe primary role in regulating a combination product is determined based on the primary mode of action of the product. Generally, if theprimary mode of action is as a device, the FDA’s Center for Devices and Radiological Health (CDRH) takes the lead. Alternatively,if the primary mode of action is cellular, then the CBER takes the lead. On October 18, 2016, we also received written confirmation fromthe CBER that the FDA intends to regulate our CEI as a combination product under the primary jurisdiction of CBER. We further understandthat CBER may choose to consult or collaborate with CDRH with respect to the characteristics of the synthetic scaffold component of ourproduct based on CBER’s determination of need for such assistance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The process of obtaining FDA marketing approval is lengthy, expensive,and uncertain, and we cannot be certain that our products, including products pertaining to the esophagus, airways, or otherwise, willbe cleared or approved in a timely fashion, or at all. In addition, the review of combination products is often more complex and can bemore time consuming than the review of a product under the jurisdiction of only one center within the FDA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We cannot be certain that the FDA will not elect to have our combinationproducts reviewed and regulated by only one FDA center and/or different legal authority, in which case the path to regulatory approvalwould be different and could be more lengthy and costly.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        If the FDA does not approve or clear our products in a timely fashion,or at all, our business and financial condition will be adversely affected.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         In the E.U., our esophagus product will likely be regulated as acombined advanced therapy medicinal product and our other products, including for the trachea or bronchus, may also be viewed as advancedtherapy medicinal products, which could delay approvals and clearances and increase costs of obtaining such approvals and clearances.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On May 28, 2014, we received notice from the European Medicines Agency(EMA) that our first-generation trachea product would be regulated as a combined advanced therapy medicinal product. While we have nothad any formal interaction with the EMA with respect to our Cellframe implant technology, including pertaining to the esophagus, we believethat such implant technology would likely be regulated as a combined advanced therapy medicinal product. In the event of such classification,it would be necessary to seek a marketing authorization for these products granted by the European Commission before being marketed inthe E.U.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Other products we may develop, including any products pertaining tothe airways or otherwise, may similarly be regulated as advanced therapy medicinal products or combined advanced therapy medicinal products.The regulatory procedures leading to marketing approval of our products vary among jurisdictions and can involve substantial additionaltesting. Compliance with the FDA requirements does not ensure clearance or approval in other jurisdictions, and the ability to legallymarket our products in any one foreign country does not ensure clearance, or approval by regulatory authorities in other foreign jurisdictions.The foreign regulatory process leading to the marketing of the products may include all of the risks associated with obtaining FDA approvalin addition to other risks. In addition, the time required to comply with foreign regulations and market products may differ from thatrequired to obtain FDA approval, and we may not obtain foreign approval or clearance on a timely basis, if at all.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <!-- Field: Page; Sequence: 28; Value: 17 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         25         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Risk Associated with Product Marketing        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Even if our products are cleared or approved by regulatory authorities,if we or our suppliers fail to comply with ongoing FDA or other foreign regulatory authority requirements, or if we experience unanticipatedproblems with our products, these products could be subject to restrictions or withdrawal from the market.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Any product for which we obtain clearance or approval in the U.S.,China, or Europe, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities forsuch product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreignregulatory authorities or notified bodies. In particular, we and our suppliers are required to comply with the FDA’s Quality SystemRegulations (QSR), and current Good Manufacturing Practices (cGMP), for our medical products, and International Standards Organization(ISO), regulations for the manufacture of our products and other regulations which cover the methods and documentation of the design,testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which we obtain clearanceor approval. Manufacturing may also be subject to controls by the FDA for parts of the system or combination products that the FDA mayfind are controlled by the biologics regulations. Equivalent regulatory obligations apply in foreign jurisdictions. Regulatory authorities,such as the FDA, China’s National Medical Products Administration, the competent authorities of the E.U. Member States, the EMAand notified bodies, enforce the QSR, cGMP and other applicable regulations in the U.S. and in foreign jurisdictions through periodicinspections. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA andother regulatory authorities or notified bodies in the U.S. or in foreign jurisdictions, or the failure to timely and adequately respondto any adverse inspectional observations or product safety issues, could result in, among other things, any of the following enforcementactions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           unanticipated expenditures to address or defend such actions;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           customer notifications for repair, replacement, or refunds;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           recall, detention or seizure of our products;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           operating restrictions or partial suspension or total shutdown of production;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           withdrawing BLA or NDA approvals that have already been granted;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%; text-align: justify">           withdrawal of the marketing authorization granted by the European Commission or delay in obtaining such marketing authorization;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%; text-align: justify">           withdrawal of the CE Certificates of Conformity granted by the notified body or delay in obtaining these certificates;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           refusal to grant export approval for our products; and          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           criminal prosecution.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Post-market enforcement actions can generateadverse commercial consequences.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Even if regulatory approval of a product is granted, such clearanceor approval may be subject to limitations on the intended uses for which the product may be marketed and reduce our potential to successfullycommercialize the product and generate revenue from the product. If the FDA or a foreign regulatory authority determines that our promotionalmaterials, labeling, training or other marketing or educational activities constitute promotion of an unapproved use, it could requestthat we cease or modify our training or promotional materials or subject us to regulatory enforcement actions. It is also possible thatother federal, state or foreign enforcement authorities might take action if they consider our training or other promotional materialsto constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities,such as laws prohibiting false claims for reimbursement. In addition, we may be required to conduct costly post-market testing and surveillanceto monitor the safety or effectiveness of our products, and we must comply with medical products reporting requirements, including thereporting of adverse events and malfunctions related to our products. Later discovery of previously unknown problems with our products,including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure tocomply with regulatory requirements such as QSR, may result in changes to labeling, restrictions on such products or manufacturing processes,withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of anymedical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the impositionof civil or criminal penalties which would adversely affect our business, operating results and prospects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 29; Value: 17 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         26         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Related to Our Separation from Harvard Bioscience        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         We may have received better terms from unaffiliated third partiesthan the terms we received in our agreements with Harvard Bioscience.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The agreements related to the Separation, including the separationand distribution agreement, tax sharing agreement, transition services agreement and the other agreements, were negotiated in the contextof the Separation while we were still part of Harvard Bioscience and, accordingly, may not reflect terms that would have resulted fromarm’s-length negotiations among unaffiliated third parties. The terms of the agreements we negotiated in the context of the Separationrelated to, among other things, allocation of assets, liabilities, rights, indemnifications and other obligations among Harvard Bioscienceand us. We may have received better terms from third parties because third parties may have competed with each other to win our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Third parties may seek to hold us responsible for liabilities ofHarvard Bioscience that we did not assume in our agreements.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In connection with the Separation, Harvard Bioscience has generallyagreed to retain all liabilities that did not historically arise from our business. Third parties may seek to hold us responsible forHarvard Bioscience’s retained liabilities. Under our agreements with Harvard Bioscience, Harvard Bioscience has agreed to indemnifyus for claims and losses relating to these retained liabilities. However, if those liabilities are significant and we are ultimately liablefor them, we cannot assure you that we will be able to recover the full amount of our losses from Harvard Bioscience.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Any disputes that arise between us and Harvard Bioscience with respectto our past and ongoing relationships could harm our business operations.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Disputes may arise between Harvard Bioscience and us in a number ofareas relating to our past and ongoing relationships, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           intellectual property, technology and business matters, including failure to make required technology transfers and failure to comply with non-compete provisions applicable to Harvard Bioscience and us;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           labor, tax, employee benefit, indemnification and other matters arising from the Separation;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           distribution and supply obligations;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           employee retention and recruiting;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           business combinations involving us;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           sales or distributions by Harvard Bioscience of all or any portion of its ownership interest in us; and          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           business opportunities that may be attractive to both Harvard Bioscience and us.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We may not be able to resolve any potential conflicts, and even ifwe do, the resolution may be less favorable than if we were dealing with a different party.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 30; Value: 17 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         27         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risks Relating to Our Common Stock        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Our principal stockholders hold a majority of voting power and willbe able to exert significant control over us.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         The stockholderswho purchased shares of our common stock and related warrants pursuant to a Securities Purchase Agreement dated December 27, 2017 collectivelyhold shares of common stock that represent approximately 37% of all outstanding voting power, and as such may significantly influencethe results of matters voted on by our shareholders. The interests of these stockholders may conflict with your interests. These stockholdershave the right to nominate a majority of our Board of Directors and, therefore, effectively could control many other major decisions regardingour operations.        </font>        This significant concentration of share ownership may adversely affect the trading price for our        <font style="font-family: Times New Roman, Times, Serif">         commonstock        </font>        because investors may perceive disadvantages in owning stock in companies with controlling stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         A trading market that will provide you with adequate liquidity maynot develop for our common stock.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The current public market for our common stock has limited tradingvolume and liquidity. We cannot predict the extent to which investor interest in our company will lead to the development of a more activetrading market in our common stock, or how liquid that market might be.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Our revenues, operating results and cash flows may fluctuate infuture periods and we may fail to meet investor expectations, which may cause the price of our common stock to decline.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Variations in our quarterly and year-end operating results are difficultto predict and may fluctuate significantly from period to period. If our revenues or operating results fall below the expectations ofinvestors or securities analysts, the price of our common stock could decline substantially. In addition to the other factors discussedunder these “Risk Factors,” specific factors that may cause fluctuations in our operating results include:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           demand and pricing for our products;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           government or private healthcare reimbursement policies;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           adverse events or publicity related to our products, our research or investigations, or our collaborators or other partners;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           physician and patient acceptance of any of our current or future products;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           manufacturing stoppages or delays;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           introduction of competing products or technologies;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           our operating expenses which fluctuate due to growth of our business; and          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 6%">           •          </td>          <td style="width: 93%">           timing and size of any new product or technology acquisitions we may complete.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Any issuance of preferred stock in the future may dilute the rightsof our common stockholders.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our Board of Directors has the authority to issue up to 2,000,000 sharesof preferred stock and to determine the price, privileges and other terms of these shares. Our Board of Directors is empowered to exercisethis authority without any further approval of stockholders. The rights of the holders of common stock may be adversely affected by therights of future holders of preferred stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have in the past issued, and we may at any time in the future issue,additional shares of authorized preferred stock. For example, in our December 2017 private placement transaction, we authorized 12,000shares of Series D convertible preferred stock, of which we issued 3,108 shares, all of which have been converted into shares of commonstock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <!-- Field: Page; Sequence: 31; Value: 17 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         28         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         We do not intend to pay cash dividends on our common stock.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Currently, we do not anticipate paying any cash dividends to holdersof our common stock. As a result, capital appreciation, if any, of our common stock will be a stockholder’s sole source of gain.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Our common stock has been delisted on the NASDAQ Capital Market,which may negatively impact the trading price of our common stock and the levels of liquidity available to our stockholders.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our common stock was suspended from trading on the NASDAQ Capital Market,prior to the opening of the market on October 6, 2017 and began quotation on the OTCQB Venture Market on that date, retaining the symbol “BSTG”. On December 7, 2017, the NASDAQ Capital Market filed a Form 25-NSE with the SEC to complete the delisting process.The trading of our common stock on the OTCQB Venture Market rather than The NASDAQ Capital Market may negatively impact the trading priceof our common stock and the levels of liquidity available to our stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Upon such delisting, our common stock became subject to the regulationsof the SEC relating to the market for penny stocks. A penny stock is any equity security not traded on a national securities exchangethat has a market price of less than $5.00 per share. The regulations applicable to penny stocks may severely affect the market liquidityfor our common stock and could limit the ability of shareholders to sell securities in the secondary market. Accordingly, investors inour common stock may find it more difficult to dispose of or obtain accurate quotations as to the market value of our common stock, andthere can be no assurance that our common stock will continue to be eligible for trading or quotation on the OTCQB Venture Market or anyother alternative exchanges or markets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The delisting of our common stock from the NASDAQ Capital Market mayadversely affect our ability to raise additional financing through public or private sales of equity securities, may significantly affectthe ability of investors to trade our securities, and may negatively affect the value and liquidity of our common stock. Such delistingmay also have other negative results, including the potential loss of confidence by employees, the loss of institutional investor interestand fewer business development opportunities. Furthermore, because of the limited market and low volume of trading in our common stockthat could occur, the share price of our common stock could more likely be affected by broad market fluctuations, general market conditions,fluctuations in our operating results, changes in the market’s perception of our business, and announcements made by us, our competitors,parties with whom we have business relationships or third parties.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 32; Value: 17 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         29         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Split-Segment; Name: split 4 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         General Risk Factors        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         The ongoing COVID-19 pandemic has and may continue to affect ourability to initiate, resume and complete current or future preclinical studies or clinical trials, disrupt regulatory activities or haveother adverse effects on our business and operations. In addition, this pandemic may continue to adversely impact economies worldwide,which could result in adverse effects on our business and operations.         <b>         </b>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The ongoing COVID-19 pandemic has caused many governments to implementmeasures to slow the spread of the outbreak through quarantines, travel restrictions, heightened border scrutiny, and other measures.The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses andcommerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demandfor certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such astravel, has fallen. The future progression of the outbreak and its effects on our business and operations are uncertain.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We and our third-party manufacturers and prospective contract researchorganizations, or CROs, may face disruptions that may affect our ability to initiate, resume and complete preclinical studies or clinicaltrials, including disruptions in procuring items that are essential for our research and development activities, including, for example,raw materials used in the manufacturing of our product candidates, and laboratory supplies for our current and future preclinical studiesand clinical trials, in each case, for which there may be shortages because of ongoing efforts to address the outbreak. We and our third-partymanufacturers and prospective CROs, may face disruptions or future clinical trials arising from delays in IND-enabling studies, manufacturingdisruptions, and the ability to obtain necessary institutional review board or other necessary site approvals, as well as other delaysat clinical trial sites.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We may also face difficulties recruiting or enrolling patients forfuture clinical trials if patients are affected by the COVID-19 virus or are fearful of visiting or traveling to clinical trial sitesbecause of the outbreak.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The response to the COVID-19 pandemic may redirect resources with respectto regulatory and intellectual property matters in a way that would adversely impact our ability to progress regulatory approvals andprotect our intellectual property. For example, the FDA has announced that in order to bring new therapies to patients sick with COVID-19as quickly as possible, it has redeployed medical and regulatory staff from other areas to work on COVID-19 therapies. In addition, wemay face impediments to regulatory meetings and approvals due to measures intended to limit in-person interactions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have modified our business practices, including implementing a workfrom home policy for all employees who are able to perform their duties remotely and restricting all nonessential travel, and we expectto continue to take actions as may be required or recommended by government authorities or as we determine are in the best interests ofour employees, and other business partners in light of COVID-19. In the event of a continuation of shelter-in-place orders and/or othermandated local travel restrictions, our employees conducting research and development activities may not be able to access our researchspace, and our core activities may be significant limited or curtailed, possibly for an extended period of time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The pandemic has already caused significant disruptions in the financialmarkets, and may continue to cause such disruptions, which could impact our ability to raise additional funds through public offeringsand may also impact the volatility of our stock price and trading in our stock. Moreover, it is possible the pandemic will significantlyimpact economies worldwide, which could result in adverse effects on our business and operations. We cannot be certain what the overallimpact of the COVID-19 pandemic will be on our business and it has the potential to adversely affect our business, financial condition,results of operations and prospects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 33; Options: NewSection; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         30         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         We are subject to new U.S. foreign investment regulations, whichmay impose additional burdens on or may limit certain investors’ ability to purchase our common stock, potentially making our commonstock less attractive to investors, and may also impact our ability to generate revenues outside of the U.S.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In October 2018, the U.S. Department of Treasuryannounced a pilot program to implement part of the FIRRMA, effective November 10, 2018. The pilot program expands the jurisdictionof CFIUS to include certain direct or indirect foreign investments in a defined category of U.S. companies, which may include companiessuch as Biostage in the biotechnology industry. Among other things, FIRRMA empowers CFIUS to require certain foreign investors tomake mandatory filings and permits CFIUS to charge filing fees related to such filings. Such filings are subject to review by CFIUS. Anysuch restrictions on the ability to purchase shares of our common stock may have the effect of delaying or deterring any particular investmentand could also affect the price that some investors are willing to pay for our common stock. In addition, such restrictions could alsolimit the opportunity for our stockholders to receive a premium for their shares of our common stock in relation to any potential changein control.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We intend to generate significant revenues outsidethe U.S., including in China. Restrictions, such as those related to CFIUS, not only affect foreign ownership and investments, but alsothe transfer or licensing of technology from the U.S. into certain foreign markets, including China. Such restrictions, including to theextent they block strategic transactions that might otherwise be in shareholders’ interests, may materially and adversely affectour ability to generate revenues in those foreign markets and the results of our operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         If we incur higher costs as a result of trade policies, treaties,government regulations or tariffs, it could have a materially adverse effect on our business, financial condition or results of operations.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There is currently significant uncertainty about the future relationshipbetween the United States and China, including with respect to trade policies, treaties, government regulations and tariffs. The currentU.S. administration has called for substantial changes to U.S. foreign trade policy including greater restrictions on international tradeand significant increases in tariffs on goods imported into the U.S. Under the current status, we do not expect that this tariff willsignificantly impact any Biostage products and thus the tariff should not have a materially adverse effect on our business, financialcondition or results of operations. We are unable to predict whether or when additional tariffs will be imposed or the impact of any suchfuture tariff increases.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         We are exposed to a variety of risks relating to our internationalsales and operations, including fluctuations in exchange rates, local economic conditions and delays in collection of accounts receivable.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We intend to generate significant revenues outside the U.S. in multipleforeign currencies including Chinese Renminbi, Euros, British pounds, and in U.S. dollar-denominated transactions conducted with customerswho generate revenue in currencies other than the U.S. dollar. For those foreign customers who purchase our products in U.S. dollars,currency fluctuations between the U.S. dollar and the currencies in which those customers do business may have a negative impact on thedemand for our products in foreign countries where the U.S. dollar has increased in value compared to the local currency.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Since we may have vendors and customers outside the U.S. and we maygenerate revenues and incur operating expenses in multiple foreign currencies, we will experience currency exchange risk with respectto any foreign currency-denominated revenues and expenses. We cannot predict the consolidated effects of exchange rate fluctuations uponour future operating results because of the number of currencies involved, the variability of currency exposure and the potential volatilityof currency exchange rates. Our international activities subject us to laws regarding sanctioned countries, entities and persons, customs,import-export, laws regarding transactions in foreign countries, the U.S. Foreign Corrupt Practices Act and local anti-bribery and otherlaws regarding interactions with healthcare professionals. Among other things, these laws restrict, and in some cases prohibit, U.S. companiesfrom directly or indirectly selling goods, technology or services to people or entities in certain countries. In addition, these lawsrequire that we exercise care in structuring our sales and marketing practices in foreign countries.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Local economic conditions, legal, regulatory or political considerations,disruptions from strikes, the effectiveness of our sales representatives and distributors, local competition and changes in local medicalpractice could also affect our sales to foreign markets. Relationships with customers and effective terms of sale frequently vary by country,often with longer-term receivables than are typical in the U.S.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <!-- Field: Page; Sequence: 34; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         31         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Comprehensive tax reform legislation could adversely affect ourbusiness and financial condition.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In December 2017, the U.S. government enacted the Tax Cuts and JobsAct of 2017 (TCJA), which significantly reforms the Internal Revenue Code of 1986, as amended. The TCJA, among other things, containssignificant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rateof 21%, effective January 1, 2018; limitation of the tax deduction for interest expense; limitation of the deduction for net operatinglosses and elimination of net operating loss carrybacks, in each case, for losses arising in taxable years beginning after December 31,2017 (though any such tax losses may be carried forward indefinitely); and modifying or repealing many business deductions and credits,including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseasesor conditions generally referred to as “orphan drugs”. The tax rate change resulted in (i) a reduction in the gross amountof our deferred tax assets recorded as of December 31, 2017, without an impact on the net amount of our deferred tax assets, which arerecorded with a full valuation allowance. We continue to examine the impact this tax reform legislation may have on our business. However,the effect of the TCJA on us and our affiliates, whether adverse or favorable, is uncertain and may not become evident for some periodof time. We urge investors to consult with their legal and tax advisers regarding the implications of the TCJA on an investment in ourcommon stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Changes in the European regulatory environment regarding privacyand data protection regulations could have a materially adverse impact on our results of operations.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The European Union (E.U.) has adopted a comprehensive overhaul of itsdata protection regime in the form of the General Data Protection Regulation (GDPR), which came into effect in May 2018. GDPR extendsthe scope of the existing E.U. data protection law to foreign companies processing personal data of E.U. residents. The regulation imposesa strict data protection compliance regime with severe penalties of 4% of worldwide turnover or €20 million, whichever is greater,and includes new rights such as the right of erasure of personal data. Although the GDPR will apply across the E.U., as has been the caseunder the current data protection regime, E.U. Member States have some national derogations and local data protection authorities thatwill still have the ability to interpret the GDPR, which has the potential to create inconsistencies on a country-by-country basis. Implementationof, and compliance with the GDPR could increase our cost of doing business and/or force us to change our business practices in a manneradverse to our business. In addition, violations of the GDPR may result in significant fines, penalties and damage to our brand and businesswhich could, individually or in the aggregate, materially harm our business and reputation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Healthcare legislative reform measures mayhave a materially adverse effect on our business and results of operations.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In the United States, there have been and continue to be a number oflegislative initiatives to contain healthcare costs. For example, in March 2010, the Affordable Care Act (ACA) was passed, which substantiallychanges the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry.The ACA, among other things, subjects biological products to potential competition by lower-cost biosimilars, addresses a new methodologyby which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled,implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extendsthe rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturersof certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agreeto offer 50% (70% commencing January 1, 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiariesduring their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D. Someof the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to Judicial and Congressionalchallenges, as well as efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, PresidentTrump has signed two Executive Orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent someof the requirements for health insurance mandated by the ACA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Concurrently, Congress has considered legislation that would repealor repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting theimplementation of certain taxes under the ACA have been signed into law. The TCJA includes a provision repealing, effective January 1,2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coveragefor all or part of a year that is commonly referred to as the “individual mandate.” Additionally, on January 22, 2018, formerPresident Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandatedfees, including the so-called “Cadillac” tax, an annual fee on certain high-cost employer-sponsored insurance plans, the annualfee imposed on certain health insurance providers based on market share, and the Medical Device Excise Tax (MDET) on non-exempt medicaldevices. Since then, The Further Consolidated Appropriations Act, 2020 H.R. 1865, signed into law on December 20, 2019, repealed the MDET.Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amends the ACA, effective January 1, 2019, to reduce the coveragegap in most Medicare drug plans, commonly referred to as the “donut hole.” The effect that the ACA and its possible repealand replacement may have on our business remains unclear.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 35; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         32         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Other legislative changes have been proposed and adopted in the UnitedStates since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011, among other things, created measures for spendingreductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least$1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automaticreduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year.These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effectthrough 2027 unless additional congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signedinto law, which, among other things, further reduced Medicare payments to several types of providers.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Moreover, payment methodologies may be subject to changes in healthcarelegislation and regulatory initiatives. For example, the Middle Class Tax Relief and Job Creation Act of 2012 required that the Centersfor Medicare &amp; Medicaid Services (CMS), the agency responsible for administering the Medicare program, reduce the Medicare clinicallaboratory fee schedule by 2% in 2013, which served as a base for 2014 and subsequent years. In addition, effective January 1, 2014, CMSalso began bundling the Medicare payments for certain laboratory tests ordered while a patient received services in a hospital outpatientsetting. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limitthe amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand forany product candidate we develop or complementary diagnostics or companion diagnostics or additional pricing pressures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Additionally, there has been increasing legislative and enforcementinterest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressionalinquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing,reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reformgovernment program reimbursement methodologies for drugs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Any of these regulatory changes and events could limit our abilityto form collaborations and our ability to commercialize our products, and if we fail to comply with any such new or modified regulationsand requirements it could adversely affect our business, operating results and prospects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         If we fail to complete the required IRS formsfor exemptions, make timely semi-monthly payments of collected excise taxes, or submit quarterly reports as required by the MDET, we maybe subject to penalties, such as Section 6656 penalties for any failure to make timely deposits.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Section 4191 of the Internal Revenue Code, enacted by Section 1405of the Health Care and Education Reconciliation Act of 2010, Public Law 111-152 (124 Stat. 1029 (2010)), in conjunction with the PatientProtection and the ACA, Public Law 111-148 (124 Stat. 119 (2010)), imposed as of January 1, 2013, an excise tax on the sale of certainmedical devices. The MDET imposed by Section 4191 is 2.3% of the price for which a taxable medical device is sold within the U.S.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Substantial sales of common stock have and may continue to occur,or may be anticipated, which have and could continue to cause our stock price to decline.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We expect that we will seek to raise additional capital from time totime in the future, which may involve the issuance of additional shares of common stock, or securities convertible or exercisable intocommon stock. The purchasers of the shares of common stock and warrants to purchase shares of common stock from our public offerings andprivate placements= may sell significant quantities of our common stock in the market, which may cause a decline in the price of our commonstock. Further, we cannot predict the effect, if any, that any additional market sales of common stock, or anticipation of such sales,or the availability of those shares of common stock for sale will have on the market price of our common stock. Any future sales of significantamounts of our common stock, or the perception in the market that this will occur, may result in a decline in the price of our commonstock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         The market price of our shares may fluctuate widely.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The market price of our common stock may fluctuate widely, dependingupon many factors, some of which may be beyond our control, including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>           <font style="font-family: Symbol">           </font>          </td>          <td style="width: 94%">           the success and costs of preclinical and clinical testing and obtaining regulatory approvals or clearances for our products;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 94%">           the success or failure of surgeries and procedures involving the use our products;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 94%">           a shift in our investor base;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 94%">           our quarterly or annual results of operations, or those of other companies in our industry;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <!-- Field: Page; Sequence: 36; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         33         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 94%">           actual or anticipated fluctuations in our operating results due to factors related to our business;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 94%">           changes in accounting standards, policies, guidance, interpretations or principles;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 94%">           announcements by us or our competitors of significant acquisitions, dispositions or intellectual property developments or issuances;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 94%">           the failure of securities analysts to cover our common stock;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 94%">           changes in earnings estimates by securities analysts or our ability to meet those estimates;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 94%">           the operating and stock price performance of other comparable companies; our issuance of equity, debt or other financing instruments;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 94%">           overall market fluctuations; and          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">           <font style="font-family: Symbol">            ·           </font>          </td>          <td style="width: 94%">           general macroeconomic conditions.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Stock markets in general have experienced volatility that has oftenbeen unrelated to the operating performance of a particular company. These broad market fluctuations may adversely affect the tradingprice of our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Your percentage ownership will be diluted in the future.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Your percentage ownership will be diluted in the future because ofequity awards that we expect will be granted to our directors, officers and employees, as well as shares of common stock, or securitiesconvertible into common stock, we issue in connection with future capital raising or strategic transactions. Our Amended and RestatedEquity Incentive Plan provides for the grant of equity-based awards, including restricted stock, restricted stock units, stock options,stock appreciation rights and other equity-based awards to our directors, officers and other employees, advisors and consultants. Theissuance of any shares of our stock would dilute the proportionate ownership and voting power of existing security holders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Provisions of Delaware law, of our amended and restated charterand amended and restated bylaws may make a takeover more difficult, which could cause our stock price to decline.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Provisions in our amended and restated certificate of incorporationand amended and restated bylaws and in the Delaware corporate law may make it difficult and expensive for a third party to pursue a tenderoffer, change in control or takeover attempt, which is opposed by management and the Board of Directors. Public stockholders who mightdesire to participate in such a transaction may not have an opportunity to do so. We have a staggered Board of Directors that makes itdifficult for stockholders to change the composition of the Board of Directors in any one year. Any removal of directors will requirea super-majority vote of the holders of at least 75% of the outstanding shares entitled to be cast on the election of directors whichmay discourage a third party from making a tender offer or otherwise attempting to obtain control of us. These anti-takeover provisionscould substantially impede the ability of public stockholders to change our management and Board of Directors. Such provisions may alsolimit the price that investors might be willing to pay for shares of our common stock in the future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         We are a smaller reporting company and thereduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are a smaller reporting company (“SRC”) and a non-acceleratedfiler, which allows us to take advantage of exemptions from various reporting requirements that are applicable to other public companiesthat are not SRCs or non-accelerated filers, including not being required to comply with the auditor attestation requirements of Section404 of the Sarbanes-Oxley Act of 2002, as amended, reduced disclosure obligations, including disclosures regarding executive compensation,in our Annual Report and our periodic reports and proxy statements and providing only two years of audited financial statements in ourAnnual Report and our periodic reports. We will remain an SRC until (a) the aggregate market value of our outstanding common stock heldby non-affiliates as of the last business day our most recently completed second fiscal quarter exceeds $250 million or (b) in the eventwe have over $100 million in annual revenues, the aggregate market value of our outstanding common stock held by non-affiliates as ofthe last business day our most recently completed second fiscal quarter exceeds $700 million. We cannot predict whether investors willfind our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractiveas a result, there may be a less active trading market for our common stock and our stock price may be more volatile and may decline.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 37; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         34         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        <i>         We incur increased costs as a result of operatingas a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governancepractices.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.3pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        As a public company, we incur significant legal,accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform andConsumer Protection Act, FINRA rules and other applicable securities rules and regulations impose various requirements on public companies,including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our managementand other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulationsincrease our legal and financial compliance costs and make some activities more time-consuming and costly.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.3pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        We continue to evaluate these rules and regulationsand cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations areoften subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practicemay evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regardingcompliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 38; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         35         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_021">           </a>           <b>            Item 1B.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Unresolved Staff Comments.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_022">           </a>           <b>            Item 2.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Properties.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On November 1, 2013 we entered into a sublease of approximately 17,000square feet of mixed-use space of the facility located at 84 October Hill Road, Suite 11, Holliston, Massachusetts, which is our corporateheadquarters, from Harvard Bioscience. Our principal facilities incorporate manufacturing, laboratory, development, sales and marketing,and administration functions. We believe our current facilities are adequate for our needs for the foreseeable future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_023">           </a>           <b>            Item 3.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Legal Proceedings.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On April 14, 2017, representatives for the estate of a deceased individualfiled a civil lawsuit in the Suffolk Superior Court, in Boston, Massachusetts, against the Company, Harvard Bioscience and other defendants.The complaint alleges that the decedent’s injury and death were caused by two tracheal implants that incorporated synthetic tracheascaffolds and a biologic component combined by the implanting surgeon with a bioreactor, and surgically implanted in the decedent in twosurgeries performed in 2012 and 2013. The civil complaint seeks a non-specific sum of money to compensate the plaintiffs. This civil lawsuitrelates to the Company’s first-generation trachea scaffold technology for which the Company discontinued development in 2014, andnot to the Company’s current Cellframe technology nor to its lead development product candidate, the CEI. The litigation is in thediscovery stage and the Company intends to vigorously defend this case. While the Company believes that such claim lacks merit, the Companyis unable to predict the ultimate outcome of such litigation. In accordance with a separation and distribution agreement between HarvardBioscience and the Company relating to the spin-off, the Company would be required to indemnify Harvard Bioscience against losses thatHarvard Bioscience may suffer as a result of this litigation. The Company has been informed by its insurance provider that the case hasbeen accepted as an insurable claim under the Company’s product liability insurance policy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        From time to time, the Company may be involved in various claims andlegal proceedings arising in the ordinary course of business. Other than the above matter, there are no such matters pending that theCompany expects to be material in relation to its business, financial condition, and results of operations or cash flows.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_024">           </a>           <b>            Item 4.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Mine Safety Disclosures.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Not Applicable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 39; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         36         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="zz_026">        </a>        <b>         PART II        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_025">           </a>           <b>            Item 5.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Market Information        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our common stock was initially quoted on the OTCQB Venture Marketplaceat the opening of business on October 6, 2017 under the symbol “BSTG.” Prior to that time, our common stock traded on theNASDAQ Capital Market also under the symbol “BSTG.” From our initial public offering on October 21, 2013 until April 1, 2016,in connection with our name change, our common stock traded on the NASDAQ Capital Market under the symbol “HART.”       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There were 155 holders of record of our common stock as of April 8,2021, which does not include persons or entities that hold their stock in nominee or “street” name through various brokeragefirms. We believe that the number of beneficial owners of our common stock at that date was substantially greater.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Dividend Policy        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have never declared or paid cash dividends on our common stock inthe past and do not intend to pay cash dividends on our common stock in the foreseeable future. Any future determination to pay cash dividendswill be at the discretion of our Board of Directors and will depend on our financial condition, results of operations, capital requirementsand other factors our Board of Directors deems relevant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Recent Sales of Unregistered Securities        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During the fiscal year ended December 31, 2020, in addition to unregisteredsales we previously disclosed in our Quarterly Reports on Form 10-Q or in Current Reports on Form 8-K in relation to the applicable periods,we also completed the following transactions under the Securities Act of 1933 (the Securities Act) in reliance on the exemptions providedby Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the SecuritiesAct as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_027">           </a>           <b>            Item 6.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Selected Financial Data.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Not Applicable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 40; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         37         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_028">           </a>           <b>            Item 7.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Management’s Discussion and Analysis of Financial Condition and Results of Operations.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Forward-Looking Statements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         The following section of this Annual Report on Form 10-K entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contains statements that arenot statements of historical fact and are forward-looking statements within the meaning of federal securities laws. These statements involveknown and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materiallydifferent from any future results, performance or achievements expressed or implied by the forward-looking statements. These statementsreflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         In some cases, you can identify forward-looking statements by termssuch as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “could,” “would,” “target,” “seek,” “aim,” “believe,” “predicts,” “think,” “objectives,” “optimistic,” “new,” “goal,” “strategy,” “potential,” “is likely,” “will,” “expect,” “plan” “project,” “permit” and similar expressions intended to identify forward-looking statements. These statementsreflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. Given theseuncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detailin Item 1A.“Risk Factors” of this Annual Report on Form 10-K. You should carefully review all of these factors, as well asthe comprehensive discussion of forward-looking statements on page 1 of this Annual Report on Form 10-K.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Overview        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are a biotechnology company developing bioengineered organ implantsbased on our novel technology. Our technology is comprised of a proprietary biocompatible scaffold, which is the foundation of our Cellframe        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        technology, that is seeded with the recipient’s own mesenchymal stromal cells to form our Cellspan        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        implant, combining the clinically proven principles of tissue engineering, cell biology and materials science. This technology is beingdeveloped to treat life-threatening conditions of the esophagus, trachea and bronchus with the objective of dramatically improving thetreatment paradigm for those patients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 44pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe our technology will provide surgeons with new ways to addressdamage to the esophagus, bronchus, and trachea due to congenital abnormalities, diseases, infections and traumas. Products being developedbased on our technology for those indications are called Cellspan        <font style="font-size: 10pt">         <sup>          TM         </sup>        </font>        products. Our CellspanEsophageal Implant (CEI) product candidates have been our lead development product candidates. At this time our resources have been primarilyfocused on pursuing a development program that addresses conditions of the esophagus: esophageal atresia in pediatric patients and esophagealdisease in adult patients. Our Cellspan esophageal product candidate is intended to provide a surgical solution to stimulate regenerationof a segment of the esophagus missing due to a congenital abnormality or following surgical removal, to establish or reestablish the organ’scontinuity and integrity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We are working to develop a CEI product candidate to address newborns’esophageal atresia to provide a simpler, more effective and potentially organ-sparing solution.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        A portion of all patients diagnosed with esophageal diseases, infectionstraumas or congenital abnormalities are treated via a surgical procedure known as an esophagectomy. The current standard of care for anesophagectomy requires a complex surgical procedure that involves moving the patient’s stomach or a portion of their colon intothe chest to replace the portion of esophagus resected by the removal of the tumor. These current procedures have high rates of complications,can lead to a severely diminished quality of life and require costly ongoing care. Our CEIs aim to simplify the procedure, reduce complications,result in a better quality of life and reduce the overall cost of these patients to the healthcare system.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 44pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In November 2016, we were granted Orphan Drug Designation for our CEIby the U.S. Food and Drug Administration (FDA) to restore the structure and function of the esophagus subsequent to esophageal damagedue to cancer, injury or congenital abnormalities. Orphan drug status provides market exclusivity in the U.S. for seven years from thedate of the product’s approval for marketing. This exclusivity is in addition to any exclusivity we may obtain due to our patents.Additionally, orphan designation provides certain incentives, including tax credits and a waiver of the Biologics License Application(BLA) fee. We also intend to apply for Orphan Drug Designation for our CEI in Europe in the future. Orphan drug status in Europe providesmarket exclusivity there for ten years from the date of the product’s approval for marketing.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 41; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         38         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In October 2019, we filed an IND application with the FDA to treatpatients with esophageal disease, absent of cancer, in adults that would require a short segment esophageal implant following clinicallyindicated short segment resection of the thoracic esophagus with our CEI product candidate. In November 2019, we received notice fromthe FDA placing our IND on clinical hold and providing a preliminary list of clinical hold and non-clinical hold questions. In December2019, we received the formal letter with clinical hold and non-clinical hold questions and submitted our response to the clinical holdquestions on February 18, 2020. On March 19, 2020, the FDA notified us that the IND for our CEI product candidate has been removed fromclinical hold and that we can proceed with our study. This FDA approval enables us to start our transition to a clinical-stage biotechnologycompany, and start clinical planning, engaging with a clinical research organization and site readiness in advance of starting the clinicaltrial for our CEI product candidate. On May 7, 2020, we submitted responses to certain non-clinical hold questions and finalized a majorityof remaining non-clinical hold responses in the third quarter of 2020, and submitted the remaining responses in the fourth quarter of2020, except for responses to our clinical trial details that we will submit once a clinical research organization is selected. The COVID-19pandemic could adversely impact our business, including planned clinical trials, as discussed elsewhere in this document.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         We have alsoformed        </font>        a subsidiary in Hong Kong, Harvard Apparatus Regenerative Technology Limited, as we continue to assess the market and regulatoryapproval pathway in China as to our implant products. We are not certain at this time as to which market, including U.S. or China forexample, may provide the most viable initial pathway for regulatory approval to a commercial product. This will depend on a number offactors, including the approval and development processes, related costs, ability to raise capital and the terms and conditions thereof,as well as the ongoing impact of the COVID-19 pandemic, among other factors. Any development and capital raising efforts in China mayinclude a joint venture in relation to our Hong Kong subsidiary, and would also involve a number of commercial variables, including rightsand obligations pertaining to licensing, development and financing, among others. Our failure to receive or obtain such clearances orapprovals on a timely basis or at all, whether that be in the U.S., China or otherwise, would have an adverse effect on our results ofoperations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We were incorporated and commenced operations on November 1, 2013 asa result of a spin-off from Harvard Bioscience, Inc. (Harvard Bioscience). On that date, we became an independent company that operatesthe regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution of allthe shares of common stock of Biostage to Harvard Bioscience stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Since our incorporation, we have devoted substantially all of our resourcesto developing our programs, building our intellectual property portfolio, business planning, raising capital and providing general andadministrative support for these operations. To date, we have financed our operations with proceeds from the sales of common stock andpreferred stock. In December 2017, we sold the inventory and rights to manufacture and sell research-only versions of our bioreactorsto Harvard Bioscience. We did not recognize any revenues during the years ended December 31, 2020 and December 31, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our products are currently in development and have not yet receivedregulatory approval for sale anywhere in the world.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have incurred substantial operating losses since our inception,and as of December 31, 2020 had an accumulated deficit of approximately $69.0 million and will require additional financing to fund futureoperations. We expect that our operating cash on-hand as of December 31, 2020 of approximately $1.0 million, along with proceeds of approximately$0.2 million during the first quarter of 2021 from the receipt of Phase II of the SBIR grant will enable us to fund our operating expensesand capital expenditure requirements into June of 2021. We expect to continue to incur operating losses and negative cash flows from operationsfor 2021 and in future years. Therefore, as disclosed in Note 1 to our consolidated financial statements, these conditions raise substantialdoubt about our ability to continue as a going concern.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We will need to raise additional funds to fund our operations. In theevent we do not raise additional capital from outside sources in the second quarter, we may be forced to curtail or cease its operations.Cash requirements and cash resource needs will vary significantly depending upon the timing of the financial and other resource needsthat will be required to complete ongoing development, pre-clinical and clinical testing of products, as well as regulatory efforts andcollaborative arrangements necessary for our products that are currently under development. We are currently seeking and will continueto seek financings from other existing and/or new investors to raise necessary funds through a combination of public or private equityofferings. We may also pursue debt financings, other financing mechanisms, research grants, or strategic collaborations and licensingarrangements. We may not be able to obtain additional financing on favorable terms, if at all.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our operations will be adversely affected if it is unable to raiseor obtain needed funding and may materially affect our ability to continue as a going concern. Our consolidated financial statements havebeen prepared assuming that we will continue as a going concern and therefore, the consolidated financial statements do not include anyadjustments to reflect the possible future effects on the recoverability and classification of assets or the amount and classificationsof liabilities that may result from the outcome of this uncertainty.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          2020 Financing Activities         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During 2020 we completed the following financing activities:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           During the year ended December 31, 2020, we issued a total of 151,027 and 125,000 shares, respectively, of our common stock at a purchaseprices of $3.70 and $4.00 per share, respectively, and warrants to purchase 151,027 shares of common stock at an exercise price of $3.70per share to a group of investors for aggregate gross and net proceeds of approximately $1.1 million.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           During the year ended December 31, 2020, we issued 414,000 shares of our common stock to a group of investors in connection with theexercise of 414,000 previously issued warrants at $2.00 per share for aggregate gross and net proceeds of approximately $0.8 million.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 42; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         39         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           During the year ended December 31, 2020, we issued 516,877 shares of our common stock to a group of investors in connection with theexercise of 516,877 previously issued warrants at $3.70 per share for aggregate gross and net proceeds of approximately $1.9 million.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           On May 4, 2020, we were granted a loan from the Bank of America in the aggregate amount of $0.4 million, pursuant to the PaycheckProtection Program (PPP), established as part of the CARES Act (See Note 3 in the Consolidated Financial Statements included in Part I “Financial Information”, Item 1 of this report for further discussion).          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           During the year ended December 31, 2020, we issued a total of 25,948 shares of our common stock to the former chief executive officerand an employee due to the vesting of restricted stock units and issuance of a common stock award.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          2019 Financing Activities         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During 2019 we completed the following financing activities:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           On June 12, 2019, we issued a total of 345,174 shares of our common stock and warrants to purchase 345,174 shares of common stockto a group of investors at an exercise price of $3.70 per share, in exchange for aggregate gross and net proceeds of approximately $1.3million.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           On December 31, 2019, we issued a total of 143,230 shares of our common stock at a purchase price of $3.70 per share and warrantsto purchase 143,230 shares of common stock at an exercise price of $3.70 per share to a group of investors for gross and net proceedsin the amount of $0.5 million.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           During the year ended December 31, 2019, we issued 1,994,000 shares of our common stock to a group of investors in connection withthe exercise of 1,994,000 previously issued warrants at $2.00 per share for aggregate gross and net proceeds in the amount of approximately$4.0 million.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Small Business Innovation Research Grant         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On March 28, 2018, we were awarded a Fast-Track Small Business InnovationResearch (SBIR) grant by the Eunice Kennedy National Institute of Child Health and Human Development (NICHD) to support testing of pediatricCellspan™ Esophageal Implants (CEIs). The award for Phase I provided for the reimbursement of approximately $0.2 million of qualifiedresearch and development costs which was received and recognized as grant income during 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On October 26, 2018, we were awarded the Phase II Fast-Track SBIR grantfrom the Eunice Kennedy NICHD grant aggregating $1.1 million to support development, testing, and translation to the clinic through September2019 and represented years one and two of the Phase II portion of the award. On August 3, 2020, we were awarded a third year of the PhaseII grant totaling $0.5 million for support of development, testing, and translation to the clinic covering qualified expenses incurredfrom October 1, 2019 through September 30, 2020. In September of 2020, we filed and were granted a one year, no-cost extension for thePhase II grant period extending through September 30, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the years ended December 31, 2020 and 2019, we recognized $0.4million and $0.5 million of grant income, respectively, from Phase II of the SBIR grant. The aggregate SBIR grant to date provides a totalaward of $1.8 million, of which, approximately $1.3 million has been recognized through December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In March 2021, we received additional cash proceeds of $0.2 millionfrom the Phase II grant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Management         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We disclosed in our Current Report on Form 8-K dated February 7, 2020that James McGorry, our former Chief Executive Officer, resigned from his role effective February 7, 2020. We also disclosed in our CurrentReport on Form 8-K dated August 31, 2020 that Peter Chakoutis, our Vice President of Finance and Principal Accounting Officer, had takena leave of absence from his role for personal reasons effective August 24, 2020. We disclosed in our Current Report on Form 8-K datedOctober 30, 2020 that Mr. Chakoutis would not be returning to the Company and we named Peter Pellegrino as Interim Vice President of Finance.We are currently in the process of evaluating our options to fill these positions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As of December 31, 2020, we had 7 employees, 6 of whom were full-timeand one part-time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <!-- Field: Page; Sequence: 43; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         40         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Components of Operating Loss         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        <i>         Research and Development Expense        </i>        . Researchand development expense consists of salaries and related expenses, including share-based compensation, for personnel and contracted consultantsand various materials and other costs to develop our new products, primarily: synthetic scaffolds, including investigation and developmentof materials and investigation and optimization of cellularization, autoseeders, and 3D bioreactors, as well as studies of cells and cellbehavior. Other research and development expenses include the costs of outside service providers and material costs for prototype andtest units and outside laboratories and testing facilities performing cell growth and materials experiments, as well as the costs of allother preclinical research and testing including animal studies and expenses related to potential patents. We expense research and developmentcosts as incurred.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        <i>         Selling, General and Administrative Expense        </i>        .Selling, general and administrative expense consists primarily of salaries and other related expenses, including share-based compensation,for personnel in executive, accounting, information technology and human resources roles. Other costs include professional fees for legaland accounting services, insurance, investor relations and facility costs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Other Income (Expense)         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Grant Income.        </i>        Grant income reflects income earned under theSBIR grant. Grant income is recognized based on timing of when qualified research and development costs are incurred.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        <i>         Changes in Fair Value of Warrant Liability.        </i>        Changes in fair value of warrant liability represent the change in the fair value of common stock warrants classified as liability awardsduring the years ended December 31, 2020 and 2019. We use the Black-Scholes pricing model to value the related warrant liability. Thecosts associated with the issuance of the warrants have been recorded as an expense upon issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Critical Accounting Estimates         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Management’s discussion and analysis of our financial conditionand results of operations is based on our consolidated financial statements, which have been prepared in accordance with Generally AcceptedAccounting Principles in the United States (U.S. GAAP). The preparation of these consolidated financial statements requires us to makeestimates and assumptions for the reported amounts of assets, liabilities, revenues, expenses and related disclosures. We believe thefollowing policies to be critical to the judgments and estimates used in the preparation of our financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 44; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         41         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Share-based Compensation        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We account for our share-based compensation in accordance with thefair value recognition provisions of current authoritative guidance. Share-based awards, including stock options, are measured at fairvalue as of the grant date and recognized as expense over the requisite service period (generally the vesting period), which we have electedto amortize on a straight-line basis. Expense on share-based awards for which vesting is performance or milestone based is recognizedon a straight-line basis from the date when we determine the achievement of the milestone is probable to the vesting/milestone achievementdate. We estimate the fair value of options granted using the Black-Scholes option valuation model. Significant judgment is required indetermining the proper assumptions used in these models. The assumptions used include the risk-free interest rate, expected term, expectedvolatility and expected dividend yield. We base our assumptions on historical data when available or, when not available, on a peer groupof companies. However, these assumptions consist of estimates of future market conditions, which are inherently uncertain and subjectto our judgment, and therefore any changes in assumptions could significantly impact the future grant date fair value of share-based awards.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Total share-based compensation expense for the years ended December31, 2020 and 2019 was $1.1 million and $1.7 million, respectively. Share-based compensation is further described in Note 15 to our consolidatedfinancial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Warrant Liability        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Most of the warrants to purchase shares of our common stock have beenclassified on our consolidated balance sheets as equity. We classify warrants as a liability in our consolidated balance sheets if thewarrant is a free-standing financial instrument that may require us to transfer cash consideration upon exercise and that cash transferevent would be out of our control. Such a “liability warrant” is initially recorded at fair value on the date of grant usingthe Black-Scholes model, net of issuance costs, and it is subsequently re-measured to fair value at each subsequent balance sheet date.Changes in fair value of the warrant are recognized as a component of other income (expense) in the consolidated statements of operations.We will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 45; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         42         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table summarizes the results of our operations for theyears ended December 31, 2020 and 2019 ($ in thousands):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           For the Year Ended          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Change 2020 vs. 2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Change          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           %          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; font-weight: bold; text-align: left">           Operating expenses          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 48%; font-size: 10pt; text-align: left">           Research and development          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           2,069          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           4,852          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           (2,783          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           )          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           (57          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           )%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Selling, general and administrative          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           3,256          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           4,018          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (762          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (19          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; font-weight: bold; text-align: left">           Total operating expenses          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           5,325          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           8,870          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (3,545          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (40          </td>          <td style="font-size: 10pt; text-align: left">           )%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; font-weight: bold; text-align: left">           Other income (expense)          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Grant income          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           447          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           473          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (26          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (5          </td>          <td style="font-size: 10pt; text-align: left">           )%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Change in fair value of warrant liability          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           16          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           65          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (49          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (75          </td>          <td style="font-size: 10pt; text-align: left">           )%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Other income (expense), net          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (3          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           nm          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           nm          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 2.5pt">           Net loss          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (4,865          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (8,332          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           3,467          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (42          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="background-color: White; font-size: 10pt; font-weight: bold; text-align: left">           nm = not meaningful          </td>          <td style="background-color: White; font-size: 10pt">          </td>          <td style="background-color: White; font-size: 10pt; text-align: left">          </td>          <td style="background-color: White; font-size: 10pt; text-align: right">          </td>          <td style="background-color: White; font-size: 10pt; text-align: left">          </td>          <td style="background-color: White; font-size: 10pt">          </td>          <td style="background-color: White; font-size: 10pt; text-align: left">          </td>          <td style="background-color: White; font-size: 10pt; text-align: right">          </td>          <td style="background-color: White; font-size: 10pt; text-align: left">          </td>          <td style="background-color: White; font-size: 10pt">          </td>          <td style="background-color: White; font-size: 10pt; text-align: left">          </td>          <td style="background-color: White; font-size: 10pt; text-align: right">          </td>          <td style="background-color: White; font-size: 10pt; text-align: left">          </td>          <td style="background-color: White; font-size: 10pt">          </td>          <td style="background-color: White; font-size: 10pt; text-align: left">          </td>          <td style="background-color: White; font-size: 10pt; text-align: right">          </td>          <td style="background-color: White; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Results of Operations        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Year Ended December 31, 2020 Compared to Year Ended December31, 2019         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Research and Development Expense        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Research and development expense decreased approximately $2.8 million,or approximately 57%, to $2.1 million for the year ended December 31, 2020 as compared to $4.9 million for the year ended December 31,2019. This was due primarily to $1.1 million of lower outsourced study costs and lab operating supplies, a $0.8 million decrease in regulatoryconsulting expenses, $0.8 million of lower employee and share-based compensation expenses, and a $0.2 million decrease in all other expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Selling, General and Administrative Expense        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Selling, general and administrative expense decreased approximately$0.7 million, or approximately 19%, to $3.3 million for the year ended December 31, 2020 compared to $4.0 million for the year ended December31, 2019. This decrease was due primarily to $0.9 million of lower employee and share-based expenses due to the separations of our formerchief executive officer and chief financial officer partially offset by $0.2 million increase to consulting fees to support public companyrequirements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Grant income        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the year ended December 31, 2020 we recorded grant income of $0.4million for qualified expenditures under the SBIR grant for the period October 1, 2019 to September 30, 2020. In September of 2020, wefiled and were granted a one year, no-cost extension for the Phase II grant period extending through September 30, 2021. For the yearended December 31, 2019 we recorded grant income of $0.5 million for qualified expenditures under the SBIR grant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Change in Fair Value of Warrant Liability        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the year ended December 31, 2020, the change in fair value of ourwarrant liability resulted in other income of $16,000 due primarily to a lower stock price of the underlying common shares during theyear. This compared to other income of $65,000 for the year ended December 31, 2019 due primarily to a lower volatility of the underlyingcommon shares and a decrease in the expected term.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 46; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         43         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Liquidity and Capital Resources         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Sources of Liquidity.        </i>        We have incurred operating losses sinceinception, and as of December 31, 2020 we had an accumulated deficit of approximately $69.0 million. We are currently investing significantresources in the development and commercialization of our products for use by clinicians and researchers in the field of regenerativemedicine. As a result, we expect to incur operating losses and negative operating cash flow for the foreseeable future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Operating Activities.        </i>        Net cash used in operating activitiesof $4.0 million for the year ended December 31, 2020 was primarily a result of our net loss of $4.9 million, offset by $1.3 million ofnon-cash expenses related to share-based compensation and depreciation, and increased by $0.4 million of cash provided from working capitaldue to the timing of prepaid expenses and accounts payable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Net cash used in operating activities of $6.1 million for the yearended December 31, 2019 was primarily a result of our net loss of $8.3 million, partially offset by $1.8 million of non-cash expensesrelated to share-based compensation and depreciation, and $0.4 million of cash provided from working capital due to the timing of prepaidexpenses and accounts payable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Investing Activities.        </i>        Net cash used in investing activitiesfor the years ended December 31, 2020 and 2019 totaled $7,000 and $129,000, respectively, and represented purchases of property, plantand equipment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Financing Activities.        </i>        Net cash generated from financing activitiesof $4.2 million during the year ended December 31, 2020 consisted of $1.1 million of net proceeds received from private placement transactionsthat resulted in the issuance of 276,027 shares of our common stock and warrants to purchase 151,027 shares of common stock to a groupof investors at exercise prices of $3.70 and $4.00 per share, respectively, $2.7 million received from the issuance of 930,877 sharesof our common stock to a group of investors in connection with previously issued warrants, and $0.4 million received under the paycheckprotection program loan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Net cash generated from financing activities of $5.8 million duringthe year ended December 31, 2019 consisted of $1.8 million of net proceeds received from private placement transactions and $4.0 millionreceived from the exercise of warrants.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We continue to pursue our esophageal program, including advancing tooperate as a clinical stage company. Given our current limited cash resources, we intend to closely monitor our cash expenses as suchcash resources are expected to only allow us to meet our operating needs into June of 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Recently Issued Accounting Pronouncements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        A description of recently issued accounting pronouncements that maypotentially impact our financial position and results of operations is disclosed in Note 2 to our consolidated financial statements appearingat the end of this Annual Report on Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Off-Balance Sheet Arrangements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We did not have, during the periods presented, and we do not currentlyhave, any off-balance sheet arrangements, as defined under applicable Securities and Exchange Commission rules.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_011">           </a>           <b>            Item 7A.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Quantitative and Qualitative Disclosures about Market Risk.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Not Applicable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_012">           </a>           <b>            Item 8.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Financial Statements and Supplementary Data.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The information required by this item is contained in the consolidatedfinancial statements filed as part of this Annual Report on Form 10-K listed under Item 15 of Part IV below.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 47; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         44         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_009">           </a>           <b>            Item 9.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_010">           </a>           <b>            Item 9A.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Controls and Procedures.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        This Report includes the certifications of our principal executiveofficer and principal financial officer required by Rule 13a-14 of the Securities Exchange Act of 1934, as amended (the Exchange Act).See Exhibits 31.1 and 31.2. This Item 9A includes information concerning the controls and control evaluations referred to in those certifications.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         (a) Evaluation of Disclosure Controls and Procedures        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Disclosure controls and procedures (as defined in Rules 13a-15(e) and15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted underthe Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission’srules and forms and that such information is accumulated and communicated to management, including our President, who is our acting principalexecutive officer, and our Vice President of Finance, who is our acting principal financial officer, to allow timely decisions regardingrequired disclosures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In connection with the preparation of this Annual Report on Form 10-K,our management, under the supervision and with the participation of our principal executive officer and principal financial officer, conductedan evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2020. Ourdisclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by us in thereports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specifiedin the Securities and Exchange Commission’s rules and forms, and our management necessarily was required to apply its judgment inevaluating and implementing our disclosure controls and procedures. Based upon the evaluation described above, our principal executiveofficer and principal financial officer have concluded that they believe that our disclosure controls and procedures were effective, asof the end of the period covered by this report, in providing reasonable assurance that information required to be disclosed by us inthe reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executiveofficer and principal financial officer, to allow timely decisions regarding required disclosures, and is recorded, processed, summarizedand reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         (b) Management’s Annual Report on Internal Control Over FinancialReporting        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our management, under the supervision of the principal executive officerand the principal financial officer, is responsible for establishing and maintaining an adequate system of internal control over financialreporting. Internal control over financial reporting (as defined in Rules 13a-15(f) and 15d(f) under the Exchange Act) is a process designedto provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for externalpurposes in accordance with U.S. GAAP.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        A company’s internal control over financial reporting includesthose policies and procedures that: (a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflectthe transactions and dispositions of our assets; (b) provide reasonable assurance that transactions are recorded as necessary to permitpreparation of consolidated financial statements in accordance with U.S. GAAP; (c) provide reasonable assurance that receipts and expendituresare being made only in accordance with appropriate authorization of management and the Board of Directors; and (d) provide reasonableassurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a materialeffect on the consolidated financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Due to its inherent limitations, internal control over financial reportingmay not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the riskthat controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or proceduresmay deteriorate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In connection with the preparation of this report, our management conductedan evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2020 based on the criteria establishedin        <i>         Internal Control - Integrated Framework (2013)        </i>        issued by the Committee of Sponsoring Organizations of the TreadwayCommission (COSO). As a result of that evaluation, management has concluded that a        <font style="background-color: white">         material weaknessin internal control over financial reporting existed as of December 31, 2020, being that w        </font>        e did not design or maintain effectiveinternal controls over the timely identification and recording of financial statement adjustments. Specifically, we did not identify,analyze, record, and disclose certain non-routine accounting matters, such as a lease extension and a grant contract, timely andaccurately.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As a smaller reporting company, we are exempt from the auditor attestationrequirements of Section 404 of the Sarbanes-Oxley Act of 2002. As a result, RSM US LLP, our independent registered public accounting firm,has not audited or issued an attestation report with respect to the effectiveness of our internal control over financial reporting asof December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.2pt">       </p>       <!-- Field: Page; Sequence: 48; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         45         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         (c) Changes in Internal Controls Over Financial Reporting        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our management, with the participation of the principal executive officerand the principal financial officer, has evaluated whether any change in our internal control over financial reporting occurred duringthe fourth quarter ended December 31, 2020. Based on that evaluation, management concluded that there were no changes in our internalcontrols over financial reporting during the quarter ended December 31, 2020 that materially affected, or are reasonably likely to materiallyaffect, our internal controls over financial reporting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         (d) Remediation Plan        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; background-color: white">         Weare committed to remediating the material weaknesses in a timely fashion, including through the engagement of        </font>        Point ProvidenceConsulting and related appointment of Mr. Pellegrino as our Interim Vice President of Finance        <font style="background-color: white">         .As management continues to evaluate and work to improve its internal control over financial reporting, management may determine it isnecessary to take additional measures to address the material weakness. Until the controls have been operating for a sufficient periodof time and management has concluded, through testing, that these controls are operating effectively, the material weakness describedabove will continue to exist.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_008">           </a>           <b>            Item 9B.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Other Information.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 49; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         46         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="zz_032">        </a>        <b>         PART III        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_003">           </a>           <b>            Item 10.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Directors, Executive Officers and Corporate Governance.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Incorporated by reference to our definitive Proxy Statement to be filedpursuant to Regulation 14A under the Exchange Act, in connection with our 2021 Annual Meeting of Stockholders. Information concerningexecutive officers of our company is included in Part I of this Annual Report on Form 10-K as Item 1. Business - Information about ourExecutive Officers and incorporated herein by reference.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_004">           </a>           <b>            Item 11.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Executive Compensation.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Incorporated by reference to our definitive Proxy Statement to be filedpursuant to Regulation 14A under the Exchange Act in connection with our 2021 Annual Meeting of Stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_005">           </a>           <b>            Item 12.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Incorporated by reference to our definitive Proxy Statement to be filedpursuant to Regulation 14A under the Exchange Act in connection with our 2021 Annual Meeting of Stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_006">           </a>           <b>            Item 13.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Certain Relationships and Related Transactions, and Director Independence.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Incorporated by reference to our definitive Proxy Statement to be filedpursuant to Regulation 14A under the Exchange Act in connection with our 2021 Annual Meeting of Stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_007">           </a>           <b>            Item 14.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Principal Accounting Fees and Services.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Incorporated by reference to our definitive Proxy Statement to be filedpursuant to Regulation 14A under the Exchange Act in connection with our 2021 Annual Meeting of Stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 50; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         47         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="zz_001">        </a>        <b>         PART IV        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 10%">           <a name="zz_002">           </a>           <b>            Item 15.           </b>          </td>          <td style="width: 90%">           <b>            <i>             Exhibits, Financial Statement Schedules.            </i>           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        (a) Documents Filed. The following documents are filed as part of thisAnnual Report on Form 10-K:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           (1)          </td>          <td>           Financial Statements. The consolidated financial statements of Biostage, Inc. and its subsidiaries filed under this Item 15:          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="width: 95%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.25in">        <tbody>         <tr>          <td style="vertical-align: top; width: 90%; padding-left: 9.9pt; text-indent: -9.9pt">          </td>          <td style="vertical-align: top; width: 1%; text-align: center">          </td>          <td style="vertical-align: bottom; width: 9%; border-bottom: black 1pt solid; text-align: center">           <b>            Page           </b>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; padding-left: 9.9pt; text-indent: -9.9pt">           <a href="#zz_029">            Index to Consolidated Financial Statements           </a>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_029">            F-1           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; padding-left: 9.9pt; text-indent: -9.9pt">           <a href="#zz_013">            Report of Independent Registered Public Accounting Firm           </a>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_013">            F-2           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; padding-left: 9.9pt; text-indent: -9.9pt">           <a href="#zz_014">            Consolidated Balance Sheets as of December 31, 2020 and 2019           </a>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_014">            F-4           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; padding-left: 9.9pt; text-indent: -9.9pt">           <a href="#zz_015">            Consolidated Statements of Operations for the years ended December 31, 2020 and 2019           </a>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_015">            F-5           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; padding-left: 9.9pt; text-indent: -9.9pt">           <a href="#zz_016">            Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2020 and 2019           </a>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_016">            F-6           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; padding-left: 9.9pt; text-indent: -9.9pt">           <a href="#zz_017">            Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019           </a>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_017">            F-7           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; padding-left: 9.9pt; text-indent: -9.9pt">           <a href="#zz_018">            Notes to Consolidated Financial Statements           </a>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_018">            F-8           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; padding-left: 9.9pt; text-indent: -9.9pt">          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           (2)          </td>          <td>           Financial Statement Schedules:  None. Financial statement schedules have been omitted since the required information isincluded in our consolidated financial statements contained elsewhere in this Annual Report on Form 10-K.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           (3)          </td>          <td>           Exhibits.  The exhibits listed in the accompanying Exhibit Index are filed as a part of this Annual Report on Form 10-K.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        (b) Exhibits: The exhibits listed in the accompanying Exhibit Indexare filed as a part of this Annual Report on Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        (c) Separate Financial Statements and Schedules:  None.Financial statement schedules have been omitted since the required information is included in our consolidated financial statements containedelsewhere in this Annual Report on Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 51; Value: 30 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         48         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <a name="zz_029">        </a>        <b>         INDEX TO CONSOLIDATED FINANCIALSTATEMENTS        </b>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">        <b>         BIOSTAGE, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr>          <td style="vertical-align: top; width: 91%">          </td>          <td style="vertical-align: top; width: 1%; text-align: center">          </td>          <td style="vertical-align: bottom; width: 8%; border-bottom: black 1pt solid; text-align: center">           <b>            Page           </b>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_013">            Report of Independent Registered Public Accounting Firm           </a>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_013">            F-2           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <a href="#zz_014">            Consolidated Balance Sheets as of December 31, 2020 and 2019           </a>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_014">            F-4           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_015">            Consolidated Statements of Operations for the years ended December 31, 2020 and 2019           </a>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_015">            F-5           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <a href="#zz_016">            Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2020 and 2019           </a>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_016">            F-6           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top">           <a href="#zz_017">            Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019           </a>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_017">            F-7           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <a href="#zz_018">            Notes to Consolidated Financial Statements           </a>          </td>          <td style="vertical-align: top; text-align: center">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="#zz_018">            F-8           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 52; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          1          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="zz_013">        </a>        <b>         Report of Independent Registered Public AccountingFirm        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        To the Shareholders and the Board of Directors of       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Biostage, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Opinion on the Financial Statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have audited the accompanying consolidated balance sheets of Biostage,Inc. and its subsidiaries (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations, stockholders’equity and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively, the financialstatements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Companyas of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accountingprinciples generally accepted in the United States of America.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Emphasis of Matter Regarding Going Concern       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The accompanying financial statements have been prepared assuming thatthe Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring lossesfrom operations, has an accumulated deficit, uses cash flows in operations, and will require additional financing to continue to fundoperations. This raises substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard tothese matters also are described in Note 1. The financial statements do not include any adjustments that might result from the outcomeof this uncertainty.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Basis for Opinion       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        These financial statements are the responsibility of the Company’smanagement. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a publicaccounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independentwith respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securitiesand Exchange Commission and the PCAOB.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We conducted our audits in accordance with the standards of the PCAOB.Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are freeof material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an auditof its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal controlover financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal controlover financial reporting. Accordingly, we express no such opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our audits included performing procedures to assess the risks of materialmisstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such proceduresincluded examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also includedevaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentationof the financial statements. We believe that our audits provide a reasonable basis for our opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Critical Audit Matters       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The critical audit matters communicated below are matters arising fromthe current period audit of the financial statements that were communicated or required to be communicated to the audit committee andthat: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements,taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical auditmatters or on the accounts or disclosures to which they relate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Share-based Compensation – Performance-Based Awards        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As described in Note 15 to the consolidated financial statements, theCompany has 243,532 unvested performance-based options outstanding for which there is unrecognized compensation expense of $0.8 millionat December 31, 2020. No expense has been recognized for these unvested awards as of December 31, 2020 given that the milestone achievementsfor these awards have not yet been deemed probable for accounting purposes. As described in Note 2 to the consolidated financial statements,the Company measures all stock options and restricted stock awards granted to employees, directors and non-employees based on the fairvalue on the date of the grant and recognizes compensation expense of those awards, net of estimated forfeitures, over the requisite serviceperiod. Expense on share-based awards for which vesting is performance or milestone based is recognized on a straight-line basis fromthe date when it is determined that the achievement of the milestone is probable to the vesting/milestone achievement date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 53; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          2          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We identified the Company’s expense recognition for share-basedawards that contain performance-based vesting provisions as a critical audit matter. The principal considerations for our determinationthat the expense recognition for share-based awards that contain performance-based vesting provision awards is a critical audit matterare the assumptions and risk of bias related to the conclusion of the probability of achievement of the performance conditions impactingvesting of the awards, or more specifically the achievement of the business milestones, as defined in the grant agreements. Auditing management’sassumptions regarding the probability of achievement of the business milestones defined in the grant agreements was complex and requireda high degree of auditor judgment and increased audit effort.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our audit procedures related to the expense recognition of share-basedawards that contain performance-based vesting provisions included the following, among others:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We obtained and read the grant agreements for all outstanding share-basedawards with performance-based vesting provisions,           </font>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We recalculated the total outstanding share-based awards with performance-basedvesting provisions at year-end based upon cumulative grants, net of cumulative forfeitures, and           </font>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Symbol">            ·           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">            We discussed with management their conclusion and we evaluated their conclusionon the probability of achievement of the business milestone within the performance-based awards by assessing the Company’s liquidityrequirements needed to fund achievement of milestones outlined in the grant agreements and review of the Company’s public pressreleases through issuance date.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        /s/ RSM US LLP       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have served as the Company's auditor since 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Boston, Massachusetts       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        April 13, 2021       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 54; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          3          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="zz_014">        </a>        <b>         BIOSTAGE, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         CONSOLIDATED BALANCE SHEETS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        (        <i>         In thousands, except par value and share data        </i>        )       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           December 31,          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           December 31,          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; font-weight: bold">           ASSETS          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Current assets:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt; padding-left: 9pt">           Cash          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           1,026          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           913          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-left: 9pt">           Restricted cash          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           50          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           50          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-left: 9pt">           Grant receivable          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           77          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">           Prepaid expenses and other current assets          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           524          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           444          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Total current assets          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,677          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,407          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-left: 9pt">           Property, plant and equipment, net          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           217          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           394          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">           Right-of-use assets          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           182          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           191          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Total assets          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           2,076          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,992          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; font-weight: bold; text-align: left">           LIABILITIES AND STOCKHOLDERS' EQUITY          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Current liabilities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-left: 9pt">           Accounts payable          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           31          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           241          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-left: 9pt">           Accrued and other current liabilities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           317          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           438          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-left: 9pt">           Current portion of notes payable          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           284          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-left: 9pt">           Warrant liability          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           17          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           33          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">           Current portion of operating lease liability          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           107          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           102          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Total current liabilities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           756          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           814          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-left: 9pt">           Notes payable, net of current portion          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           120          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">           Operating lease liability, net of current portion          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           75          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           89          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Total liabilities          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           951          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           903          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Commitments and contingencies (Note 9)          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Stockholders' equity:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-indent: -9pt; padding-left: 0.25in">           Preferred stock, $0.01 par value; 2,000,000 shares authorized as of December 31, 2020 and 2019,0 issued and outstanding          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-indent: -9pt; padding-left: 0.25in">           Common stock, par value $0.01 per share, 60,000,000 shares authorized as of December 31, 2020 and 2019; 9,388,407 and 8,155,555 issued and outstanding at December 31, 2020 and 2019, respectively          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           94          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           82          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">           Additional paid-in capital          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           69,991          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           65,102          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">           Accumulated deficit          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (68,960          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (64,095          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Total stockholders' equity          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           1,125          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           1,089          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Total liabilities and stockholders' equity          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           2,076          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,992          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <i>         See accompanying notes to consolidated financialstatements.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 55; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          4          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="zz_015">        </a>        <b>         BIOSTAGE, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         CONSOLIDATED STATEMENTS OF OPERATIONS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <i>         (In thousands, except per share data)        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Year ended December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Revenues          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Operating expenses:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; width: 74%; font-size: 10pt; text-align: left">           Research and development          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           2,069          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           4,852          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">           Selling, general and administrative          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           3,256          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           4,018          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Total operating expenses          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           5,325          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           8,870          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Operating loss          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (5,325          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (8,870          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">           Other income (expense), net:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.25in; text-align: left">           Grant income          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           447          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           473          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Change in fair value of warrant liability          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           16          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           65          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">           Other expense          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (3          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Total other income (expense), net          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           460          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           538          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Net loss          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (4,865          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (8,332          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Basic and diluted net loss per share          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (0.55          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (1.21          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 2.5pt">           Weighted average common shares, basic and diluted          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           8,794          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           6,898          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <i>         See accompanying notes to consolidated financialstatements.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 56; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          5          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="zz_016">        </a>        <b>         BIOSTAGE, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <i>         (In thousands)        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">           <font style="font-size: 9pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-size: 9pt">             <b>              Number                                            of Common             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-size: 9pt">             <b>              Shares             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-size: 9pt">             <b>              Outstanding             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           <font style="font-size: 9pt">            Common    Stock           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           <font style="font-size: 9pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-size: 9pt">             <b>              Additional             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-size: 9pt">             <b>              Paid-in             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-size: 9pt">             <b>              Capital             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">           <font style="font-size: 9pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-size: 9pt">             <b>              Accumulated             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-size: 9pt">             <b>              Deficit             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">           <font style="font-size: 9pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-size: 9pt">             <b>              Total             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-size: 9pt">             <b>              Stockholders'             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-size: 9pt">             <b>              Equity             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 45%; font-size: 10pt; font-weight: bold">           <font style="font-size: 9pt">            Balance at December 31, 2018           </font>          </td>          <td style="width: 1%; font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 8%; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            5,670           </font>          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%; font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="width: 8%; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            57           </font>          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%; font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="width: 8%; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            57,677           </font>          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%; font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="width: 8%; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            (55,763           </font>          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="width: 1%; font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="width: 8%; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            1,971           </font>          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           <font style="font-size: 9pt">            Net loss           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            (8,332           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            (8,332           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            Share-based compensation           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            1,654           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            1,654           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            Issuance of common stock and warrants to purchase common    stock           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            492           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            5           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            1,802           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            1,807           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           <font style="font-size: 9pt">            Issuance of common stock from exercise    of warrants           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            1,994           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            20           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            3,969           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            3,989           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; font-weight: bold">           <font style="font-size: 9pt">            Balance at December 31, 2019           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            8,156           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            82           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            65,102           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            (64,095           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            1,089           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           <font style="font-size: 9pt">            Net loss           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            (4,865           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            (4,865           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            Share-based compensation           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            38           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            1,144           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            1,144           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            Common stock withheld for taxes           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            (12           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            (42           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            (42           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            Issuance of common stock and warrants to purchase common    stock           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            276           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            2           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            1,056           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            1,058           </font>          </td>          <td style="font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           <font style="font-size: 9pt">            Issuance of common stock from exercise    of warrants           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            930           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            10           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            2,731           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            -           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            2,741           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">           <font style="font-size: 9pt">            Balance at December 31, 2020           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            9,388           </font>          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            94           </font>          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            69,991           </font>          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            (68,960           </font>          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            )           </font>          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">           <font style="font-size: 9pt">           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">            $           </font>          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           <font style="font-size: 9pt">            1,125           </font>          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           <font style="font-size: 9pt">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <i>         See accompanying notes to unaudited consolidatedfinancial statements.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 57; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          6          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="zz_017">        </a>        <b>         BIOSTAGE, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         CONSOLIDATED STATEMENTS OF CASH FLOWS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <i>         (In thousands)        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">           <b>            Year ended December 31,           </b>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">           <b>            2020           </b>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">           <b>            2019           </b>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; font-weight: bold; text-align: left">           OPERATING ACTIVITIES          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 74%; font-size: 10pt; text-align: left">           Net loss          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           (4,865          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           )          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           (8,332          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Adjustments to reconcile net loss to net cash used in operating activities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-left: 9pt">           Share-based compensation expense          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,144          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,654          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-left: 9pt">           Depreciation          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           184          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           214          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-left: 9pt">           Change in fair value of warrant liability          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (16          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (65          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-left: 9pt">           Changes in operating assets and liabilities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-left: 0.25in">           Grant receivable          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (77          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           176          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-left: 0.25in">           Prepaid expenses and other current assets          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (80          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           179          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-left: 0.25in">           Accounts payable          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (210          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           81          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">           Accrued and other current liabilities          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (121          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           34          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Net cash used in operating activities          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (4,041          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (6,059          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; font-weight: bold; text-align: left">           INVESTING ACTIVITIES          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Purchases of property, plant and equipment          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (7          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (129          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Net cash used in investing activities          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (7          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (129          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; font-weight: bold; text-align: left">           FINANCING ACTIVITIES          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 9pt">           Proceeds from issuance of common stock and warrants          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,058          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,807          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-indent: -9pt; padding-left: 9pt">           Proceeds from exercise of warrants          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           2,741          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           3,989          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 9pt">           Proceeds from notes payable          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           404          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">           Acquisition of common stock for tax withholding obligations          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (42          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Net cash provided by financing activities          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           4,161          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           5,796          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Net increase (decrease) in cash and restricted cash          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           113          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           (392          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Cash and restricted cash at the beginning of the year          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           963          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           1,355          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Cash and restricted cash at the end of the year          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,076          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           963          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Supplemental disclosure of non-cash investing and financing activities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 9.9pt">           Issuance of vested common stock          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           42          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">           Supplemental disclosure of non-cash operating activities:          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 9.9pt">           Increase of right-of-use asset and liability due to lease extension          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           94          </td>          <td style="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           90          </td>          <td style="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <i>         See accompanying notes to consolidated financialstatements.        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 58; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          7          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <!-- Field: Split-Segment; Name: split 7 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="zz_018">        </a>        <b>         BIOSTAGE, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         Years Ended December 31, 2020 and 2019        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         1. Organization        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Overview        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Biostage, Inc. (Biostage or the Company) is a biotechnologycompany developing bioengineered organ implants based on the Company’s novel Cellframe        <font style="font-size: 10pt">         ™        </font>        and Cellspan        <font style="font-size: 10pt">         ™        </font>        technology. The Company’s technology is comprised of a biocompatiblescaffold that is seeded with the recipient’s own cells. The Company believes that this technology may prove to be effectivefor treating patients across a number of life-threatening medical indications who currently have unmet medical needs. The Company iscurrently developing its technology to treat life-threatening conditions of the esophagus, bronchus or trachea with the objective ofdramatically improving the treatment paradigm for those patients. Since inception, the Company has devoted substantially all of itsefforts to business planning, research and development, recruiting management and technical staff, and acquiring operatingassets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On October 31, 2013, Harvard Bioscience, Inc. (Harvard Bioscience)contributed its regenerative medicine business assets, plus $15 million of cash, into Biostage (the Separation). On November 1, 2013,the spin-off of the Company from Harvard Bioscience was completed. On that date, the Company became an independent company that operatesthe regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution to HarvardBioscience stockholders of all the shares of common stock of Biostage (the Distribution).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Basis of Presentation        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The consolidated financial statements reflect the Company’s financialposition, results of operations and cash flows in conformity with generally accepted accounting principles in the United States (U.S.GAAP).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Going Concern        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has incurred substantial operating losses since its inception,and as of December 31, 2020 had an accumulated deficit of approximately $69.0 million and will require additional financing to fund futureoperations. The Company expects that its operating cash on-hand as of December 31, 2020 of approximately $1.0 million, along with cashproceeds of approximately $0.2 million received during the first quarter of 2021 from Phase II of the SBIR grant will enable it to fundits operating expenses and capital expenditure requirements into June of 2021. Therefore, these conditions raise substantial doubt aboutthe Company’s ability to continue as a going concern.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company will need to raise additional funds to fund its operations.In the event the Company does not raise additional capital from outside sources in the second quarter, it may be forced to curtail orcease its operations. Cash requirements and cash resource needs will vary significantly depending upon the timing of the financial andother resource needs that will be required to complete ongoing development, pre-clinical and clinical testing of products, as well asregulatory efforts and collaborative arrangements necessary for the Company’s products that are currently under development. TheCompany is currently seeking and will continue to seek financings from other existing and/or new investors to raise necessary funds througha combination of public or private equity offerings. The Company may also pursue debt financings, other financing mechanisms, researchgrants, or strategic collaborations and licensing arrangements. The Company may not be able to obtain additional financing on favorableterms, if at all.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s operations will be adversely affected if it isunable to raise or obtain needed funding and may materially affect the Company’s ability to continue as a going concern. The accompanyingconsolidated financial statements have been prepared assuming that the Company will continue as a going concern and therefore, the consolidatedfinancial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification ofassets or the amount and classifications of liabilities that may result from the outcome of this uncertainty.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 59; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          8          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         2. Summary of Significant Accounting Policies        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Principles of Consolidation        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The consolidated financial statements include the accounts of Biostage,and three wholly-owned subsidiaries, Harvard Apparatus Regenerative Technology Limited (Hong Kong), Harvard Apparatus Regenerative TechnologyGmbH (Germany) and Biostage Limited (UK). The three wholly-owned subsidiaries do not have any net assets as of December 31, 2020. Thefunctional currency for these subsidiaries is the U.S dollar. All intercompany balances and transactions have been eliminated in consolidation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Use of Estimates        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The process of preparing consolidated financial statements in conformitywith U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statementsand accompanying notes. Such estimates include, but are not limited to, share-based compensation, valuation of warrant liability, accruedexpenses and the valuation allowance for deferred income taxes. Actual results could differ from those estimates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Segment        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has one business segment and does not have significantcosts or assets outside the U.S.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Restricted Cash        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Restricted cash consists of $50,000 held as collateral for the Company’scredit card program as of December 31, 2020 and December 31, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Property, Plant and Equipment        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Property, plant and equipment are carried at cost and depreciated usingthe straight-line method over the estimated useful lives of the assets as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 58%">           Leasehold improvements          </td>          <td style="width: 8%; text-align: center">          </td>          <td style="width: 34%; text-align: right">           Shorter of expected useful life or lease term          </td>         </tr>         <tr style="vertical-align: top">          <td>           Furniture, machinery and equipment, computer equipment and software          </td>          <td style="text-align: center">          </td>          <td style="text-align: right">           3-7 years          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Maintenance and repairs are charged to expense as incurred, while anyadditions or improvements are capitalized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Impairment of Long-Lived Assets        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Assessments of long-lived assets and the remaining useful lives ofsuch long-lived assets are reviewed for impairment whenever a triggering event occurs or changes in circumstances indicate that the carryingamount of the assets may not be recoverable. An asset, or group of assets, are considered to be impaired when the undiscounted estimatednet cash flows expected to be generated by the asset, or group of assets, are less than its carrying amount. The impairment recognizedis the amount by which the carrying amount exceeds the fair market value of the impaired asset, or group of assets, based on the presentvalue of the expected future cash flows associated with the use of the asset. Through December 31, 2020, no such impairment charge hasbeen recorded.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Research and Development        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Research and development costs are expensed as incurred.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Share-based Compensation        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         The Companymeasures all stock options and restricted stock awards granted to employees, directors and non-employees based on the fair value on thedate of the grant and recognizes compensation expense of those awards, net of forfeitures, over the requisite service period, which isgenerally the vesting period of the respective award. Generally, the Company issues stock options and restricted stock awards with onlyservice-based vesting conditions on a straight-line basis over the requisite service period for the entire award (that is, over the requisiteservice period of the last separately vesting portion of the award).        </font>        Expense on share-based awards for which vesting is performanceor milestone based is recognized on a straight-line basis from the date when it is determined that the achievement of the milestone isprobable to the vesting/milestone achievement date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 60; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          9          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company elected to use the Black-Scholes option-pricing modelfor valuation of stock-based payment awards. The determination of fair value of stock-based payment awards on the date of grantusing the Black-Scholes option-pricing model is affected by its stock price as well as assumptions regarding a number of subjectivevariables. These variables include, but are not limited to, its expected stock price volatility over the term of the awards andactual and projected employee stock option exercise behaviors. When performance-based grants are issued, the Company recognizes noexpense until achievement of the performance requirement is deemed probable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Share-based compensation expense is based on awards ultimately expectedto vest and has been reduced for annualized estimated forfeiture where the minimum amount of expense recorded is at least equal to thepercent of an award vested. Forfeitures are estimated based on historical experience and weighting of various employee classes under therespective plan at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The fair value of Restricted Stock Units (RSU) are based on the numberof shares granted and market price of the stock on the date of grant and are recorded as compensation expense ratably over the applicableservice period, which is generally four years. Unvested restricted stock units and vested and unvested stock options are forfeited inthe event of termination of employment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Income Taxes        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Income taxes are accounted for under the asset and liability method.Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statementcarrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured usingenacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recoveredor settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includesthe enactment date. Deferred tax assets and liabilities are recorded net as long-term on the consolidated balance sheets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        A valuation allowance is recorded when it is more likely than not thatsome or all of the deferred tax assets will not be realized. Accordingly, the Company provides a valuation allowance, if necessary, toreduce deferred tax assets to amounts that are expected to be realizable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Tax positions taken or expected to be taken in the course of preparingthe Company’s tax returns are required to be evaluated to determine whether the tax positions are “more-likely-than-not”of being sustained by the applicable tax authority. Tax positions not deemed to meet a “more-likely-than-not” threshold wouldbe recorded as a tax expense in the current year.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        When necessary, the Company recognizes interest and penalties relatedto uncertain tax positions in income tax expense.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Net Loss per Share        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Basic net loss per share is computed using the weighted average numberof common shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted average number ofcommon shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common stock, includingthe assumed exercise of stock options, warrants, and the impact of unvested restricted stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company applies the two-class method to calculate basic and dilutednet loss per share attributable to common stockholders as its warrants to purchase common stock are participating securities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The two-class method is an earnings allocation formula that treatsa participating security as having rights to earnings that otherwise would have been available to common stockholders. However, the two-classmethod does not impact the net loss per share of common stock as the Company has been in a net loss position and the warrant holders donot participate in losses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Basic and diluted shares outstanding are the same for each period presentedas all common stock equivalents would be antidilutive due to the net losses incurred.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 61; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          10          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Warrant Liability        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company classifies warrants to purchase shares of its common stockas a liability on its consolidated balance sheets when the warrant is a free-standing financial instrument that may require the Companyto transfer cash consideration upon exercise and that cash transfer event would be out of the Company’s control. Such a “liabilitywarrant” is initially recorded at fair value on date of grant using the Black-Scholes model and net of issuance costs, and it issubsequently re-measured to fair value at each subsequent balance sheet date. Changes in fair value of the warrant are recognized as acomponent of other income (expense), net in the consolidated statements of operations. The Company will continue to adjust the liabilityfor changes in fair value until the earlier of the exercise or expiration of the warrant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For warrants that do not meet the criteria of a liability warrant andare classified on the Company’s consolidated balance sheets as equity instruments, the Company uses the Black-Scholes model to measurethe value of the warrants at issuance and then applies the relative fair-value of the equity transaction between common stock, preferredstock and warrants. Common stock, and equity-classified warrants each are considered permanent equity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Concentration of Credit Risk        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Financial investments that potentially subject the Company to creditrisk consists of cash. Deposits at banks may exceed the insurance provided on such deposits. Generally, these deposits may be redeemedupon demand and, therefore, bear minimal risk.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Grant Income        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Grant income is recognized when qualified research and developmentcosts are incurred and recorded in other income (expense), net in the consolidated statements of operations. When evaluating grant revenuefrom the SBIR grant, the Company considered accounting requirements under the Financial Accounting Standards Board (FASB) Accounting StandardsCodification (ASC) 606,        <i>         Revenue From Contracts With Customers        </i>        . The Company concluded that ASC 606 did not apply as there isno exchange of goods or services or an exchange of intellectual property between the parties; therefore, the Company presents grant incomein other income.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On March 28, 2018, the Company was awarded a Fast-Track Small BusinessInnovation Research (SBIR) grant by the Eunice Kennedy National Institute of Child Health and Human Development (NICHD) to support testingof pediatric Cellspan™ Esophageal Implants (CEIs). The award for Phase I provided for the reimbursement of approximately $0.2 millionof qualified research and development costs which was received and recognized as grant income during 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On October 26, 2018, the Company was awarded the Phase II Fast-TrackSBIR grant from the Eunice Kennedy NICHD grant aggregating $1.1 million to support development, testing, and translation to the clinicthrough September 2019 and represented years one and two of the Phase II portion of the award. On August 3, 2020, the Company was awardeda third year of the Phase II grant totaling $0.5 million for support of development, testing, and translation to the clinic covering qualifiedexpenses incurred from October 1, 2019 through September 30, 2020._In September of 2020, the Company filed and was granted a one year,no-cost extension for the Phase II grant period extending through September 30, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For the years ended December 31, 2020 and 2019, the Company recognized$0.4 million and $0.5 million of grant income, respectively, from Phase II of the SBIR grant. The aggregate SBIR grant to date providesa total award of $1.8 million, of which, approximately $1.3 million has been recognized through December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In March 2021, the Company received additional cash proceeds of $0.2million from the Phase II of the SBIR grant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Recently Adopted Accounting Pronouncements        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">        In August 2018, the FASB issued ASU 2018-13,        <i>         FairValue Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement        </i>        . This standardmodifies certain disclosure requirements on fair value measurements. This standard was effective for the Company on January 1, 2020. Theadoption of this standard did not have a material impact on the Company’s disclosures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 62; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          11          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Recently Issued Accounting Pronouncements Not Yet Adopted        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In June 2016, the FASB issued ASU No. 2016-13,        <i>         Financial Instruments- Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-12)        </i>        .        <font style="background-color: white">         Thenew standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-saledebt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-saledebt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized creditlosses if fair value increases. The Company expects to delay adoption until January 1, 2023 and is evaluating the impact that the adoptionof ASU 2016-13 will have on its consolidated financial statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="background-color: white">         In August 2020, the FASB issuedASU No. 2020-06,         <i>          Debt – Debt with Conversion and Other Options (Subtopic 470-20)         </i>         and Derivatives and Hedging         <i>          —Contractsin Entity’s Own Equity (Subtopic 815-40)         </i>         . This standard amends the guidance on convertible instruments and the derivatives scopeexception for contracts in an entity’s own equity and improves and amends the related earnings per share (“EPS”) guidancefor both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annualperiods and early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company does not expect this pronouncementto have a material impact on its condensed consolidated financial statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Other accounting standards that have been issued or proposed by theFASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact onthe Company’s financial statements upon adoption.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         3. Notes Payable        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On May 4, 2020, the Company obtained a loan (Loan) from the Bank ofAmerica (Lender) in the aggregate amount of $0.4 million, pursuant to the Paycheck Protection Plan (PPP), established as part of the CARESAct. The Loan is evidenced by a promissory note dated May 4, 2020 issued by the Company and will accrue interest at a fixed interest rateof 1% per annum from the funding date of May 4, 2020. Payments of principal and interest have been deferred since the funding under theoriginal terms of the promissory note. However, the Loan and accrued interest may be forgivable at the conclusion of this period.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Under the terms of the PPP, certain amounts of the Loan may be forgivenif they are used for qualifying expenses as described in the CARES Act. The terms of the promissory note, including eligibility and forgiveness,may be subject to additional requirements adopted by the SBA. Any unforgiven portion of the PPP loan, including principal and interest,will mature on May 4, 2022 and will be required to be payable monthly. The Note may be prepaid by the Company at any time prior to maturitywith no prepayment penalties.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has accounted for the loan under FASB ASC 470,        <i>         Debt        </i>        .Repayment amounts due within one year have been recorded as current liabilities, and the remaining amounts due in more than one year aslong-term liabilities. On December 18, 2020, the Company submitted the loan forgiveness application for the entire borrowings of $0.4million to the Lender and was notified on January 7, 2021 that the application was submitted to the Small Business Administration (SBA)for review. The SBA has up to 90 days from the date of submittal to make a final decision on loan forgiveness. The Company has yet tobe notified of the SBA’s forgiveness decision.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        If the Company is successful in receiving forgiveness for any portionof the loan used for qualifying expenses, those amounts will be recorded as a gain upon extinguishment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         4. Fair Value Measurements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Fair value is defined as the exchange price that would be receivedfor an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability inan orderly transaction between market participants on the measurement date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 63; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          12          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company utilizes a valuation hierarchy for disclosure of the inputsto the valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputsare quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assetsand liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through marketcorroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the Company’sown assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within thehierarchy is determined based on the lowest level input that is significant to the fair value measurement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company had no assets or liabilities classified as Level 2.The Company’s restricted cash that serves as collateral for the Company’s credit card program is held in a demand money marketaccount and is measured at fair value based on quoted prices, which are Level 1 inputs. The Company has concluded that warrants to purchasecommon stock, which are accounted for as liabilities as discussed in Note 7 are classified as Level 3.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following fair value hierarchy table presents information aboutthe Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and 2019:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="14" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Fair Value Measurement as of December 31, 2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="14" style="font-size: 10pt; text-align: center">           (in thousands)          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Level 1          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Level 2          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Level 3          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Total          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Assets:          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 48%; font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -4.2pt; padding-left: 13.2pt">           Restricted cash          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           50          </td>          <td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           50          </td>          <td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 2.5pt; text-indent: -13.2pt; padding-left: 13.2pt">           Total          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           50          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           50          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Liabilities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -4.2pt; padding-left: 13.2pt">           Warrant liability          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           17          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           17          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 2.5pt; text-indent: -13.2pt; padding-left: 13.2pt">           Total          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           17          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           17          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="14" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Fair Value Measurement as of December 31, 2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="14" style="font-size: 10pt; text-align: center">           (in thousands)          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Level 1          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Level 2          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Level 3          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Total          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Assets:          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 48%; font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -4.2pt; padding-left: 13.2pt">           Restricted cash          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           50          </td>          <td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           50          </td>          <td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 2.5pt; text-indent: -13.2pt; padding-left: 13.2pt">           Total          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           50          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           50          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Liabilities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -4.2pt; padding-left: 13.2pt">           Warrant liability          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           33          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           33          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 2.5pt; text-indent: -13.2pt; padding-left: 13.2pt">           Total          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           33          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           33          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There were no transfers between Level 1, Level 2 and Level3 in either of the years ended December 31, 2020 and December 31, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 64; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          13          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         5. Prepaid Expenses and Other Current Assets        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Prepaid expenses and other current assets consist of the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="6" style="font-size: 10pt; text-align: center">           (in thousands)          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt">           Insurance          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           403          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           284          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Sponsored research          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           97          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           123          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Other current assets          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           24          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           37          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Total prepaid expenses and other current assets          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           524          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           444          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         6. Property, Plant and Equipment, Net        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Property, plant and equipment, net consist of the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="6" style="font-size: 10pt; text-align: center">           (in thousands)          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt; text-align: left">           Leasehold improvements          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           584          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           584          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Furniture, machinery and equipment          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,553          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,546          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Computer equipment and software          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           477          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           477          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Total property, plant and equipment          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           2,614          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           2,607          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Less: accumulated depreciation          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (2,397          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (2,213          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Property, plant and equipment, net          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           217          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           394          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Depreciation expense amounted to $184,000 and $214,000 for the yearsended December 31, 2020 and 2019, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         7. Accrued and Other Current Liabilities        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Accrued and other current liabilities consist of the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="6" style="font-size: 10pt; text-align: center">           (in thousands)          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt; text-align: left">           Professional fees          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           178          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           179          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Advisory costs          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           75          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           65          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Payroll          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           39          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           177          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-bottom: 1pt">           Other          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           25          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           17          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Total accrued and other current liabilities          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           317          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           438          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         8. Warrant Liability        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On May 19, 2016 and February 10, 2017, the Company closed a sale ofshares of the Company’s common stock, the issuance of warrants to purchase shares of common stock, and the issuance of warrantsto the placement agent for each transaction. Due to a cash put provision within the warrant agreement, which could be enacted in certainchange in control events, a liability associated with those warrants was initially recorded at fair value in the Company’s consolidatedbalance sheets upon issuance, and subsequently re-measured each fiscal quarter. The changes in the fair value between issuance and theend of each reporting period is recorded as a component of other income (expense), net in the consolidated statements of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.1pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During 2017, warrant holders of 952,184 warrants agreed to a modificationof the terms of their warrants which resulted in placing all situations that would allow the warrant holder to put the warrant for cashfully in control of the Company. As a result of the modification, the modified warrants are no longer liability classified and do notneed to be re-measured. These modifications resulted in a $3.7 million value of those warrants being reclassified from Warrant Liabilitiesto Additional Paid in Capital. The remaining un-modified 92,212 warrants, which remain outstanding as of December 31, 2020, continue tobe re-measured at each reporting period as long as they are outstanding and un-modified.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 65; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          14          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: split 8 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has re-measured the liability to estimated fair value atinception, prior to modification and at each reporting date using the Black-Scholes option pricing model with the following weighted averageassumptions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           Assumptions for Estimating Fair Value           <br/>           on Reporting Dates of:          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           December 31,           <br/>           2020          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           December 31,           <br/>           2019          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 48%; font-size: 10pt; text-align: left">           Risk-free interest rate          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           0.12          </td>          <td style="white-space: nowrap; width: 4%; font-size: 10pt; text-align: left">           %          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           1.58          </td>          <td style="white-space: nowrap; width: 4%; font-size: 10pt; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Expected volatility          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           137.89          </td>          <td style="white-space: nowrap; font-size: 10pt; text-align: left">           %          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           90.53          </td>          <td style="white-space: nowrap; font-size: 10pt; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Expected term (in years)          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1.1          </td>          <td style="white-space: nowrap; font-size: 10pt; text-align: left">           years          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           2.1          </td>          <td style="white-space: nowrap; font-size: 10pt; text-align: left">           years          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Expected dividend yield          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="white-space: nowrap; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="white-space: nowrap; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Exercise Price          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           8.00          </td>          <td style="white-space: nowrap; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           8.00          </td>          <td style="white-space: nowrap; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">           Market value of common stock          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           1.25          </td>          <td style="white-space: nowrap; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           $          </td>          <td style="font-size: 10pt; text-align: right">           2.01          </td>          <td style="white-space: nowrap; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           Warrants to purchase shares of common stock          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           92,212          </td>          <td style="white-space: nowrap; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           92,212          </td>          <td style="white-space: nowrap; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table presents a reconciliation of the Company’swarrant liabilities for the years ended December 31, 2020 and 2019:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">          </td>          <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">           Warrant Liability          </td>          <td style="white-space: nowrap; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">           (in thousands)          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 87%; font-size: 10pt">           Balance as of December 31, 2018          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           98          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Change in fair value upon re-measurement          </td>          <td style="font-size: 10pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (65          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Balance as of December 31, 2019          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           33          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Change in fair value upon re-measurement          </td>          <td style="font-size: 10pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (16          </td>          <td style="font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">           Balance as of December 31, 2020          </td>          <td style="font-size: 10pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           17          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         9. Commitments and Contingencies        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On April 14, 2017, representatives for the estate of a deceasedindividual filed a civil lawsuit in the Suffolk Superior Court, in Boston, Massachusetts, against the Company and HarvardBioscience, Inc., the Company’s former parent company. The complaint alleges that the decedent’s injury and death werecaused by two tracheal implants that incorporated synthetic trachea scaffolds and a biologic component combined by the implantingsurgeon with a bioreactor, and surgically implanted in the decedent in two surgeries performed in 2012 and 2013. The civil complaintseeks a non-specific sum of money to compensate the plaintiffs. This civil lawsuit relates to the Company’s first-generationtrachea scaffold technology for which the Company discontinued development in 2014, and not to the Company’s current Cellframetechnology nor to its lead development product candidate, the CEI. The Company intends to vigorously defend this case. While theCompany believes that such claim lacks merit, the Company is unable to predict the ultimate outcome of such litigation. Inaccordance with the Separation and Distribution agreement between Harvard Bioscience and the Company relating to the spin-off of theCompany in 2013, the Company would be required to indemnify Harvard Bioscience against losses that Harvard Bioscience may suffer asa result of this litigation. The Company has been informed by its insurance provider that the case has been accepted as an insurableclaim under the Company’s product liability insurance policy. The Company has not accrued for a potential liability as it isnot considered probable at this time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 66; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          15          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        From time to time, the Company may be involved in various claims andlegal proceedings arising in the ordinary course of business. Other than the above matter, there are no such matters pending that theCompany expects to be material in relation to its business, financial condition, and results of operations or cash flows.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         10. Leases        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company leases laboratory and office space and certain equipmentwith remaining terms ranging from 1 year to 5 years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The laboratory and office arrangement is under a sublease that wasrenewed in December of 2020 and currently extends through May 31, 2022. This lease automatically renews annually for a one-year periodunless the Company or Harvard Bioscience provides a notice of termination within one hundred and eighty days prior to May 31 of each year.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        All of the Company’s leases qualify as operating leases. Thefollowing table summarizes the presentation of the Company’s operating leases in its consolidated balance sheets:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td colspan="3" style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="3" style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td colspan="3" style="font-size: 10pt">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="6" style="font-size: 10pt">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt">           <font style="font-size: 1pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; font-weight: bold">           (in thousands)          </td>          <td style="font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold">           Balance Sheet Classification          </td>          <td style="font-size: 10pt">          </td>          <td colspan="6" style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; font-style: italic">           Assets:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 37%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Operating lease assets          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="width: 36%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Right-of-use asset          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           182          </td>          <td style="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           191          </td>          <td style="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; font-style: italic">           Liabilities:          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Current portion of operating lease liabilities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">           Current portion of operating lease liabilities          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           107          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           102          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Operating lease liabilities, net of current portion          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Operating lease liabilities, net of current portion          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           75          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           89          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Total operating lease liabilities          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           182          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           191          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Cash paid for leases included in cash used in operating activitiesin the Company’s consolidated statement of cash flows during the years ended December 31, 2020, and 2019 amounted to approximately$121,000 and $114,000, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The weighted average remaining lease terms and weighted average discountrates as of December 31, 2020 and 2019 were as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">        <tbody>         <tr style="vertical-align: bottom; background-color: White">          <td style="white-space: nowrap; font-size: 10pt; text-align: left">          </td>          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td colspan="6" style="white-space: nowrap; font-size: 10pt; text-align: center">           <b>            Year ended December 31,           </b>          </td>          <td style="white-space: nowrap; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">          </td>          <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">           <b>            2020           </b>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">          </td>          <td style="text-align: center; padding-bottom: 1pt; font-size: 10pt">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">           <b>            2019           </b>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt; text-align: left">           Remaining lease term (in years)          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           1.92          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           2.37          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           Discount rate          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           10.16          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           13.13          </td>          <td style="font-size: 10pt; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table summarizes the effect of lease costs in the Company’scondensed consolidated statements of operations:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-style: normal; white-space: nowrap; font-size: 10pt; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font-style: normal; white-space: nowrap; font-size: 10pt; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font-style: normal; white-space: nowrap; font-size: 10pt; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; white-space: nowrap">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td colspan="6" style="font: normal 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">           <font style="font-style: normal; font-weight: normal">            For    the Year Ended December 31           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; white-space: nowrap">           <font style="font-style: normal; font-weight: normal">           </font>          </td>         </tr>         <tr style="font-style: normal; vertical-align: bottom; font-weight: normal">          <td style="border-bottom: Black 1pt solid; font: normal 10pt Times New Roman, Times, Serif">           <font style="font-style: normal; font-weight: normal">            (in    thousands)           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font: normal 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-style: normal; font-weight: normal">            Statement    of Operations Classification           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: normal 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-style: normal; font-weight: normal">            2020           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: normal 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-style: normal; font-weight: normal">            2019           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-style: normal; font-weight: normal">           </font>          </td>         </tr>         <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">          <td style="font: normal 10pt Times New Roman, Times, Serif; width: 37%; text-align: left">           <font style="font-style: normal; font-weight: normal">            Operating    lease expense           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; width: 36%; text-align: left">           <font style="font-style: normal; font-weight: normal">            Research    and development           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-style: normal; font-weight: normal">            $           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">           <font style="font-style: normal; font-weight: normal">            77           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-style: normal; font-weight: normal">            $           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">           <font style="font-style: normal; font-weight: normal">            73           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">           <font style="font-style: normal; font-weight: normal">           </font>          </td>         </tr>         <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">          <td style="font-style: normal; font-size: 10pt; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">           <font style="font-style: normal; font-weight: normal">            Selling,    general and administrative           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-style: normal; font-weight: normal">            44           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-style: normal; font-weight: normal">            41           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; text-align: left">           <font style="font-style: normal; font-weight: normal">           </font>          </td>         </tr>         <tr style="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">          <td style="font-style: normal; font-size: 10pt; padding-bottom: 1pt; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font-style: normal; font-size: 10pt; padding-bottom: 1pt; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font-style: normal; font-size: 10pt; padding-bottom: 1pt; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font-style: normal; font-size: 10pt; padding-bottom: 1pt; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font-style: normal; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font-style: normal; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font-style: normal; padding-bottom: 1pt; font-size: 10pt; text-align: left; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font-style: normal; font-size: 10pt; padding-bottom: 1pt; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font-style: normal; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font-style: normal; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font-style: normal; padding-bottom: 1pt; font-size: 10pt; text-align: left; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>         </tr>         <tr style="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">          <td style="font-style: normal; font-size: 10pt; padding-bottom: 1pt; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font-style: normal; font-size: 10pt; padding-bottom: 1pt; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font-style: normal; font-size: 10pt; padding-bottom: 1pt; font-weight: normal">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font: normal 10pt Times New Roman, Times, Serif; text-align: left">           <font style="font-style: normal; font-weight: normal">            $           </font>          </td>          <td style="border-bottom: Black 1pt solid; font: normal 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-style: normal; font-weight: normal">            121           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           <font style="font-style: normal; font-weight: normal">           </font>          </td>          <td style="border-bottom: Black 1pt solid; font: normal 10pt Times New Roman, Times, Serif; text-align: left">           <font style="font-style: normal; font-weight: normal">            $           </font>          </td>          <td style="border-bottom: Black 1pt solid; font: normal 10pt Times New Roman, Times, Serif; text-align: right">           <font style="font-style: normal; font-weight: normal">            114           </font>          </td>          <td style="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">           <font style="font-style: normal; font-weight: normal">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 67; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          16          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The minimum lease payments for the next five years and thereafter areexpected to be as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">           (In thousands)          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">           As of           <br/>           December 31, 2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 80%; font-size: 10pt; text-align: left">           2021          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 16%; font-size: 10pt; text-align: right">           121          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left">           2022          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           62          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left">           2023          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           12          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           2024          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           7          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font-size: 10pt; text-align: left">           Total lease payments          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; font-variant: small-caps">          </td>          <td style="font-size: 10pt; font-variant: small-caps; text-align: left">           $          </td>          <td style="font-size: 10pt; font-variant: small-caps; text-align: right">           202          </td>          <td style="font-size: 10pt; font-variant: small-caps; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">           Less: imputed interest          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           20          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           Present value of operating lease liabilities          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           182          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         11. Income Taxes        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s net loss was generated entirely in the U.S. in2020 and 2019. Income taxes for the years ended December 31, 2020 and 2019 differed from the amount computed by applying the U.S. federalincome tax rate of 21% for both 2020 and 2019 to pre-tax loss as a result of the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Years ended December 31,            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2020            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2019            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: center">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="6" style="text-align: center">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="6" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (in thousands)           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 74%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Computed “expected” income tax benefit           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1,022           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1,750           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            State income tax benefit, net of federal income tax benefit           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (307           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (527           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Permanent items, primarily change in fair value of warrants and non-deductible share-based compensation           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            32           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            76           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Tax credits           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (126           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (280           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Stock-option cancellations           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            402           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Adjustment of prior year income tax           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (192           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Change in valuation allowance           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,021           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,673           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Total income taxes           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The components of the Company’s deferred tax asset are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Years ended December 31,            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             2020            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             2019            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: center">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="6" style="text-align: center">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="6" style="text-align: center">           <font style="font-size: 10pt">            (in thousands)           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Deferred tax assets:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="width: 74%; padding-left: 9pt">           <font style="font-size: 10pt">            Operating loss and credit carryforwards           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            15,217           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            13,734           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Capitalized research and development           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,873           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            2,276           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Stock-based compensation           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,078           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,054           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Lease liabilities           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            30           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            52           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Excess book over tax depreciation           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            34           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            103           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 9pt">           <font style="font-size: 10pt">            Accrued expenses           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            12           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Total deferred tax assets           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            18,252           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            17,231           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 9pt">           <font style="font-size: 10pt">            Less: valuation allowance           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (18,200           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (17,179           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            Deferred tax assets           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            52           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            52           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Deferred tax liability:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 9pt">           <font style="font-size: 10pt">            Operating lease assets           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (52           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (52           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            Total deferred tax liability           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (52           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (52           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">        <font style="font-size: 10pt">        </font>       </p>       <!-- Field: Page; Sequence: 68; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          17          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">        <font style="font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has recorded a valuation allowance against its deferredtax assets for the years ended December 31, 2020 and 2019, because the Company’s management believes that it is more likely thannot that these assets will not be realized. The valuation allowance increased by approximately $1.0 million and $2.7 million for the yearsended December 31, 2020 and 2019, respectively, primarily as a result of operating losses generated with no corresponding financial statementbenefit.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        As of December 31, 2020, the Company had federal net operating losscarryforwards (NOLs) of approximately $47.9 million to offset future federal taxable income and state NOLs of approximately $47.4 millionto offset future state taxable income. The federal and state NOLs generated for annual periods prior to January 1, 2018 begin to expirein 2033. The Company’s federal NOL generated for the years ended December 31, 2018 through December 31, 2020, which amounted to$21.4 million, can be carried forward indefinitely. As of December 31, 2020, the Company also has federal and state tax research and developmentcredit carryforwards of approximately $1.4 million and $1.0 million, respectively, to offset future income taxes. The federal and stateresearch and development tax credit carryforwards begin to expire in 2033 and 2029, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Under the provisions of the Internal Revenue Code, the net operatingloss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities.Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changesin the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that canbe utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on thevalue of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in futureyears. The Company has recently completed several equity financings transactions which have either individually or cumulatively resultedin a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.The Company does not believe the impact of any limitation on the use of its net operating loss or credit carryforwards will have a materialimpact on the Company’s consolidated financial statements since the Company has a full valuation allowance against its deferredtax assets due to the uncertainty regarding future taxable income for the foreseeable future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        For all years through December 31, 2020, the Company generated researchcredits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company's researchand development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presentedas an uncertain tax position. A full valuation allowance has been provided against the Company's research and development credits and,if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the researchand development credit carryforwards and the valuation allowance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Harvard Bioscience received a Supplemental Ruling to the PrivateLetter Ruling dated March 22, 2013 from the IRS to the effect that, among other things, the Separation and Distribution by HarvardBioscience will qualify as a transaction that is tax-free for U.S. federal income tax purposes under Section 355 and 368(a)(1)(D) ofthe Internal Revenue Code continuing in effect. The private letter and supplemental rulings and the tax opinion that HarvardBioscience received from legal counsel to Harvard Bioscience rely on certain representations, assumptions and undertakings,including those relating to the past and future conduct of the Biostage business, and neither the private letter and supplementalrulings nor the opinion would be valid if such representations, assumptions and undertakings were incorrect. Moreover, the privateletter and supplemental rulings do not address all the issues that are relevant to determining whether the Distribution will qualifyfor tax-free treatment. Notwithstanding the private letter and supplemental rulings and opinion, the IRS could determine theDistribution should be treated as a taxable transaction for U.S. federal income tax purposes if, among other reasons, it determinesany of the representations, assumptions or undertakings that were included in the request for the private letter and supplementalrulings are false or have been violated or if it disagrees with the conclusions in the opinion that are not covered by the IRSruling.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        To preserve the tax-free treatment to Harvard Bioscience of the Separationand Distribution, for the two-year period following the Distribution, which such period ended November 1, 2015, the Company was limited,except in specified circumstances, from entering into certain transactions pursuant to which all or a portion of the Company’s stockwould be acquired, whether by merger or otherwise; issuing equity securities beyond certain thresholds; repurchasing the Company’scommon stock; and ceasing to actively conduct the Company’s regenerative medicine business. In addition, at all times, includingduring and following such two-year period, the Company may not take or fail to take any other action that prevents the Separation andDistribution and related transactions from being tax-free.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        If the Distribution fails to qualify for tax-free treatment, in general,Harvard Bioscience would be subject to tax as if it had sold the Company’s common stock in a taxable sale for its fair market value,and Harvard Bioscience stockholders who receive shares of Biostage common stock in the Distribution would be subject to tax as if theyhad received a taxable Distribution equal to the fair market value of such shares.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 69; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          18          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Under the tax sharing agreement between Harvard Bioscience and theCompany, the Company would generally be required to indemnify Harvard Bioscience against any tax resulting from the Distribution to theextent that such tax resulted from (i) an acquisition of all or a portion of the Company’s stock or assets, whether by merger orotherwise, (ii) other actions or failures to act by the Company, or (iii) any of the Company’s representations or undertakings beingincorrect or violated. The Company’s indemnification obligations to Harvard Bioscience and its subsidiaries, officers and directorsare not limited by any maximum amount. If the Company is required to indemnify Harvard Bioscience or such other persons under the circumstancesset forth in the tax sharing agreement, the Company may be subject to substantial liabilities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        All deferred tax assets prior to the Separation remained with HarvardBioscience.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has determined that any uncertain tax positions would haveno material impact on the consolidated financial statements of the Company and there are no unrecognized tax benefits or related interestand penalties accrued for the period for the years ended December 31, 2020 and 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company is subject to U.S. federal income tax and Massachusettsstate income tax. The statute of limitations for assessment by the IRS and state tax authorities is open for all periods from inceptionthrough December 31, 2019; currently, no federal or state income tax returns are under examination by the respective taxing authorities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security(CARES) Act was signed into law making several changes to the Internal Revenue Code. The changes include but are not limited to increasingthe limitation on the amount of deductible interest expense, allowing companies to carryback certain net operating losses, and increasingthe amount of net operating loss carryforwards that corporations can use to offset taxable income. The tax law changes in the CARES Actdid not have a material impact on the Company’s income tax provision.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         12. Employee Benefit Plan        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company sponsors a retirement plan for its U.S. employees, whichincludes an employee savings plan established under Section 401(k) of the U.S. Internal Revenue Code (the 401(k) Plan). The 401(k) Plancovers substantially all full-time employees who meet certain eligibility requirements. Contributions to the retirement plan are at thediscretion of management. The Company’s matching contributions to the plan were approximately $62,000 and $109,000 for the yearsended December 31, 2020 and 2019, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         13. Preferred Stock        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There are no shares of any class of preferred stock outstanding asof December 31, 2020 or December 31, 2019. Authorized shares for each preferred stock class is as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; font-size: 10pt">          </td>          <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            <b>            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            <b>             Authorized            </b>           </p>          </td>          <td style="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 87%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -9.35pt; padding-left: 9.35pt">           Undesignated Preferred Stock          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           984,000          </td>          <td style="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -9.35pt; padding-left: 9.35pt">           Series B Convertible Preferred Stock          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,000,000          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -9.35pt; padding-left: 9.35pt">           Series C Convertible Preferred Stock          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           4,000          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -9.35pt; padding-left: 9.35pt">           Series D Convertible Preferred Stock          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           12,000          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 70; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          19          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Split-Segment; Name: split 9 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         14. Common Stock        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During 2019, the Company decreased the number of authorized sharesof common stock from 120 million to 60 million. As of December 31, 2020, there were approximately 50.6 million shares of common stockavailable for issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following represent the Company’s common stock transactionsduring December 31, 2020 and 2019:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         2020 Capital Transactions        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During the year ended December 31, 2020, the Company issued a totalof 151,027 and 125,000 shares of its common stock at purchase prices of $3.70 and $4.00 per share, respectively, and warrants to purchase151,027 shares of common stock at an exercise price of $3.70 per share to a group of investors for aggregate gross and net proceeds ofapproximately $1.1 million, of which, $1.0 million and $0.1 million was allocated to the common stock and warrants, respectively, utilizingthe relative fair value. The Company classified these warrants on its consolidated balance sheets as equity, and valued using the Black-Scholesmodel based on the following weighted average assumptions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">        <tbody>         <tr style="background-color: rgb(204,238,255)">          <td style="padding-right: 5.4pt; padding-left: 0in">           Risk-free interest rate          </td>          <td style="width: 6%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">          </td>          <td style="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">          </td>          <td style="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">           0.88          </td>          <td style="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt">           %          </td>         </tr>         <tr style="background-color: White">          <td style="padding-right: 5.4pt; padding-left: 0in">           Expected volatility          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">           107          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt">           %          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="padding-right: 5.4pt; padding-left: 0in">           Expected term          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">           2          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt">           months          </td>         </tr>         <tr style="background-color: White">          <td style="padding-right: 5.4pt; padding-left: 0in">           Expected dividend yield          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">           -          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="padding-right: 5.4pt; padding-left: 0in">           Exercise price          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">           $          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">           3.7          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt">          </td>         </tr>         <tr style="background-color: White">          <td style="padding-right: 5.4pt; padding-left: 0in">           Market value of common stock          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">           $          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">           3.11          </td>          <td style="padding-right: 5.4pt; padding-left: 5.4pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During the year ended December 31, 2020, the Company issued 516,877shares of our common stock to a group of investors in connection with the exercise of 516,877 previously issued warrants at $3.70 pershare for aggregate gross and net proceeds of approximately $1.9 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During the year ended December 31, 2020, the Company issued 414,000shares of our common stock to a group of investors in connection with the exercise of 414,000 previously issued warrants at $2.00 pershare for aggregate gross and net proceeds of approximately $0.8 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During the year ended December 31, 2020, the Company issued a totalof 25,948 shares of our common stock to former chief executive officer and an employee due to the vesting of restricted stock units andissuance of a common stock award.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         2019 Capital Transactions        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On June 12, 2019, the Company issued a total of 345,174 shares of ourcommon stock and warrants to purchase 345,174 shares of common stock to a group of investors at an exercise price of $3.70 per share,in exchange for aggregate gross and net proceeds of approximately $1.3 million, of which $0.7 million and $0.6 million was allocated tothe common stock and warrants, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On December 31, 2019, the Company issued a total of 143,230 sharesof our common stock at a purchase price of $3.70 per share and warrants to purchase 143,230 shares of common stock at an exercise priceof $3.70 per share to a group of investors for aggregate gross and net proceeds in the amount of $0.5 million, of which $0.4 million and$0.1 million was allocated to the common stock and warrants, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During the year ended December 31, 2019, the Company issued 1,994,000shares of our common stock to a group of investors in connection with the exercise of 1,994,000 previously issued warrants at $2.00 pershare for aggregate gross and net proceeds of approximately $4.0 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        During the year ended December 31, 2019, the Company issued a totalof 3,506 shares of our common stock to employees due to the vesting of restricted stock units.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <!-- Field: Page; Sequence: 71; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          20          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Warrant to purchase common stock activity for the year ended December31, 2020 was as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Amount          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Weighted-average            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             exercise price            </b>           </p>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt">           Outstanding at December 31, 2019          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           2,673,051          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           5.20          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-left: 6.6pt">           Issued          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           151,027          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           3.70          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 6.6pt">           Exercised          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (930,877          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           2.94          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-bottom: 2.5pt">           Outstanding at December 31, 2020          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,893,201          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           6.44          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Employee Stock Purchase Plan        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In 2013, the Company approved the 2013 Employee Stock Purchase Plan(the ESPP Plan). Under the ESPP Plan, participating employees can authorize the Company to withhold a portion of their base pay duringconsecutive six-month payment periods for the purchase of shares of the Company’s common stock. At the conclusion of the period,participating employees can purchase shares of the Company’s common stock at 85% of the lower of the fair market value of the Company’scommon stock at the beginning or end of the period. Shares are issued under the plan for the six-month periods ending June 30 and December31. Under this plan, 7,500 shares of common stock are authorized for issuance of which 4,534 shares have been issued as of December 31,2020. There are 2,966 shares available for issuance as of December 31, 2020 and December 31, 2019. There was no ESPP Plan activity in2020 or 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         15. Share-based Compensation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Biostage Amended and Restated Equity Incentive Plan        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.9pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company maintains the Amended and Restated Equity Incentive Plan(the Plan) for the benefit of certain officers, employees, non-employee directors, and other key persons (including consultants and advisoryboard members). All options and awards granted under the Plan consist of the Company’s shares of common stock. The Company’spolicy is to issue stock available from its registered but unissued stock pool through its transfer agent to satisfy stock option exercisesand the vesting of restricted stock units. The vesting period for awards is generally four years and the contractual life is ten years.Canceled and forfeited options and awards are available to be reissued under the Plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In June 2020, the Company’s shareholders approved the Amendedand Restated Equity Incentive Plan (the 2013 Equity Incentive Plan) to, among other things, increase of the number of shares of the Company’scommon stock available for issuance pursuant thereto by 3,000,000 shares, which increased the total shares authorized to be issued underthe Plan to 5,098,000. There are 3,477,504 shares available for issuance as of December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Stock option activity under the Plan for the year ended December 31,2020 was as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Amount          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Weighted-average            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             exercise price            </b>           </p>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Weighted-average            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             contractual life            </b>           </p>          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 61%; font-size: 10pt">           Outstanding at December 31, 2019          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           1,772,761          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           6.04          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           7.94          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-left: 6.6pt">           Granted          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           313,261          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           2.70          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 6.6pt">           Canceled          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (486,302          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           2.83          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-bottom: 2.5pt">           Outstanding at December 31, 2020          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,599,720          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           6.33          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           5.77          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Options exercisable          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,152,581          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           7.75          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           5.02          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Options vested and expected to vest          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,504,040          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           6.58          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s outstanding stock options include 338,663 performance-basedawards that have vesting provisions subject to the achievement of certain business milestones. In September 2019, the Company deemed theachievement of one of the performance-based milestones totaling 95,131 shares probable for accounting purposes, are now exercisable, andhas recognized approximately $0.3 million expense associated with this milestone during the year ended December 31, 2019. Total unrecognizedcompensation expense for the remaining 243,532 performance-based awards is approximately $0.8 million. No expense has been recognizedfor these awards as of December 31, 2020 given that the milestone achievements for these awards have not yet been deemed probable foraccounting purposes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 72; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          21          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Aggregate intrinsic value for outstanding options and exercisable optionsfor the year ended December 31, 2020 was $0 based on the Company’s closing stock price of $1.25 per share as of December 31, 2020.As of December 31, 2020, unrecognized compensation cost related to unvested non-performance-based awards amounted to $0.4 million, whichwill be recognized over a weighted-average period of 0.5 years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The weighted average assumptions for valuing the Company’s stockoptions granted were as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="5" style="border-bottom: black 1pt solid; text-align: center">           <b>            Year Ended December 31,           </b>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <b>            2020           </b>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <b>            2019           </b>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           Risk-free interest rate          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           0.68          </td>          <td style="width: 5%">           %          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           1.70          </td>          <td style="width: 5%">           4%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Expected volatility          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           111.47          </td>          <td>           %          </td>          <td>          </td>          <td style="text-align: right">           115.5          </td>          <td>           4%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           Expected term (in years)          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           4.4          </td>          <td>           years          </td>          <td>          </td>          <td style="text-align: right">           5.3          </td>          <td>           years          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           Expected dividend yield          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           n/a          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           n/a          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The grant date fair value of stock options is estimated using the Black-Scholesoption pricing model that takes into account the fair value of its common stock, the exercise price, the expected life of the option,the expected volatility of its common stock, expected dividends on its common stock, and the risk-free interest rate over the expectedlife of the option. The risk-free interest rate assumption is based upon observed Treasury bill interest rates (risk-free) appropriatefor the expected term of the Company’s employee stock options. The computation of expected volatility is based on the historicalvolatility of the Company’s common stock. The simplified method of estimating expected term was used. The Company has not paid anddo not anticipate paying cash dividends on the Company’s shares of common stock; therefore, the expected dividend yield is assumedto be zero.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In February 2020, as part of the termination arrangement with the Company’sformer chief executive officer, the Company modified certain options to purchase 236,970 shares of common stock, issued an 80,000 fullyvested stock option grant, and accelerated the vesting of 3,300 restricted stock units resulting in recording $153,000, $70,000, and $4,000,respectively, of share-based compensation for the year ended December 31, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        In June 2019, the Company modified certain options to purchase commonstock and issued a 35,000 fully vested stock option grant as part of the termination arrangement for the Company’s former chieffinancial officer, resulting in recording $92,000 and $62,000, respectively, of share-based compensation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company also estimated the fair value of non-employee share optionsusing the Black-Scholes option pricing model reflecting the same assumptions as applied to employee and director options in each of thereporting periods, other than the expected life, which is assumed to be the remaining contractual life of the options.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The weighted average estimated fair value of stock options grantedusing the Black-Scholes model was $1.84 per share during 2020 and $2.12 per share during 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company also has issued restricted stock units under the Plan.Unvested shares of restricted common stock may not be sold or transferred by the holder. The following table summarizes the Company’sunvested restricted stock unit activity under the Plan for the year ended December 31, 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: justify">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Amount          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 87%; font-size: 10pt; text-indent: -9.9pt; padding-left: 9.9pt">           Unvested at December 31, 2019          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           3,300          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-indent: -9.9pt; padding-left: 9.9pt">           Canceled          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           -          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; padding-bottom: 1pt; text-indent: -9.9pt; padding-left: 9.9pt">           Vested          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           (3,300          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-bottom: 2.5pt; text-indent: -9.9pt; padding-left: 9.9pt">           Unvested at December 31, 2020          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The grant date fair value for all restricted stock units activity duringthe year ended December 31, 2020 was $7.68 per share. The fair value of restricted shares of common stock vested during the year endedDecember 31, 2020 amounted to approximately $8,000 in the aggregate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 73; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          22          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Share-based compensation expense related to the Plan for the yearsended December 31, 2020 and 2019 was allocated as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Years Ended December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="6" style="font-size: 10pt; text-align: center">           (in thousands)          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt; text-align: left">           Research and development          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           311          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>          <td style="width: 1%; font-size: 10pt">          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; font-size: 10pt; text-align: right">           523          </td>          <td style="width: 1%; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Selling, general and administrative          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           833          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           1,131          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Total stock-based compensation          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,144          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           1,654          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         16. Net Loss per Share        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Basic and diluted net loss per share was calculated as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Years Ended December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">           <font style="font-size: 1pt">           </font>          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center">           <font style="font-size: 1pt">           </font>          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">           <font style="font-size: 1pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="6" style="white-space: nowrap; font-size: 10pt; text-align: center">           (in thousands, except per share data)          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Net loss          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (4,865          </td>          <td style="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (8,332          </td>          <td style="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-bottom: 2.5pt">           Weighted-average shares outstanding          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           8,794          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           6,898          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">           Net loss per share – basic and diluted          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (0.55          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           (1.21          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company’s potentially dilutive securities, which includestock options, unvested restricted common stock units and warrants, have been excluded from the computation of diluted net loss per sharewhenever the effect of including them would be to reduce the net loss per share. In periods where there is a net loss, the weighted averagenumber of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders isthe same.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following potential common shares were excluded from the calculationof diluted net loss per share attributable to common stockholders for the years ended December 31, 2020 and 2019 because including themwould have had an anti-dilutive effect:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           Years Ended December 31,          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>          <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt; text-align: left; width: 74%">           Warrants to purchase common stock          </td>          <td style="font-size: 10pt; width: 1%">          </td>          <td style="font-size: 10pt; text-align: left; width: 1%">          </td>          <td style="font-size: 10pt; text-align: right; width: 10%">           1,893,201          </td>          <td style="font-size: 10pt; text-align: left; width: 1%">          </td>          <td style="font-size: 10pt; width: 1%">          </td>          <td style="font-size: 10pt; text-align: left; width: 1%">          </td>          <td style="font-size: 10pt; text-align: right; width: 10%">           2,673,051          </td>          <td style="font-size: 10pt; text-align: left; width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">           Options to purchase common stock          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,599,720          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">           1,772,761          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">           Unvested restricted common stock units          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>          <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>          <td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">           3,300          </td>          <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-bottom: 2.5pt">           Total          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           3,492,921          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">           4,449.112          </td>          <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         17. Subsequent Events        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company has performed an evaluation of subsequent events throughthe time of filing this Annual Report on Form 10-K with the SEC and has determined that there are no such events to report other thanthose already disclosed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 74; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          F-          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          23          <!-- Field: /Sequence -->         </font>        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <a name="zz_030">        </a>        <b>         Item 16.        </b>        <b>         <i>          Form 10-K Summary.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 75; Options: NewSection; Value: 49 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         49         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: center">          </td>          <td style="width: 98%; text-align: center">           <a name="zz_031">           </a>           <b>            SIGNATURES           </b>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Pursuant to the requirements of Section 13 or 15(d) of the SecuritiesExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td>          </td>          <td colspan="2">           Biostage, Inc.          </td>         </tr>         <tr style="vertical-align: top">          <td style="width: 50%">           Date: April 13, 2021          </td>          <td style="width: 3%">          </td>          <td style="width: 47%">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           By:          </td>          <td style="border-bottom: black 1pt solid">           /s/ Hong Yu          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>           Hong Yu          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>           President          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.8pt; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Pursuant to the requirements of the Securities Exchange Act of 1934,this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="border-bottom: black 1pt solid; text-align: center">           <b>            Signature           </b>          </td>          <td style="text-align: center">          </td>          <td style="border-bottom: black 1pt solid; text-align: center">           <b>            Title           </b>          </td>          <td colspan="2" style="text-align: center">          </td>          <td style="border-bottom: black 1pt solid; text-align: center">           <b>            Date           </b>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td colspan="2" style="text-align: center">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            /s/ Hong Yu           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Hong Yu            </b>           </p>          </td>          <td style="text-align: center">          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            President           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            (principal executive officer)           </p>          </td>          <td style="text-align: center">          </td>          <td colspan="2" style="text-align: center">           April 13, 2021          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td colspan="2">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            /s/ Peter A. Pellegrino Jr.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Peter Pellegrino            </b>           </p>          </td>          <td style="text-align: center">          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            Interim Vice President of Finance           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            (principal financial officer and principal accounting officer)           </p>          </td>          <td style="text-align: center">          </td>          <td colspan="2" style="text-align: center">           April 13, 2021          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td colspan="2">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            /s/ Jason Jing Chen           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Jason Jing Chen            </b>           </p>          </td>          <td style="text-align: center">          </td>          <td>           Chairman          </td>          <td style="text-align: center">          </td>          <td colspan="2" style="text-align: center">           April 13, 2021          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td colspan="2" style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            /s/ Ting Li           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Ting Li            </b>           </p>          </td>          <td style="text-align: center">          </td>          <td>           Director          </td>          <td style="text-align: center">          </td>          <td colspan="2" style="text-align: center">           April 13, 2021          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td colspan="2" style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            /s/ Herman Sanchez           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Herman Sancez            </b>           </p>          </td>          <td style="text-align: center">          </td>          <td>           Director          </td>          <td style="text-align: center">          </td>          <td colspan="2">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            April 13, 2021           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            /s/ James Shmerling           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             James Shmerling            </b>           </p>          </td>          <td style="text-align: center">          </td>          <td>           Director          </td>          <td style="text-align: center">          </td>          <td colspan="2">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            April 13, 2021           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            /s/ Wei Zhang           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Wei Zhang             <br style="clear: both"/>            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>            </b>           </p>          </td>          <td style="text-align: center">          </td>          <td>           Director          </td>          <td style="text-align: center">          </td>          <td colspan="2" style="text-align: center">           April 13, 2021          </td>         </tr>         <tr>          <td style="width: 30%">          </td>          <td style="width: 1%">          </td>          <td style="width: 50%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 17%">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 76; Value: 49 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         50         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         EXHIBIT INDEX        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following exhibits are filed as part of this Annual Report on Form10-K. Where such filing is made by incorporation by reference to a previously filed document, such document is identified.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="vertical-align: top; width: 11%; border-bottom: black 1pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Exhibit            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Number            </b>           </p>          </td>          <td style="vertical-align: top; width: 1%; text-align: center">          </td>          <td style="vertical-align: bottom; width: 88%; border-bottom: black 1pt solid; text-align: center">           <b>            Description of Exhibit           </b>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413059292/v359548_ex2-1.htm" style="-sec-extract: exhibit">            2.1§           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413059292/v359548_ex2-1.htm" style="-sec-extract: exhibit">            Separation and Distribution Agreement between Biostage, Inc. and Harvard Bioscience, Inc. dated as of October 31, 2013 (previously filed as an exhibit to the Company’s Current Report on Form 8-K, filed on November 6, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex3-1.htm" style="-sec-extract: exhibit">            3.1           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex3-1.htm" style="-sec-extract: exhibit">            Amended and Restated Certificate of Incorporation of Biostage, Inc. (previously filed as an exhibit to the Company’s Registration Statement on Form 10-12B, filed July 31, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420416091767/v435709_ex3-1.htm" style="-sec-extract: exhibit">            3.2           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420416091767/v435709_ex3-1.htm" style="-sec-extract: exhibit">            Certificate of Amendment to Amended and Restated Certificate of Incorporation of Biostage, Inc. dated March 30, 2016 (previously filed as an exhibit to the Company’s Current Report on Form 8-K, filed on March 31, 2016, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420417015232/v461044_ex3-3.htm" style="-sec-extract: exhibit">            3.3           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420417015232/v461044_ex3-3.htm" style="-sec-extract: exhibit">            Certificate of Amendment to Amended and Restated Certificate of Incorporation of Biostage, Inc. dated May 26, 2016 (previously filed as an exhibit to the Company’s Annual Report on Form 10-K, filed on March 17, 2017, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413058044/v358484_ex3-1.htm" style="-sec-extract: exhibit">            3.4           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413058044/v358484_ex3-1.htm" style="-sec-extract: exhibit">            Certificate of Designations, Preferences and Rights of Series A Preferred Stock of Biostage, Inc. classifying and designating the Series A Junior Participating Cumulative Preferred Stock (previously filed as an exhibit to the Company’s Registration Statement on Form 8-A, filed October 31, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420415008487/v401226_ex3-1.htm" style="-sec-extract: exhibit">            3.5           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420415008487/v401226_ex3-1.htm" style="-sec-extract: exhibit">            Certificate of Designation of Series B Convertible Preferred Stock of Biostage, Inc. classifying and designating the Series B Convertible Preferred Stock (previously filed as an exhibit to the Company’s Current Report on Form 8-K, filed on February 12, 2015, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420417022374/v465285_ex3-1.htm" style="-sec-extract: exhibit">            3.6           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420417022374/v465285_ex3-1.htm" style="-sec-extract: exhibit">            Certificate of Amendment to Amended and Restated Certificate of Incorporation of Biostage, Inc. dated April 26, 2017 (previously filed as an exhibit to the Company's Current Report on Form 8-K, filed on April 27, 2017, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420417043880/v473354_ex3-1.htm" style="-sec-extract: exhibit">            3.7           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420417043880/v473354_ex3-1.htm" style="-sec-extract: exhibit">            Certificate of Designations, Preferences, Rights and Limitations of Series C Convertible Preferred Stock of Biostage, Inc. classifying and designating the Series C Convertible Preferred Stock (previously filed as an exhibit to the Company's Current Report on Form 8-K, filed on August 17, 2017, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420417043880/v473354_ex3-2.htm" style="-sec-extract: exhibit">            3.8           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420417043880/v473354_ex3-2.htm" style="-sec-extract: exhibit">            Certificate of Elimination of Series A Junior Participating Cumulative Preferred Stock (previously filed as an exhibit to the Company's Current Report on Form 8-K, filed on August 17, 2017, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420417064920/tv481923_ex3-1.htm" style="-sec-extract: exhibit">            3.9           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420417064920/tv481923_ex3-1.htm" style="-sec-extract: exhibit">            Certificate of Amendment to Amended and Restated Certificate of Incorporation of Biostage, Inc. dated December 22, 2017 (previously filed as an exhibit to the Company's Current Report on Form 8-K, filed on December 22, 2017, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420418000347/tv482498_ex3-1.htm" style="-sec-extract: exhibit">            3.10           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420418000347/tv482498_ex3-1.htm" style="-sec-extract: exhibit">            Certificate of Designations, Preferences, Rights and Limitations of Series D Convertible Preferred Stock of Biostage, Inc. classifying and designating the Series D Convertible Preferred Stock (previously filed as an exhibit to the Company's Current Report on Form 8-K, filed on January 3, 2018, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420419028445/tv522547_ex3-1.htm" style="-sec-extract: exhibit">            3.11           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420419028445/tv522547_ex3-1.htm" style="-sec-extract: exhibit">            Certificate of Amendment to Amended and Restated Certificate of Incorporation of Biostage, Inc. dated May 24, 2019 (previously filed as an exhibit to the Company's Current Report on Form 8-K, filed on May 28, 2019, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420416091767/v435709_ex3-2.htm" style="-sec-extract: exhibit">            3.12           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420416091767/v435709_ex3-2.htm" style="-sec-extract: exhibit">            Amended and Restated By-laws of the Biostage, Inc. (previously filed as an exhibit to the Company’s Current Report on Form 8-K, filed on March 31, 2016, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex4-1.htm" style="-sec-extract: exhibit">            4.1           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex4-1.htm" style="-sec-extract: exhibit">            Specimen Stock Certificate evidencing shares of common stock (previously filed as an exhibit to the Company’s Registration Statement on Form 10-12B, filed July 31, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420415018746/v404965_ex4-2.htm" style="-sec-extract: exhibit">            4.2           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420415018746/v404965_ex4-2.htm" style="-sec-extract: exhibit">            Specimen Series B Convertible Preferred Stock Certificate (previously filed as an exhibit to the Company’s Annual Report on Form 10-K, filed on March 27, 2015, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420416102650/v440050_ex4-1.htm" style="-sec-extract: exhibit">            4.3           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420416102650/v440050_ex4-1.htm" style="-sec-extract: exhibit">            Form of Common Stock Purchase Warrant (previously filed as an exhibit to the Company’s Current Report on Form 8-K, filed on May 16, 2016, and incorporated by reference thereto).           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 77; Value: 49 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         51         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 11%; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420416102650/v440050_ex4-1.htm" style="-sec-extract: exhibit">            4.4           </a>          </td>          <td style="width: 1%; text-align: center">          </td>          <td style="width: 88%">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420416102650/v440050_ex4-1.htm" style="-sec-extract: exhibit">            Form of Common Stock Purchase Warrant (previously filed as an exhibit to the Company's Amendment No. 2 to Form S-1 Registration Statement, filed on February 7, 2017, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420417006516/v458640_ex4-2.htm" style="-sec-extract: exhibit">            4.5           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420417006516/v458640_ex4-2.htm" style="-sec-extract: exhibit">            Form of Placement Agent Common Stock Purchase Warrant (previously filed as an exhibit to the Company's Amendment No. 2 to Form S-1 Registration Statement, filed on February 7, 2017, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420418000347/tv482498_ex4-1.htm" style="-sec-extract: exhibit">            4.6           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420418000347/tv482498_ex4-1.htm" style="-sec-extract: exhibit">            Form of Common Stock Purchase Warrant (previously filed as an exhibit to the Company's Current Report on Form 8-K, filed on January 3, 2018, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000110465919073783/tm1926533-1_ex41.htm" style="-sec-extract: exhibit">            4.7           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000110465919073783/tm1926533-1_ex41.htm" style="-sec-extract: exhibit">            Form of Amendment to Common Stock Purchase Warrant (previously filed as an exhibit to the Company's Current Report on Form 8-K, filed on December 18, 2019, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000110465920000424/tm201082d1_ex4-1.htm" style="-sec-extract: exhibit">            4.8           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000110465920000424/tm201082d1_ex4-1.htm" style="-sec-extract: exhibit">            Form of Common Stock Purchase Warrant (previously filed as an exhibit to the Company's Current Report on Form 8-K, filed on January 2, 2020, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000110465920039631/tm205241d1_ex4-9.htm" style="-sec-extract: exhibit">            4.9           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000110465920039631/tm205241d1_ex4-9.htm" style="-sec-extract: exhibit">            Description of Securities (previously filed as an exhibit to the Company’s Annual Report on Form 10-K, filed on March 27, 2020, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413059292/v359548_ex10-1.htm" style="-sec-extract: exhibit">            10.1           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413059292/v359548_ex10-1.htm" style="-sec-extract: exhibit">            Intellectual Property Matters Agreement between Biostage, Inc. and Harvard Bioscience, Inc. dated as of October 31, 2013 (previously filed as an exhibit to the Company’s Current Report on Form 8-K, filed on November 6, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413059292/v359548_ex10-2.htm" style="-sec-extract: exhibit">            10.2           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413059292/v359548_ex10-2.htm" style="-sec-extract: exhibit">            Product Distribution Agreement between Biostage, Inc. and Harvard Bioscience, Inc. dated as of October 31, 2013 (previously filed as an exhibit to the Company’s Current Report on Form 8-K, filed on November 6, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413059292/v359548_ex10-3.htm" style="-sec-extract: exhibit">            10.3           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413059292/v359548_ex10-3.htm" style="-sec-extract: exhibit">            Tax Sharing Agreement between Biostage, Inc. and Harvard Bioscience, Inc. dated as of October 31, 2013 (previously filed as an exhibit to the Company’s Current Report on Form 8-K, filed on November 6, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413059292/v359548_ex10-5.htm" style="-sec-extract: exhibit">            10.4           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413059292/v359548_ex10-5.htm" style="-sec-extract: exhibit">            Sublease by and between Biostage, Inc. and Harvard Bioscience, Inc. dated as of October 31, 2013 (previously filed as an exhibit to the Company’s Current Report on Form 8-K, filed on November 6, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-7.htm" style="-sec-extract: exhibit">            10.5           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-7.htm" style="-sec-extract: exhibit">            Form of Indemnification Agreement for Officers and Directors (previously filed as an exhibit to the Company’s Registration Statement on Form 10-12B, filed July 31, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000110465920052446/tm2016731-2_def14a.htm#t2ECP" style="-sec-extract: exhibit">            10.6#           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000110465920052446/tm2016731-2_def14a.htm#t2ECP" style="-sec-extract: exhibit">            Amended and Restated Equity Incentive Plan (previously filed as an exhibit to the Company’s Definitive Proxy Statement on Schedule 14A, filed on April 28, 2020, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-9.htm" style="-sec-extract: exhibit">            10.7           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-9.htm" style="-sec-extract: exhibit">            Employee Stock Purchase Plan (previously filed as an exhibit to the Company’s Registration Statement on Form 10-12B, filed July 31, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-10.htm" style="-sec-extract: exhibit">            10.8#           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-10.htm" style="-sec-extract: exhibit">            Form of Incentive Stock Option Agreement (previously filed as an exhibit to the Company’s Registration Statement on Form 10-12B, filed July 31, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-11.htm" style="-sec-extract: exhibit">            10.9#           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-11.htm" style="-sec-extract: exhibit">            Form of Non-Qualified Stock Option Agreement for executive officers (previously filed as an exhibit to the Company’s Registration Statement on Form 10-12B, filed July 31, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-12.htm" style="-sec-extract: exhibit">            10.10#           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-12.htm" style="-sec-extract: exhibit">            Form of Non-Qualified Stock Option Agreement for directors (previously filed as an exhibit to the Company’s Registration Statement on Form 10-12B, filed July 31, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-13.htm" style="-sec-extract: exhibit">            10.11#           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-13.htm" style="-sec-extract: exhibit">            Form of Deferred Stock Award Agreement (previously filed as an exhibit to the Company’s Registration Statement on Form 10-12B, filed July 31, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413009734/v334458_ex10-15.htm" style="-sec-extract: exhibit">            10.12†           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413009734/v334458_ex10-15.htm" style="-sec-extract: exhibit">            Sublicense Agreement dated as of December 7, 2012 between Biostage, Inc. and Harvard Bioscience, Inc., and related Trademark License Agreement, dated December 19, 2002, by and between Harvard Bioscience, Inc. and President and Fellows of Harvard College (previously filed as an exhibit to the Company’s Amendment No. 2 to Form S-1 Registration Statement, filed on February 15, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-16.htm" style="-sec-extract: exhibit">            10.13           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-16.htm" style="-sec-extract: exhibit">            Patent Rights Assignment dated December 21, 2012 between Biostage, Inc. and Dr. Paolo Macchiarini (previously filed as an exhibit to the Company’s Registration Statement on Form 10-12B, filed July 31, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-19.htm" style="-sec-extract: exhibit">            10.14           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-19.htm" style="-sec-extract: exhibit">            Novel Surgery Agreement dated as of May 21, 2012 between Biostage, Inc. and State Budget Institution of Public Health Department Regional Clinical Hospital #1 and Vladimir Alekseevich Porhanov (previously filed as an exhibit to the Company’s Registration Statement on Form 10-12B, filed July 31, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 78; Value: 49 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         52         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 11%; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-20.htm" style="-sec-extract: exhibit">            10.15           </a>          </td>          <td style="width: 1%; text-align: center">          </td>          <td style="width: 88%">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-20.htm" style="-sec-extract: exhibit">            Novel Surgery Agreement dated as of May 24, 2012 between Biostage, Inc. and OSF Healthcare System, owner and operator of Saint Francis Medical Center and Children’s Hospital of Illinois, and Mark Holterman, M.D. (previously filed as an exhibit to the Company’s Registration Statement on Form 10-12B, filed July 31, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-21.htm" style="-sec-extract: exhibit">            10.16           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-21.htm" style="-sec-extract: exhibit">            Amendment to Novel Surgery Agreement dated as of April 5, 2013 between Biostage, Inc. and OSF Healthcare System, owner and operator of Saint Francis Medical Center and Children’s Hospital of Illinois, and Mark Holterman, M.D. (previously filed as an exhibit to the Company’s Registration Statement on Form 10-12B, filed July 31, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-22.htm" style="-sec-extract: exhibit">            10.17           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420413042225/v351056_ex10-22.htm" style="-sec-extract: exhibit">            Amendment to Novel Surgery Agreement dated as of June 26, 2013 between Biostage, Inc. and State Budget Institution of Public Health Department Regional Clinical Hospital #1 and Igor S. Polyakov (previously filed as an exhibit to the Company’s Registration Statement on Form 10-12B, filed July 31, 2013, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420418037884/tv498315_ex10-1.htm" style="-sec-extract: exhibit">            10.18#           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420418037884/tv498315_ex10-1.htm" style="-sec-extract: exhibit">            Offer Letter, dated June 4, 2018, between Biostage, Inc. and William Fodor, PhD (previously filed as an exhibit to the Company's Current Report on Form 8-K, filed on July 10, 2018, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420419031095/tv523642_ex10-2.htm" style="-sec-extract: exhibit">            10.19#           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000114420419031095/tv523642_ex10-2.htm" style="-sec-extract: exhibit">            Separation and Release Agreement, dated June 14, 2019, between Biostage, Inc. and Thomas McNaughton (previously filed as an exhibit to the Company's Current Report on Form 8-K, filed on June 17, 2019, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000110465920012593/tm207080d1_ex10-1.htm" style="-sec-extract: exhibit">            10.20#           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000110465920012593/tm207080d1_ex10-1.htm" style="-sec-extract: exhibit">            Separation and Release Agreement, dated January 31, 2020, between Biostage, Inc. and James McGorry (previously filed as an exhibit to the Company's Current Report on Form 8-K, filed on February 7, 2020, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000110465920056854/tm2018655d1_ex10-1.htm" style="-sec-extract: exhibit">            10.21           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="http://www.sec.gov/Archives/edgar/data/1563665/000110465920056854/tm2018655d1_ex10-1.htm" style="-sec-extract: exhibit">            Promissory Note, dated May 1, 2020, by Biostage, Inc. in favor of Bank of America, N.A. (previously filed as an exhibit to the Company's Current Report on Form 8-K, filed on May 5, 2020, and incorporated by reference thereto).           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="tm211070d1_21-1.htm" style="-sec-extract: exhibit">            21.1*           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="tm211070d1_21-1.htm" style="-sec-extract: exhibit">            Subsidiaries of Biostage, Inc.           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="tm211070d1_23-1.htm" style="-sec-extract: exhibit">            23.1*           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="tm211070d1_23-1.htm" style="-sec-extract: exhibit">            Consent of RSM US LLP.           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="tm211070d1_31-1.htm" style="-sec-extract: exhibit">            31.1*           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="tm211070d1_31-1.htm" style="-sec-extract: exhibit">            Certification of President of Biostage., pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="tm211070d1_31-2.htm" style="-sec-extract: exhibit">            31.2*           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="tm211070d1_31-2.htm" style="-sec-extract: exhibit">            Certification of Interim Vice President of Finance of Biostage, Inc., pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="tm211070d1_32-1.htm" style="-sec-extract: exhibit">            32.1**           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="tm211070d1_32-1.htm" style="-sec-extract: exhibit">            Certification of President of Biostage, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <a href="tm211070d1_32-2.htm" style="-sec-extract: exhibit">            32.2**           </a>          </td>          <td style="text-align: center">          </td>          <td>           <a href="tm211070d1_32-2.htm" style="-sec-extract: exhibit">            Certification of Interim Vice President of Finance of Biostage, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.           </a>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           101.INS*          </td>          <td style="text-align: center">          </td>          <td>           XBRL Instance Document.          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           101.SCH*          </td>          <td style="text-align: center">          </td>          <td>           XBRL Taxonomy Extension Schema Document.          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           101.CAL*          </td>          <td style="text-align: center">          </td>          <td>           XBRL Taxonomy Extension Calculation Linkbase Document.          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           101.DEF*          </td>          <td style="text-align: center">          </td>          <td>           XBRL Taxonomy Extension Definition Linkbase Document.          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           101.LAB*          </td>          <td style="text-align: center">          </td>          <td>           XBRL Taxonomy Extension Label Linkbase Document.          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           101.PRE*          </td>          <td style="text-align: center">          </td>          <td>           XBRL Taxonomy Extension Presentation Linkbase Document.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            *           </p>          </td>          <td style="width: 94%">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            Filed herewith.           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           **          </td>          <td>           This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           #          </td>          <td>           Management contract or compensatory plan or arrangement.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 79; Value: 49 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         53         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 6%">           §          </td>          <td style="width: 94%">           The schedules and exhibits to the Separation and Distribution Agreement have been omitted. A copy of any omitted schedule or exhibit will be furnished to the SEC supplementally upon request. The Company will furnish to stockholders a copy of any exhibit without charge upon written request.          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           †          </td>          <td>           Confidential portions of this exhibit have been redacted and filed separately with the SEC pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <!-- Field: Page; Sequence: 80; Options: Last -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         54         <!-- Field: /Sequence -->        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>      </text>     </description>    </filename>   </sequence>  </type> </document></body>